
<html lang="en"     class="pb-page"  data-request-id="0dfd4805-64d5-4a89-ad11-eec65480e0d6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm400072p;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2013.56.issue-10;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors" /></meta><meta name="dc.Creator" content="Yi-Hui  Peng" /></meta><meta name="dc.Creator" content="Hui-Yi  Shiao" /></meta><meta name="dc.Creator" content="Chih-Hsiang  Tu" /></meta><meta name="dc.Creator" content="Pang-Min  Liu" /></meta><meta name="dc.Creator" content="John Tsu-An  Hsu" /></meta><meta name="dc.Creator" content="Prashanth Kumar  Amancha" /></meta><meta name="dc.Creator" content="Jian-Sung  Wu" /></meta><meta name="dc.Creator" content="Mohane Selvaraj  Coumar" /></meta><meta name="dc.Creator" content="Chun-Hwa  Chen" /></meta><meta name="dc.Creator" content="Sing-Yi  Wang" /></meta><meta name="dc.Creator" content="Wen-Hsing  Lin" /></meta><meta name="dc.Creator" content="Hsu-Yi  Sun" /></meta><meta name="dc.Creator" content="Yu-Sheng  Chao" /></meta><meta name="dc.Creator" content="Ping-Chiang  Lyu" /></meta><meta name="dc.Creator" content="Hsing-Pang  Hsieh" /></meta><meta name="dc.Creator" content="Su-Ying  Wu" /></meta><meta name="dc.Description" content="The Asp-Phe-Gly (DFG) motif plays an important role in the regulation of kinase activity. Structure-based drug design was performed to design compounds able to interact with the DFG motif; epiderma..." /></meta><meta name="Description" content="The Asp-Phe-Gly (DFG) motif plays an important role in the regulation of kinase activity. Structure-based drug design was performed to design compounds able to interact with the DFG motif; epiderma..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 10, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400072p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400072p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400072p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400072p" /></link>
        
    
    

<title>Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400072p" /></meta><meta property="og:title" content="Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0010.jpeg" /></meta><meta property="og:description" content="The Asp-Phe-Gly (DFG) motif plays an important role in the regulation of kinase activity. Structure-based drug design was performed to design compounds able to interact with the DFG motif; epidermal growth factor receptor (EGFR) was selected as an example. Structural insights obtained from the EGFR/2a complex suggested that an extension from the meta-position on the phenyl group (ring-5) would improve interactions with the DFG motif. Indeed, introduction of an N,N-dimethylamino tail resulted in 4b, which showed almost 50-fold improvement in inhibition compared to 2a. Structural studies confirmed this N,N-dimethylamino tail moved toward the DFG motif to form a salt bridge with the side chain of Asp831. That the interactions with the DFG motif greatly contribute to the potency of 4b is strongly evidenced by synthesizing and testing compounds 2a, 3g, and 4f: when the charge interactions are absent, the inhibitory activity decreased significantly." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The Asp-Phe-Gly (DFG) motif plays an important role in the regulation of kinase activity. Structure-based drug design was performed to design compounds able to interact with the DFG motif; epidermal growth factor receptor (EGFR) was selected as an example. Structural insights obtained from the EGFR/2a complex suggested that an extension from the meta-position on the phenyl group (ring-5) would improve interactions with the DFG motif. Indeed, introduction of an N,N-dimethylamino tail resulted in 4b, which showed almost 50-fold improvement in inhibition compared to 2a. Structural studies confirmed this N,N-dimethylamino tail moved toward the DFG motif to form a salt bridge with the side chain of Asp831. That the interactions with the DFG motif greatly contribute to the potency of 4b is strongly evidenced by synthesizing and testing compounds 2a, 3g, and 4f: when the charge interactions are absent, the inhibitory activity decreased significantly." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0010.jpeg" /></meta><meta name="twitter:title" content="Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400072p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400072p">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400072p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400072p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400072p&amp;href=/doi/10.1021/jm400072p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 3889-3903</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400032t" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm4000775" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Hui++Peng">Yi-Hui Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hui-Yi++Shiao">Hui-Yi Shiao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chih-Hsiang++Tu">Chih-Hsiang Tu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pang-Min++Liu">Pang-Min Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+Tsu-An++Hsu">John Tsu-An Hsu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Prashanth+Kumar++Amancha">Prashanth Kumar Amancha</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian-Sung++Wu">Jian-Sung Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mohane+Selvaraj++Coumar">Mohane Selvaraj Coumar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun-Hwa++Chen">Chun-Hwa Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sing-Yi++Wang">Sing-Yi Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wen-Hsing++Lin">Wen-Hsing Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hsu-Yi++Sun">Hsu-Yi Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu-Sheng++Chao">Yu-Sheng Chao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ping-Chiang++Lyu">Ping-Chiang Lyu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hsing-Pang++Hsieh">Hsing-Pang Hsieh</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Su-Ying++Wu">Su-Ying Wu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Institute of Bioinformatics and Structural Biology, National Tsing Hua University, 101, Sect. 2, Guangfu Road, Hsinchu 300, Taiwan, ROC</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry 605014, India</span></div><div class="corresp-info"><strong>*</strong>For S.Y.W.: phone, +886-37-246-166 extension 35713; fax, +886-37-586-456; E-mail, <a href="/cdn-cgi/l/email-protection#b7c4c2ceded9d0f7d9dfc5de99d8c5d099c3c0"><span class="__cf_email__" data-cfemail="c6b5b3bfafa8a186a8aeb4afe8a9b4a1e8b2b1">[email protected]</span></a>. For H.P.H: phone, +886-37-246-166 extension 35708; fax, +886-37-586-456; E-mail, <a href="/cdn-cgi/l/email-protection#4028302833292528002e2832296e2f32276e3437"><span class="__cf_email__" data-cfemail="e98199819a808c81a987819b80c7869b8ec79d9e">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400072p&amp;href=/doi/10.1021%2Fjm400072p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 3889–3903</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 23, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 January 2013</li><li><span class="item_label"><b>Published</b> online</span>10 May 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 May 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400072p" title="DOI URL">https://doi.org/10.1021/jm400072p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3889%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYi-Hui%2BPeng%252C%2BHui-Yi%2BShiao%252C%2BChih-Hsiang%2BTu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D10%26contentID%3Djm400072p%26title%3DProtein%2BKinase%2BInhibitor%2BDesign%2Bby%2BTargeting%2Bthe%2BAsp-Phe-Gly%2B%2528DFG%2529%2BMotif%253A%2BThe%2BRole%2Bof%2Bthe%2BDFG%2BMotif%2Bin%2Bthe%2BDesign%2Bof%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitors%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3903%26publicationDate%3DMay%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400072p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5011</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">56</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400072p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yi-Hui&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Hui-Yi&quot;,&quot;last_name&quot;:&quot;Shiao&quot;},{&quot;first_name&quot;:&quot;Chih-Hsiang&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Pang-Min&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Tsu-An Hsu&quot;},{&quot;first_name&quot;:&quot;Prashanth&quot;,&quot;last_name&quot;:&quot;Kumar Amancha&quot;},{&quot;first_name&quot;:&quot;Jian-Sung&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Mohane&quot;,&quot;last_name&quot;:&quot;Selvaraj Coumar&quot;},{&quot;first_name&quot;:&quot;Chun-Hwa&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Sing-Yi&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Wen-Hsing&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Hsu-Yi&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Yu-Sheng&quot;,&quot;last_name&quot;:&quot;Chao&quot;},{&quot;first_name&quot;:&quot;Ping-Chiang&quot;,&quot;last_name&quot;:&quot;Lyu&quot;},{&quot;first_name&quot;:&quot;Hsing-Pang&quot;,&quot;last_name&quot;:&quot;Hsieh&quot;},{&quot;first_name&quot;:&quot;Su-Ying&quot;,&quot;last_name&quot;:&quot;Wu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;3889-3903&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400072p&quot;},&quot;abstract&quot;:&quot;The Asp-Phe-Gly (DFG) motif plays an important role in the regulation of kinase activity. Structure-based drug design was performed to design compounds able to interact with the DFG motif; epidermal growth factor receptor (EGFR) was selected as an example. Structural insights obtained from the EGFR/2a complex suggested that an extension from the meta-position on the phenyl group (ring-5) would improve interactions with the DFG motif. Indeed, introduction of an N,N-dimethylamino tail resulted in 4b, which showed almost 50-fold improvement in inhibition compared to 2a. Structural studies confirmed this N,N-dimethylamino tail moved toward the DFG motif to form a salt bridge with the side chain of Asp831. That the interactions with the DFG motif greatly contribute to the potency of 4b is strongly evidenced by synthesizing and testing compounds 2a, 3g, and 4f: when the charge interactions are absent, the inhibitory activity decreased significantly.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400072p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400072p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400072p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400072p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400072p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400072p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400072p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400072p&amp;href=/doi/10.1021/jm400072p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400072p" /></input><a href="/doi/pdf/10.1021/jm400072p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400072p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400072p%26sid%3Dliteratum%253Aachs%26pmid%3D23611691%26genre%3Darticle%26aulast%3DPeng%26date%3D2013%26atitle%3DProtein%2BKinase%2BInhibitor%2BDesign%2Bby%2BTargeting%2Bthe%2BAsp-Phe-Gly%2B%2528DFG%2529%2BMotif%253A%2BThe%2BRole%2Bof%2Bthe%2BDFG%2BMotif%2Bin%2Bthe%2BDesign%2Bof%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D10%26spage%3D3889%26epage%3D3903%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/10" title="Go to Volume 56, Issue 10"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jmcmar.2013.56.issue-10/production/jmcmar.2013.56.issue-10.largecover.jpg" alt="Go to Volume 56, Issue 10"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The Asp-Phe-Gly (DFG) motif plays an important role in the regulation of kinase activity. Structure-based drug design was performed to design compounds able to interact with the DFG motif; epidermal growth factor receptor (EGFR) was selected as an example. Structural insights obtained from the EGFR/<b>2a</b> complex suggested that an extension from the meta-position on the phenyl group (ring-5) would improve interactions with the DFG motif. Indeed, introduction of an <i>N</i>,<i>N</i>-dimethylamino tail resulted in <b>4b</b>, which showed almost 50-fold improvement in inhibition compared to <b>2a</b>. Structural studies confirmed this <i>N</i>,<i>N</i>-dimethylamino tail moved toward the DFG motif to form a salt bridge with the side chain of Asp831. That the interactions with the DFG motif greatly contribute to the potency of <b>4b</b> is strongly evidenced by synthesizing and testing compounds <b>2a</b>, <b>3g</b>, and <b>4f</b>: when the charge interactions are absent, the inhibitory activity decreased significantly.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75612" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75612" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The human genome encodes more than 500 protein kinases,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> including tyrosine, serine/threonine, and dual specificity kinases. These kinases have a highly conserved catalytic domain, which binds the ATP molecule and magnesium ion at the site formed by the N- and C-terminal lobes.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Regulatory elements within kinases serve to switch on and off the activity state of the protein.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> One such element is the activation loop, which regulates kinase activity through phosphorylation. Specifically, the activation loop undergoes large conformational changes, which switches the kinase between its inactive and active forms.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> When the activation loop is phosphorylated, it forms an open and extended conformation to allow substrate binding. The DFG motif located at the beginning of the activation loop is highly conserved among kinases and is important for protein catalysis.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In active kinases, the DFG motif adopts an “in” conformation and the Asp residue is oriented toward bound ATP, which is able to coordinate the magnesium ion bound to the β- and γ- phosphate groups of ATP.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In inactive kinases, the conformation of the DFG motif is flipped outward, such that the Asp no longer coordinates the magnesium at the catalytic site.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Another regulatory element is the position of the helix αC.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In the active form of kinases, a salt bridge that coordinates the phosphate groups of ATP can be observed between the glutamate residue on helix αC and lysine residue on the N-lobe.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In inactive kinases, the helix αC moves out of position and loses this salt bridge interaction. By the coordination of these regulatory elements, the protein kinases are able to phosphorylate substrate by transferring the γ-phosphate of ATP onto the side chain of protein substrate.</div><div class="NLM_p">Protein kinases regulate many critical cellular processes through protein phosphorylation, such as proliferation and differentiation,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and therefore constitute an important drug discovery opportunity.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Among these kinases, the family of human ErbB receptor tyrosine kinase, also called epidermal growth factor receptor (EGFR), is an important drug target in oncology. The human EGFR family comprises four related members, HER-1(EGFR), HER-2, HER-3, and HER-4, which play central roles in cell proliferation and differentiation.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Deregulation of the EGFR family pathway by overexpression or constitutive activation induces numerous cancers.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Overexpression of EGFR family kinases is often observed in tumors, including colorectal, lung, breast, head, and neck carcinomas.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> All proteins in the EGFR family are transmembrane proteins, containing an extracellular ligand binding domain, a transmembrane domain, an intracellular receptor tyrosine kinase domain, and a C-terminal signaling tail domain. The members of the EGFR family share high structural homology in their tyrosine kinase domain but are distinct in their extracellular and C-terminal domains.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The binding of growth factors to the extracellular domain induces receptor homo- or heterodimerization and activates the kinase domain, which would lead to the autophosphorylation of the intracellular tyrosine residues at the C-terminal and the subsequent induction of downstream signals.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a></div><div class="NLM_p">Various approaches have been developed to target the EGFR signaling pathway, including monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs). Cetuximab,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> which has been approved by the FDA for the treatment of colorectal cancer, is a monoclonal antibody targeting the EGFR extracellular ligand-binding domain. TKIs targeting the intracellular kinase domain have also been developed with three such drugs having received FDA approval for use as cancer therapies: gefitinib,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> erlotinib,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and lapatinib<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Gefitinib and erlotinib are EGFR inhibitors used in the treatment of non-small cell lung cancer (NSCLC), while lapatinib, which inhibits EGFR and HER-2 kinases, is used in combination therapy for HER2-positive breast cancer. Clinical trials are currently evaluating the feasibility of additional drugs which target the EGFR pathway, including other reversible inhibitors [(6-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-<i>N</i>-((<i>S</i>)-1-phenylethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (AEE788),<a onclick="showRef(event, 'ref17 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref20">(17, 20)</a> ((<i>S</i>)-morpholin-3-yl)methyl 4-(1-(3-fluorobenzyl)-1<i>H</i>-indazol-5-ylamino)-5-methylpyrrolo[1,2-<i>f</i>][1,2,4]triazin-6-ylcarbamate (BMS-599626),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and <i>N</i>-(2-(4-(4-(3-(trifluoromethyl)phenoxy)-3-chlorophenylamino)-5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidin-5-yl)ethyl)-2-hydroxy-2-methylpropanamide (TAK-285)<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a>] as well as irreversible inhibitors [(<i>E</i>)-<i>N</i>-(4-(4-((pyridin-2-yl)methoxy)-3-chlorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide (HKI-272),<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a><i>N</i>-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-chloropyrimidin-4-ylamino)phenyl)acrylamide (WZ4002),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (<i>E</i>)-<i>N</i>-(7-((<i>R</i>)-tetrahydrofuran-3-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide (BIBW2992),<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> and (<i>E</i>)-<i>N</i>-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide (PF-00299804)<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a>].</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of EGFR small molecule inhibitors and their bindings to EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Nonetheless, EGFR inhibitors have been shown to cause a variety of adverse effects in patients. For example, interstitial lung disease (ILD) is a common, serious adverse effect experienced by patients with advanced NSCLC after receiving gefitinib treatment.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> In 2009, the U.S. FDA warned that the use of erlotinib could result in serious disorders in the gastrointestinal tract, skin, and eyes. Lapatinib has been associated with hepatotoxicity when used in combination with other chemotherapies.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Even the second-generation irreversible inhibitor BIBW2992 produced adverse effects: diarrhea (95%) and rash (62%) were observed in clinical trials<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> although rash has also been regarded as a positive sign of efficacy. The side effects associated with these EGFR inhibitors may be related to the cross activity with other kinases. For example, in addition to inhibiting EGFR, erlotinib also exhibited strong inhibition effects against serine/threonine kinase 10 (STK10). The inhibition of STK10 has been found to increase lymphocytic responses, such as cell migration and interleukin-2 secretion, and consequently to result in severe skin disorders.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">Many EGFR inhibitors contain a quinazoline core scaffold, including reversible inhibitors, such as erlotinib, gefitinib, and lapatinib, and the irreversible inhibitors BIBW2992, (<i>E</i>)-<i>N</i>-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide (EKB-569),<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and HKI-272. A few diverse core scaffolds can be found in recent studies, such as TAK-285 (derived from a pyrrolo[3,2-<i>d</i>]pyrimidine scaffold<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>), which is a dual EGFR/HER2 inhibitor under clinical development. All of these inhibitors share a common feature: upon the binding to EGFR, a hydrogen bond forms between the N1 atom of the quinazoline or pyrimidine core and the backbone NH of Met769 in the hinge region.<a onclick="showRef(event, 'ref14 ref25 ref37'); return false;" href="javascript:void(0);" class="ref ref14 ref25 ref37">(14, 25, 37)</a></div><div class="NLM_p">Analysis of previously published structures (PDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a>,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M">2J6M</a>,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3POZ">3POZ</a>,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV">2JIV</a>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J">4G5J</a>,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a><a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a>) of small molecule inhibitors binding to EGFR revealed two binding modes (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The first mode is characterized by the core structure of inhibitors forming strong interactions with the hinge region in EGFR and the other moiety of inhibitors extending to (or close to) the solvent exposure area. The inhibitors also expand to the ATP back pocket. Examples of inhibitors adopting this binding mode are erlotinib, gefitinib, AEE788, and BIBW2992 (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). In the second mode, the core structure of inhibitors, such as lapatinib, TAK-285, and HKI272 (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), forms H-bond and hydrophobic interactions with the hinge region while the lipophilic moiety of the inhibitors expands to the back pocket of the ATP binding site and disrupts the salt bridge between the glutamate residue on helix αC and the lysine residue on the N-lobe.</div><div class="NLM_p last">In this study, we designed the EGFR inhibitors specifically targeting the DFG motif because of the important role played by the DFG motif in the regulation of kinase activity. We selected a furanopyrimidine scaffold hit compound, <b>2a</b>, which had been discovered in our previous research via high-throughput screening,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and then employed a structure-based drug design approach to develop compounds able to interact with the DFG motif. Through the structure-guided design, a novel compound, <b>4b</b>, was identified and found to have almost 50-fold improvement in EGFR inhibition as compared to the hit compound <b>2a</b>. Compound <b>4b</b> displayed an EGFR inhibition better than that of gefitinib. Further structural biology studies confirmed that <b>4b</b> interacts with the DFG motif through the <i>N</i>,<i>N</i>-dimethylamino tail to form a salt bridge with the side chain of Asp831.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70367" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70367" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">Approximately 20 furanopyrimidine derivatives (Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) were synthesized as shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Starting materials <b>1a</b>–<b>c</b> were prepared<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and reacted with various chiral amines via an S<sub>N</sub>Ar reaction to give chiral compounds <b>2a</b>–<b>f</b>. Suzuki coupling reactions were then employed to couple bromo compound <b>2f</b> with various substituted aryl boronic acids, yielding coupling products <b>3a</b>–<b>g</b>. Finally, reacting <b>3e</b> with the corresponding carboxylic acid in the presence of EDC yielded the desired compounds <b>4a</b>–<b>f</b>. All compounds were characterized by <sup>1</sup>H NMR and LC-MS, and their purity was determined by reverse phase HPLC.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Construction of Furanopyrimidine Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amine, EtOH, Et<sub>3</sub>N, reflux: (b) boronic acid, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux; (c) carboxylic acid, EDCl, DCM, rt.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. EGFR Inhibition of Furanopyrimidine Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0006.gif" alt="" id="fx99" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0013.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Values are expressed as the mean of at least three independent determinations and are within ±15%</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. EGFR Inhibition of Furanopyrimidine Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0007.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0008.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Values are expressed as the mean of at least three independent determinations and are within ±15%</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> SAR Studies</h3><div class="NLM_p">Compound <b>2a</b>,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> previously discovered by us, was used as starting point for a structure–activity and lead optimization study.</div><div class="NLM_p">A variety of substituted derivates (<b>2a</b>–<b>3e</b>; Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) were synthesized and evaluated by biological assays. In addition to wild-type EGFR, the synthesized compounds were also screened for their inhibition against the L834R mutant (also identified as L858R in an alternative numbering of the human EGFR sequence), which has been reported<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> to be present in NSCLC patients.</div><div class="NLM_p"><b>2a</b> inhibited wild-type EGFR and L834R mutant, with IC<sub>50</sub> values of 393 and 52 nM, respectively. Replacement of the primary hydroxyl group of <b>2a</b> with various alkyl groups to produce <b>2b</b> (methyl group), <b>2c</b> (ethyl group), or <b>2d</b> (ester group) resulted in a dramatic decrease in inhibitory activity against both wild-type and L834R mutant EGFR. This suggests that the primary hydroxyl group at the R<sub>2</sub> substitution position contributes greatly to the EGFR inhibition.</div><div class="NLM_p last">Next, the role of the R<sub>1</sub> substituent at the third position of the furanopyrimidine core was investigated. Introducing an electron-withdrawing halogen, such as chlorine <b>2e</b> or bromine <b>2f</b>, at this position resulted in slightly lower inhibition compared with the phenyl substitution of <b>2a</b>. On the other hand, introduction of furan derivatives to give <b>3a</b> and <b>3b</b> resulted in retention of activity, and when the phenyl ring was replaced with a 1,3-benzodioxole moiety to give <b>3c</b>, activity slightly improved. Moreover, of the substituted phenyl derivatives <b>3d</b>–<b>e</b>, the amine-bearing substituent <b>3e</b> showed improved inhibitory activity compared with <b>2a</b>. In contrast, introduction of a nitro group in substituent <b>3d</b> decreased activity. As <b>3e</b> not only exhibited strong inhibition against EGFR but also possessed an extensible amino group, it was selected for further lead optimization.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Structural Biology Study of Compound <b>2a</b></h3><div class="NLM_p">Concurrently with the aforementioned SAR study, <b>2a</b> was cocrystallized with the wild-type EGFR kinase domain and the structure complex was solved in order to elucidate the binding mode and obtain the structural insights necessary to design a more potent EGFR kinase inhibitor. The electron density maps of EGFR in complex with <b>2a</b> clearly shows that EGFR adopts an active conformation with a salt bridge between Lys721 and Glu738, and <b>2a</b> is located in the ATP binding cleft between the N- and C-lobes (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B). The furanopyrimidine core (ring-2 and ring-3) of <b>2a</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A,B) aligns in the hinge region of EGFR, forming one H-bond with the main chain of Met769 and making hydrophobic interactions with surrounding residues, including Leu694, Ala719, Met769, and Leu820 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A,B). The phenyl moiety (ring-1) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A) also forms extensive hydrophobic interactions with residues of Val702, Ala719, Lys721, Leu764, and Thr766 in the N-lobe β-sheet and Met742 in the αC helix. The phenyl moiety (ring-4) at the second position on the furan moiety makes close contact with Leu694 and Gly772. (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A,B). The phenyl substitution (ring-5) at the R<sub>1</sub> position is perpendicular to the furanopyrimidine core (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A,B). It forms hydrophobic interactions with Leu694 on the glycine-rich loop (P-loop) and Val702 in the N-lobe β-sheet. Interestingly, the primary hydroxyl group of <b>2a</b> forms an H-bond with the side chain of Asp831 on the DFG motif (Asp831-Phe832-Gly833 in EGFR). The importance of the H-bond interaction between this primary hydroxyl group and the carboxylate group of Asp831 is revealed in a SAR study (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), which shows that when this primary hydroxyl group is replaced with alkanes, such as a methyl group <b>2b</b> and <b>2d</b> or a ethyl group <b>2c</b>, the H-bond interaction is lost and inhibitory activity is greatly reduced. Because a polar hydroxyl group at R<sub>2</sub> substitution site has proved to be a potent functional group to retain the activity, it is therefore maintained in the further lead optimization.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Interactions of <b>2a</b>, <b>3g</b>, and <b>4b</b> with EGFR. Hydrogen bonds are shown in red. Hydrophobic interactions are shown in black. Salt bridges are shown in pink. (B) Superimposition of structures of compound <b>2a</b> (orange) and <b>3g</b> (green) with EGFR. The distance of the meta position on ring-5 of <b>2a</b> to the carboxyl group (OD2 atom) of Asp831 is 5.91 Å (orange line), while adding the acetamide group to this meta position, the shortest distance between <b>3g</b> (C24 atom) with the carboxyl group (OD2 atom) of Asp831 decreases to 3.76 Å (red line). The H-bond between the primary hydroxyl group of <b>2a</b> and Asp831 is shown with a magenta dotted line. For clarity, the H-bond between <b>2a</b> and the residue M769 and all H-bonds between <b>3g</b> and EGFR are omitted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structure-Based Drug Design of Furanopyrimidine Compounds</h3><div class="NLM_p">The DFG motif regulates the catalysis of protein kinase and contributes to ATP binding.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The important biological function of DFG suggested to us that modification of the hit compound by targeting the DFG motif would enhance the activity. Indeed, the EGFR/<b>2a</b> structure (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B) showed that the distances from meta- and para-positions on the perpendicular phenyl group (ring 5) to the side chain of Asp831 are 5–7 Å (meta distance to the OD2 atom of Asp831 is 5.91 Å, and para distance to the OD2 atom of Asp831 is 6.80 Å), which allowed the extension of an appropriate moiety to interact with the DFG motif. Following this rational design approach, <b>3g</b> and <b>3f</b> bearing an acetamide moiety at the meta and para positions, respectively, were synthesized. Both compounds displayed slightly increased inhibition of EGFR kinase compared with <b>2a</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The following structural biology study of <b>3g</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B) in complex with EGFR confirmed that the amide substituted moiety moved toward the DFG motif as expected with a shorter distance to Asp831 (distance between the C24 atom in <b>3g</b> and the OD2 atom of Aps831 is 3.76 Å).</div><div class="NLM_p">To enhance the interactions of <b>3g</b> with the DFG motif, a series of meta-substituents bearing a <i>N</i>,<i>N</i>-dimethylamino group attached to different lengths of carbon chain were synthesized (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). It was thought that the cationic amino group could form a strong ionic interaction with the deprotonated carboxylic acid side chain of Asp831. Indeed, the activity of amine-bearing <b>3g</b> derivatives (<b>4a</b>–<b>d</b>) toward both wild-type EGFR and L834R mutant was improved. Compound <b>4b</b>, containing a two carbon-chain linker, was the most potent compound, with a 49-fold improvement in wild-type activity and 26-fold improvement in L834R activity compared with <b>2a</b>. It also showed improved activity compared with gefitinib (4-fold and 7-fold improvement in wild-type and L834R mutant, respectively). However, when the length of the alkyl chain was increased to five carbons (<b>4e</b>), a dramatic loss of activity was observed, particularly in wild-type EGFR. Thus, this SAR study suggested the appropriate chain length of compound would provide a suitable conformation to bind and inhibit EGFR activity.</div><div class="NLM_p last">When the nitrogen atom of the terminal <i>N</i>,<i>N</i>-dimethylamino group of <b>4c</b> was replaced with a carbon atom to generate <b>4f</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), a nearly complete loss of activity (IC<sub>50</sub> > 25 uM) resulted, indicating that the <i>N</i>,<i>N</i>-dimethylamino group plays an important role in the inhibition of EGFR.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Binding Mode of <b>4b</b> in EGFR</h3><div class="NLM_p">Because the introduction of the ethyl <i>N</i>,<i>N</i>-dimethylamino moiety to compound <b>3g</b> greatly improved the inhibitory activity in EGFR, the crystal structure of <b>4b</b> in complex with EGFR was solved in order to rationalize the observed structure–activity relationship trend. The structure was determined at 2.83 Å resolution (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Table S1">Supporting Information Table S1</a>) and showed a clear electron density map. Compound <b>4b</b> binds to the active form of EGFR, which is characterized by a salt bridge between Lys721 and Glu738 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). The structure of EGFR/<b>4b</b> presents a very special and strong hydrogen bond network in the ATP binding pocket (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). First, the N-6 nitrogen atom on the core pyrimidine ring (ring-2) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A) forms a conserved hydrogen bond with Met769 in the hinge region (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). Second, the primary hydroxyl group at the R<sub>2</sub> position forms very strong H-bonds with the side chain of Asp831 in the DFG motif. And last, but most significantly, the cationic dimethylamino group forms a salt bridge with the anionic carboxylate group of Asp831 in the DFG motif (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). This structure revealed that <b>4b</b> acted like a “clamp” that wrapped around Asp831 to block ATP binding and therefore prevent phosphate transfer to downstream protein of the signal transduction pathway. Without the <i>N</i>,<i>N</i>-dimethylaminoethyl moiety (<b>2a</b> and <b>3g</b>), the salt bridge interaction was lost and the inhibition activity greatly decreased. In particular, the nitrogen atom in the <i>N</i>,<i>N</i>-dimethylamino group serves as a base to interact with the acidic side chain of Asp831. The importance of this electrostatic interaction is emphasized by the fact that compound <b>4f</b>, in which the positively charged nitrogen atom was replaced with a neutral carbon atom, is a very poor inhibitor.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Structure of furanopyrimidine compound <b>4b</b> (yellow) bound to EGFR. (B) Superimposition of structures of EGFR (gray)/<b>2a</b> (orange) with EGFR (dark-green)/<b>4b</b> (yellow). The intramolecular and intermolecular H-bonds between <b>4b</b> and Asp831 are shown with brown dotted lines; the H-bond between <b>2a</b> and Asp831 is depicted with a purple dotted line; the salt bridge between <b>4b</b> and Asp831 is shown with a light-blue dotted line. (C) Superimposition of structures of EGFR (dark-green)/<b>4b</b> (yellow) with EGFR (purple)/<b>4c</b> (light-orange). The H-bond between <b>4c</b> and Asp831 is depicted with a dark-blue dotted line; the salt bridge between <b>4c</b> and Asp831 is shown with a magenta dotted line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition to H-bond and charge interactions, <b>4b</b> also forms strong hydrophobic interactions at the ATP binding site (Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). The ring-1 forms hydrophobic interactions with Val702, Ala719, Lys721, Met742, and Leu764 located in the N lobe of the EGFR kinase domain. The furanopyrimidine core (ring-2 and ring-3) aligns in the hinge region and forms hydrophobic interactions with Leu694, Ala719, Met769, and Leu820. The ring-4, located near the solvent exposed region, makes close contact with Leu694 and Gly772. The perpendicular ring-5 forms hydrophobic interactions with Leu694, Phe699, Val702, and Leu820.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Comparison of the Structure of EGFR/<b>4b</b> with the Structure of EGFR/<b>2a</b></h3><div class="NLM_p">The structure of the EGFR/<b>4b</b> complex was compared with the structure of the EGFR/<b>2a</b> complex to understand the enhanced potency of <b>4b</b> and examine the differences in interactions at the molecular level (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B). A detailed comparison of the binding features of these two inhibitors is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. The two compounds adopt very similar conformations, and their aromatic rings superimpose well. The most significant difference between these inhibitors is an additional tail of <b>4b</b>, which provides additional salt bridge interactions with the protein. Moreover, in comparison with structure of EGFR/<b>2a</b>, the side chain of Asp831 rotates and moves closer to the primary hydroxyl group, resulting in the formation of an additional H-bond between <b>4b</b> and the DFG motif. An extra intramolecular H-bond is also observed between the oxygen atom on the hydroxyl group (H-bond acceptor) and amine group (H-bond donor) attached to ring-5 in <b>4b</b>, whereas this intramolecular H-bond is absent in <b>2a</b>. We hypothesize that the <i>N</i>,<i>N</i>-dimethylamino tail of <b>4b</b>, through the interactions with Asp831, brings the nitrogen atom close to the hydroxyl group and consequently leads to the formation of the strong intramolecular H-bond. This intramolecular H-bond might stabilize the structure of the compound and therefore contributes to the improved activity of <b>4b</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. The Summary of Interactions between Inhibitors and EGFR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0009.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p last">In summary, an additional hydrogen bond, strong salt bridge interactions, and extra intramolecular H-bond interactions could explain the enhanced activity of <b>4b</b>.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> The Effects of Various Tail Lengths</h3><div class="NLM_p">As revealed in the SAR study (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), tails of various length differ in their effects on the inhibition of EGFR and the two carbon chain length of <i>N</i>,<i>N</i>-dimethylamino tail (<b>4b)</b> has the optimal activity. To investigate the differences at the molecular level, the crystal structure of EGFR/<b>4c</b> was solved and compared with that of EGFR/<b>4b</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C, Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Although two structures adopt very similar conformations, some differences were observed, particularly in the <i>N</i>,<i>N</i>-dimethylamino tail, the primary hydroxyl group, and Asp831 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C). The <i>N</i>,<i>N</i>-dimethylamino tail of <b>4c</b> (with one extra carbon in the chain) extends further toward the activation loop, and the side chain of Asp831 in the EGFR/<b>4c</b> structure consequently shifts to maintain the salt bridge interactions with the <i>N</i>,<i>N</i>-dimethylamino tail. Interestingly, the movement of Asp831 in the EGFR/<b>4c</b> structure toward the <i>N</i>,<i>N</i>-dimethylamino tail concurrently shifts Asp831 away from the primary hydroxyl group and consequently leads to the loss of one H-bond interaction with the primary hydroxyl group. This might explain the weaker inhibition of <b>4c</b> as compared with <b>4b</b>. When the chain length increased to five carbons (<b>4e</b>), the activity decreased by 540-fold. The reason for this dramatic loss of activity could be that the <i>N</i>,<i>N</i>-dimethylamino group would be far away from the DFG motif and so could not form the salt bridge interactions with the side chain of Asp831. Another possibility is that the flexible side chain of Asp831 could move closer to the <i>N</i>,<i>N</i>-dimethylamino group to interact with the tail, resulting in the loss of important H-bonds with the primary hydroxyl group.</div><div class="NLM_p last">The interactions between the primary hydroxyl and the <i>N</i>,<i>N</i>-dimethylamino group of compounds with the DFG motif of EGFR are two main factors that determine the potency of the inhibitors. <b>4b</b>, with a two carbon-chain tail, adopts the best conformation to allow the optimal interactions of the primary hydroxyl and <i>N</i>,<i>N</i>-dimethylamino group with the DFG motif.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Comparison with the Structures of Other Inhibitors Bound to EGFR</h3><div class="NLM_p">First, the X-ray cocrystal structures of <b>4b</b> and gefitinib (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A) were compared. Overlapping the structures of these two complexes revealed that the furanopyrimidin moiety (ring-2 and ring-3) of <b>4b</b> superimposes well with the quinazoline core (ring-2 and ring-3) of gefitinib (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>C) to form the conserved H-bonds with Met769. The ring-1 of <b>4b</b> and the 3-chloro-4-fluoro-aniline (ring-1) of gefitinib both extend to the hydrophobic pocket in the back of the ATP-binding cleft and point toward the C-helix; however, the ring-1 of <b>4b</b> makes more extensive hydrophobic interactions with the surrounding residues. The ring-4 of <b>4b</b> occupies a similar position with the methoxy group of gefitinib, which is aligned with the hinge connection loop. The significant difference occurs in the ring-5 bearing <i>N</i>,<i>N</i>-dimethylamino tail of <b>4b</b>, which adopts a spatial position different from the propyl morpholino moiety of gefitinib. The tail part of <b>4b</b> directs toward the DFG motif and forms a salt bridge with Asp831, while the propyl morpholino group of gefitinib extends to the solvent exposed region. Moreover, the carboxylic side chain of Asp831 induces conformational changes to form strong electrostatic interactions with the tail of <b>4b</b> and allow the formation of H-bonds with the primary hydroxyl; in contrast, the carboxylic side chain of Asp831 of the EGFR/gefitinib structure adopts a conformation similar to the apo EGFR and has no interactions with gefitinib.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Comparison of structures of EGFR (green)/<b>4b</b> (yellow) and EGFR (purple)/gefitinib (cyan). (B) Comparison of structures of EGFR (green)/<b>4b</b> (yellow) and EGFR (pink)/AEE788 (magenta). (C) Structures of <b>4b</b>, gefitinib, and AEE788. For comparison, the rings of compound structures are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The structure of EGFR/<b>4b</b> was also compared with that of EGFR/AEE788 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). By superimposing the structure complex of AEE788 onto <b>4b</b>, it was found that rings 1–4 of AEE788 superimpose well with rings 1–4 of <b>4b</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>C). The major difference was the orientation of the piperazine moiety of AEE788, which adopts a spatial position different from that of the ring-5 of <b>4b</b> (the ring bearing the <i>N</i>,<i>N</i>-dimethylamino tail). The piperazine moiety of AEE788 occupies the solvent exposed region and does not interact with any protein residues of EGFR. In contrast, the <i>N</i>,<i>N</i>-dimethylamino tail of <b>4b</b> greatly contributes to the improved activity through interactions with the DFG motif. Moreover, the H-bond interaction with Asp831 is lost in the structure of EGFR/AEE788 because of the absence of a substituted hydroxyl group. The additional salt bridge interactions and the H-bond with the DFG motif may explain the better inhibition of <b>4b</b> compared with AEE788 (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Kinase Profiling</h3><div class="NLM_p last">Because of the high degree of homology of the ATP binding site among all kinases, a small molecular inhibitor may inhibit many protein targets simultaneously. To assess the selectivity of <b>4b</b> over other kinases, we profiled <b>4b</b> over a panel of 317 kinases, including EGFR and HER2 (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Table S2">Supporting Information Table S2</a>). The assay to test the ability of <b>4b</b> to inhibit these kinases was performed at 1 μM concentration. The results showed that <b>4b</b> indeed inhibits EGFR, wild-type (99% at 1 μM), L834R mutant (100% at 1 μM), and L837Q mutant (106% at 1 μM), better than all of the other tested kinases. Of the 317 kinases profiled, only eight kinases (eight of 317, or 2%) including three EGFR proteins (wild-type, L834R, and L837Q mutants) were strongly inhibited by <b>4b</b> (>80% inhibition at 1 μM concentration). Compound <b>4b</b> also showed between 50% and 80% inhibition against 14 other kinases, including two EGFR mutants (T766 M mutant and T766M/L834R double mutant).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this study, a novel furanopyrimidine-based series of EGFR inhibitors was synthesized and structure-guided lead optimization by targeting the DFG motif of EGFR led to the identification of a potent EGFR inhibitor, <b>4b</b>. Structural insights obtained from X-ray cocrystal studies of <b>2a</b>, the initial compound discovered by our previous study, suggested that an extension from the meta-position on the perpendicular phenyl group (ring-5) would allow further interactions with the DFG motif and consequently improve inhibitor potency. Modification of meta-substituents with the <i>N</i>,<i>N</i>-dimethylamino group attached to carbon chains of different lengths improved the inhibition of <b>4b</b> by nearly 50-fold over that of <b>2a</b>. In addition, the potency of <b>4b</b> is superior to that of the commercial drug, gefitinib. The structure of EGFR in complex with <b>4b</b> revealed that the ethyl <i>N</i>,<i>N</i>-dimethylamino tail moves toward the DFG motif to form a salt bridge with the side chain of Asp831. That the interactions of this <i>N</i>,<i>N</i>-dimethylamino tail with the carboxylate group of Asp831 contribute greatly to the potency of <b>4b</b> is strongly evidenced by synthesizing and testing compounds <b>2a</b>, <b>3g</b>, and <b>4f</b>: the inhibitory activity of these compounds decreases significantly in the absence of charge interactions with the DFG motif.</div><div class="NLM_p">The interactions of inhibitors with the DFG motif of protein kinases have been observed in a number of structures (PDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UP7">3UP7</a>,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NPC">3NPC</a>,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2">1KV2</a>,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV1">1KV1</a>,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EYJ">4EYJ</a>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G6G">3G6G</a>,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G6H">3G6H</a>,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ">2OIQ</a>,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OO8">2OO8</a>,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2P4I">2P4I</a>,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9B">4F9B</a>,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EOI">4EOI</a>,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCI">4BCI</a>,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GK2">4GK2</a>,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ALW">4ALW</a>,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7Q">3R7Q</a>,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZDI">3ZDI</a>,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H1J">4H1J</a>,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BBF">4BBF</a>,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R">4G9R</a>,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HCU">4HCU</a>,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EQU">4EQU</a>,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OJJ">2OJJ</a><a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a>). For example, the structure of p38 MAPK kinase bound to a diaryl urea inhibitor (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV1">1KV1</a>) shows that the carbonyl group of the inhibitor forms a hydrogen bond with the backbone NH of Asp168 in the DFG motif. Another example is that the phenol moiety of the xanthine derivative inhibitor makes an H-bond interaction with the backbone NH of Asp764 in the DFG motif of erythropoietin-producing human hepatocellular carcinoma receptor A3 (EPHA3) tyrosine kinase (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GK2">4GK2</a>). H-bonds have also been observed between inhibitors and the side chain of Asp in the DFG motif in some structures. For example, in the structure of cell division cycle 7-related protein kinase (CDC7)/DBF4 protein kinase in complex with the inhibitor, the NH group in the pyridinone moiety of the inhibitor H-bonded with the side chain of Asp196 in the DFG motif (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9B">4F9B</a>). Hydrophobic interactions and π–π interactions have been observed between inhibitors and DFG motifs as well. For example, in the crystal structure of B-Raf<sup>V600E</sup> kinase in complex with the inhibitor (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R">4G9R</a>), the methylquinazoline moiety of the inhibitor makes π–π interactions with the side chain of Phe594 in the DFG motif. In another example, the structure of c-Src kinase in complex with a pyrimidine-based inhibitor (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G6H">3G6H</a>) revealed that the pyridine moiety of the inhibitor forms hydrophobic and π–π interactions with the side chain of Phe405 in the DFG motif. Most inhibitors form the H-bond, hydrophobic interactions, or π–π interactions with the DFG motif of kinases; however, charge interactions formed between the inhibitors and the DFG motif have rarely been observed. Our study demonstrates that the potency of EGFR inhibitors can be improved by targeting the DFG motif. Because the DFG motif plays an important role in the regulation of kinase activity and is highly conserved in almost all protein kinases, our strategy of designing inhibitors specifically to interact with the DFG motif is an effective approach to improve the potency of compounds, both in the initial discovery as well as in the lead optimization phase.</div><div class="NLM_p last">Finally, it is worth noting that although compound <b>4b</b> was designed to target the highly conserved DFG motif, it exhibited high selectivity showing strong inhibition in a relatively small fraction of protein kinases (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Table S2">Supporting Information Table S2</a>). The reasons this selectivity could be achieved with compound <b>4b</b> could be that the DFG motif adopts various conformations in different kinases. As discussed in the previous section, the proper spatial arrangement of <b>4b</b> with the DFG motif of EGFR is critical to the activity of the inhibitor. In the structures of other kinases, the conformation of the DFG motif is distinct from that of EGFR; therefore, the spatial arrangement of compound <b>4b</b> with other kinases will be different from that of EGFR. For example, the structural alignment of the EGFR/<b>4b</b> structure with Janus kinase 1 (JAK1)<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG">3EYG</a>) (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Figure S1A">Supporting Information Figure S1A</a>) revealed that the DFG motif of JAK1 is located far from the <i>N</i>,<i>N</i>-dimethylamino group of <b>4b</b> and could not form charge interactions with the side chain of Asp1021. This would explain, at least partially, the very weak inhibition of compound <b>4b</b> on JAK1 (−14% inhibition at 1 μM of <b>4b</b>). Another reason that compound <b>4b</b> showed selectivity even though it was designed to target the conserved motif could be that other residues within the ATP binding site also affect the binding of the inhibitor, such as the gatekeeper residue. It has been reported that the gatekeeper residue contributes to the selectivity of kinase inhibitors.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> In the protein structure of cyclin-dependent kinase 2 (CDK2) kinase<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a>(PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FIN">1FIN</a>), the gatekeeper residue has a bulky side chain (Phe80) while, in EGFR, the gatekeeper residue has a small side chain (Thr766). Structural alignment of these two structures (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Figure S1B">Supporting Information Figure S1B</a>) revealed that the side chain of Phe80 of CDK2 would cause a steric clash with the ring-1 of <b>4b</b>, which could be the reason for the loss of the inhibitory effect of <b>4b</b> on CDK2 (−4% inhibition at 1 μM of <b>4b</b>). Therefore, if applying the strategy presented in this study to design kinase inhibitors, one should carefully analyze the structures of interest (structures with bound inhibitors are preferable) and take into account the conformation of the DFG motif together with other important structure features, such as the gatekeeper residue, the hinge loop, and the P-loop, to ensure the optimal fit of the designed inhibitor into the binding site.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33362" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33362" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Methods</h3><div class="NLM_p last">All commercial chemicals and solvents are reagent grade and used as supplied unless otherwise noted. All reactions were carried out under an atmosphere of dry nitrogen. Reactions were monitored by TLC using Merck 60 F<sub>254</sub> silica gel glass backed plates (5 cm × 10 cm); zones were detected visually under ultraviolet irradiation (254 nm) or by spraying with phosphomolybdic acid reagent (Aldrich) followed by heating at 80 °C. Flash column chromatography was performed using silica gel (Merck Kieselgel 60, no. 9385, 230–400 mesh ASTM). <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained with a Varian Mercury-300 or Varian Mercury-400 spectrometers. Chemical shifts were recorded in parts per million (ppm, δ) and were reported relative to the solvent peak or TMS. Low-resolution mass spectra (LRMS) data were measured on an Agilent MSD-1100 ESI-MS/MS system. High-resolution mass spectra (HRMS) were measured with a VARIAN 901-MS (FT-ICR Mass) mass spectrometer. Purity of the final compounds was determined using a Hitachi 2000 series HPLC system equipped with a C-18 column (Agilent ZORBAX Eclipse XDB-C18 5 μm, 4.6 mm × 150 mm), using mobile phase A-acetonitrile and mobile phase B-water containing 0.1% formic acid + 10 mmol NH<sub>4</sub>OAc. Elution condition: 0 min phase A 10% + phase B 90%; at 45 min phase A 90% + phase B 10%; at 50 min phase A 10% + phase B 90%; at 60 min phase A 10% + phase B 90%. The flow-rate was 0.5 mL/min, and the injection volume was 5 μL. The system was operated at 25 °C. Peaks were detected at 254 nm. IUPAC nomenclatures of compounds were performed by ACD/Name Pro software. A JASCO P-1020 polarimeter with a sodium lamp was used for the determination of specific rotation at 20 °C.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 4,5-Dichloro-6-phenylfuro[2,3-<i>d</i>]pyrimidine (<b>1b</b>)</h3><div class="NLM_p last">Compounds <b>1b</b> was prepared from <b>1a</b> and <i>N</i>-chlorosuccinimide, in a manner similar to <b>1c</b> reported by us. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.24–7.60 (m, 3 H), 8.15–8.19 (m, 3 H), 8.78(s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 264 ([M + H]<sup>+</sup>). Purity 99.23% (<i>T</i><sub>R</sub> = 42.62 min)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (2<i>S</i>)-2-[(5-Bromo-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl)amino]-2-phenylethanol (<b>2f</b>)</h3><div class="NLM_p">To a solution of compound <b>1c</b> (20.0 g, 64.6 mmol) in EtOH (300 mL) was added Et<sub>3</sub>N (10 mL) and (<i>S</i>)-(+)-2-phenylglycinol (9.6 g, 70.0 mmol) and refluxed for overnight. After cooling to room temperature, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography using a mixture of CH<sub>2</sub>Cl<sub>2</sub>/MeOH (40:1) to give <b>2f</b> (25.86 g, 98%) as a pale-yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl3) δ 3.99–4.13 (m, 2 H), 5.50 (dt, <i>J</i> = 6.6, 4.8 Hz, 1 H), 6.91 (d, <i>J</i> = 6.6 Hz, 1 H), 7.30–7.56 (m, 8 H), 8.06 (dt, <i>J</i> = 6.6, 1.8 Hz, 2 H), 8.34 (s, 1 H).</div><div class="NLM_p last">[α]<sub>D</sub><sup>20</sup> = −223.96° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 410 ([M + H]<sup>+</sup>). HRMS (EI) calcd for C<sub>20</sub>H<sub>16</sub>BrN<sub>3</sub>O<sub>2</sub> (M<sup>+</sup>) 409.0426, found 409.0412. Purity 100.00% (<i>T</i><sub>R</sub> = 36.90 min). Compounds <b>2a</b>–<b>e</b> were prepared from <b>1a</b>–<b>b</b> and corresponding amines in 85–98% yield in a manner similar to <b>2f</b>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (2<i>S</i>)-2-[(5,6-Diphenylfuro[2,3-<i>d</i>]pyrimidin-4-yl)amino]-2-phenylethanol (<b>2a</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:3) was used as the eluent. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.67–3.90 (m, 2 H), 5.26 (td, <i>J</i> = 6.3, 3.6 Hz, 1 H), 5.35 (d, <i>J</i> = 6.3 Hz, 1 H), 6.93–7.09 (m, 2 H), 7.23–7.32 (m, 5 H), 7.47 (br, 5 H), 7.51–7.67 (m, 3 H), 8.37–8.43 (m, 1 H). [α]<sub>D</sub><sup>20</sup><b>=</b> −182.04° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 408 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>26</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub> ([M + H]<sup>+</sup>) 408.1712, found 408.1706. Purity 100.00% (<i>T</i><sub>R</sub> = 38.84 min).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 5,6-Diphenyl-<i>N</i>-[(1<i>R</i>)-1-phenylethyl]furo[2,3-<i>d</i>]pyrimidin-4-amine (<b>2b</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:5) was used as the eluent. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.28 (d, <i>J</i> = 6.9 Hz, 3 H), 4.85 (d, <i>J</i> = 7.5 Hz, 1 H), 5.29–5.34 (m, 1 H), 7.01 (d, <i>J</i> = 7.5 Hz, 2 H), 7.12–7.25 (m, 6 H), 7.36–7.52 (m, 7 H), 8.31 (s, 1 H). [α]<sub>D</sub><sup>20</sup> = −27.46° (<i>c</i> = 0.255 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 392 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>26</sub>H<sub>22</sub>N<sub>3</sub>O ([M + H]<sup>+</sup>) 392.1763, found 392.1751. Purity 99.27% (<i>T</i><sub>R</sub> = 48.69 min).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 5,6-Diphenyl-<i>N</i>-[(1<i>R</i>)-1-phenylpropyl]furo[2,3-<i>d</i>]pyrimidin-4-amine (<b>2c</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:5) was used as the eluent. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.72 (t, <i>J</i> = 7.2 Hz, 3 H), 1.64 (quinetet, <i>J</i> = 7.2 Hz, 3 H), 4.98 (d, <i>J</i> = 8.1 Hz, 1 H), 5.11–5.22 (m, 1 H), 7.04 (d, <i>J</i> = 8.1 Hz, 2 H), 7.15–7.34 (m, 6 H), 7.46–7.68 (m, 7 H), 8.36 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 406 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>27</sub>H<sub>24</sub>N<sub>3</sub>O ([M + H]<sup>+</sup>) 406.1919, found 406.1923. Purity 96.89% (<i>T</i><sub>R</sub> = 50.65 min).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Methyl (2<i>S</i>)-[(5,6-Diphenylfuro[2,3-<i>d</i>]pyrimidin-4-yl)amino](phenyl)ethanoate (<b>2d</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:4) was used as the eluent. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.67 (s, 3 H) 5.64–5.75 (m, 1 H), 5.70 (d, <i>J</i> = 7.2 Hz, 1 H), 5.83 (d, <i>J</i> = 7.2 Hz, 1 H), 7.17–7.36 (m, 8 H), 7.46–7.65 (m, 7 H), 8.39 (s, 1 H). [α]<sub>D</sub><sup>20</sup> = −26.68° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 436 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>27</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 436.1661, found 436.1643. Purity 92.40% (<i>T</i><sub>R</sub> = 38.84 min).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (2<i>S</i>)-2-[(5-Chloro-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl)amino]-2-phenylethanol (<b>2e</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:4) was used as the eluent. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.07 (t, <i>J</i> = 4.5 Hz, 2 H), 5.44–5.56 (m, 1 H), 6.64 (d, <i>J</i> = 6.6 Hz, 1 H), 7.33–7.40 (m, 1 H), 7.40–7.55 (m, 7 H), 8.05 (dd, <i>J</i> = 8.2, 1.2 Hz, 2 H), 8.35 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 366 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>20</sub>H<sub>17</sub>ClN<sub>3</sub>O<sub>2</sub> ([M + H]<sup>+</sup>) 366.1009, found 366.1005. Purity 100.00% (<i>T</i><sub>R</sub> = 36.51 min).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (2<i>S</i>)-2-{[5-(3-Nitrophenyl)-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl]amino}-2-phenylethanol (<b>3d</b>)</h3><div class="NLM_p last">To a solution of compound <b>2f</b> (34.95 g, 85.19 mmol) in dioxane (450 mL) and H<sub>2</sub>O (50 mL) was added 3-nitrophenylboronic acid (21.33 g, 127.78 mmol), Na<sub>2</sub>CO<sub>3</sub> (13.54 g, 127.78 mmol), and Pd(dppf)Cl<sub>2</sub> (6.23 g, 8.52 mmol). The mixture was degassed and then stirred at 100 °C under Ar<sub>(g)</sub> for 2 h. After cooling to rt, solvents were removed under reduced pressure, and H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub> were added to partition. Organic layers were collected, dried over MgSO<sub>4</sub>, filtered, and concentrated, and the residue was purified by silica gel column chromatography using a mixture of CH<sub>2</sub>Cl<sub>2</sub>/MeOH (40:1) to give <b>3d</b> (25.86 g, 98%) as a pale-yellow solid. Compounds <b>3a</b>–<b>c</b>,<b>e</b>–<b>g</b> were prepared from <b>2f</b> and corresponding boronic acid in 60–95% yield in a manner similar to <b>3d</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.27 (t, <i>J</i> = 5.6 Hz, 1 H), 3.85 (t, <i>J</i> = 4.8 Hz, 2 H), 5.16–5.28 (m, 2 H), 7.05–7.13 (m, 2 H), 7.27–7.37 (m, 6 H), 7.46–7.53 (m, 2 H), 7.65 (t, <i>J</i> = 8.0 Hz, 1 H), 7.82 (d, <i>J</i> = 7.6 Hz, 1 H), 8.30 (ddd, <i>J</i> = 8.0, 2.4, 1.2 Hz, 1 H), 8.40 (s, 1 H), 8.41 (s, 1 H). [α]<sub>D</sub><sup>20</sup> = −226.92° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i>: 453 ([M + H]<sup>+</sup>), 475 ([M + Na]<sup>+</sup>). HRMS (EI) calcd for C<sub>26</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub> (M<sup>+</sup>) 452.1485, found 452.1491. Purity 99.78% (<i>T</i><sub>R</sub> = 37.73 min).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (2<i>S</i>)-2-{[5-(Furan-2-yl)-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl]amino}-2-phenylethanol (<b>3a</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:3) was used as the eluent. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.97–4.02 (m, 2 H), 5.37 (td, <i>J</i> = 5.7, 3.9 Hz, H), 6.46–6.54 (m, 2 H), 6.89 (d, <i>J</i> = 5.7 Hz, 1 H), 7.28–7.50 (m, 9 H), 7.66–7.77 (m, 2 H), 8.38 (s, 1 H). [α]<sub>D</sub><sup>20</sup> = −158.12° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i>: 398 ([M + H]<sup>+</sup>). Purity 99.03% (<i>T</i><sub>R</sub> = 37.11 min).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (2<i>S</i>)-2-{[5-(Furan-3-yl)-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl]amino}-2-phenylethanol (<b>3b</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:3) was used as the eluent. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.84–3.96 (m, 2 H), 5.30 (q, <i>J</i> = 5.4 Hz, 1 H), 5.76 (d, <i>J</i> = 6.3 Hz, 1 H), 6.51–6.58 (m, 1 H), 7.13–7.23 (m, 2 H), 7.27–7.41 (m, 6 H), 7.58–7.65 (m, 2 H), 7.65–7.77 (m, 3 H), 8.37 (s, 1 H). [α]<sub>D</sub><sup>20</sup> = −188.04° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 398 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>24</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 398.1505, found 398.1494. Purity 100.00% (<i>T</i><sub>R</sub> = 36.11 min).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (2<i>S</i>)-2-{[5-(1,3-Benzodioxol-5-yl)-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl]amino}-2-phenylethanol (<b>3c</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:3) was used as the eluent. <sup>1</sup>H NMR (300 MHz, CDCl3) δ: 3.85 (d, <i>J</i> = 4.8 Hz, 2 H), 4.18 (br, 1 H), 5.20 (q, <i>J</i> = 5.1 Hz, 1 H), 5.46 (d, <i>J</i> = 4.8 Hz, 1 H), 5.72–6.13 (m, 2 H), 6.9 (br, 3 H), 7.06–7.14 (m, 2 H), 7.27–7.38 (m, 6 H), 7.53–7.67 (m, 2 H), 8.36 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 452 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>27</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub> ([M + H]<sup>+</sup>) 452.1610, found 452.1596. Purity 95.02% (<i>T</i><sub>R</sub> = 37.85 min).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (2<i>S</i>)-2-{[5-(3-Aminophenyl)-6-phenylfuro[2,3-<i>d</i>]pyrimidin-4-yl]amino}-2-phenylethanol (<b>3e</b>)</h3><div class="NLM_p last">A mixture of MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1:30) was used as the eluent. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.69–4.00 (m, 4 H), 5.26 (td, <i>J</i> = 6.4, 3.6 Hz, 1 H), 5.62 (d, <i>J</i> = 5.2 Hz, 1 H), 6.74 (dd, <i>J</i> = 8.0, 1.2 Hz, 2 H), 7.06–7.11 (m, 2 H), 7.27–7.34 (m, 8 H), 7.63 (dd, <i>J</i> = 7.6, 1.6 Hz, 2 H), 8.36 (s, 1 H). [α]<sub>D</sub><sup>20</sup> = −185.04° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i>: 423 ([M + H]<sup>+</sup>). HRMS (EI) calcd for C<sub>26</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> (M<sup>+</sup>) 422.1743, found 422.1728. Purity 99.83%, (<i>T</i><sub>R</sub> = 37.57 min).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-[4-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]acetamide (<b>3f</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:3) was used as the eluent. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.25 (s, 3 H), 3.58–3.92 (m, 3 H), 5.15–5.25 (m, 1 H), 5.42 (d, <i>J</i> = 6.3 Hz, 1 H), 7.04–7.11 (m, 2 H), 7.22–7.36 (m, 5 H), 7.46 (d, <i>J</i> = 8.1 Hz, 2 H), 7.58 (dd, <i>J</i> = 6.6, 3.0 Hz, 5 H), 8.36 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 465 ([M + H]<sup>+</sup>). HRMS (ESI) Ccalcd for C<sub>28</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 465.1927, found 465.1918. Purity 99.09% (<i>T</i><sub>R</sub> = 30.46 min).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]acetamide (<b>3g</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (1:3) was used as the eluent. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.16 (br, 3 H), 3.73 (dd, <i>J</i> = 11.2, 6.4 Hz, 1 H), 3.87 (dd, <i>J</i> = 11.2, 2.4 Hz, 1 H), 5.32 (br, 1 H), 5.58 (br, 1 H), 7.05 (dd, <i>J</i> = 7.2, 2.4 Hz, 2 H), 7.17–7.30 (m, 7 H), 7.42 (t, <i>J</i> = 7.6 Hz, 1 H), 7.49–7.56 (m, 2 H), 7.57–7.71 (m, 2 H), 8.33 (s, 1 H). [α]<sub>D</sub><sup>20</sup> = −283.32° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 465 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>28</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 465.1927, found 465.1915. Purity 100.00% (<i>T</i><sub>R</sub> = 31.00 min).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i><sup>2</sup>,<i>N</i><sup>2</sup>-dimethylglycinamide (<b>4a</b>)</h3><div class="NLM_p last">To a solution of <b>3e</b> (104 mg, 0.25 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added EDCI (80 mg, 0.42 mmol) and 2-(dimethylamino)acetic acid (60 mg, 0.58 mmol) and stirred at rt for 16 h. After the reaction was completed, H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub> were added to partition. Organic layers were collected, dried over MgSO<sub>4</sub>, filtered, and concentrated, and the residue was purified by silica gel column chromatography using a mixture of CH<sub>2</sub>Cl<sub>2</sub>/MeOH (40:1) to give <b>4a</b> (85 mg, 65%) as a white solid. Compounds <b>4b</b>–<b>f</b> were prepared from <b>3e</b> and corresponding carboxylic acid, in 45–73% yield in a manner similar to <b>4a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.34 (s, 6 H), 3.06 (br, 2 H), 3.73 (dd, <i>J</i> = 11.2, 6.4 Hz, 1 H), 3.84 (dd, <i>J</i> = 11.2, 2.8 Hz, 1 H), 5.31 (br, 1 H), 5.55 (br, 1 H), 7.03 (dd, <i>J</i> = 7.6, 1.6 Hz, 2 H), 7.17–7.31 (m, 7 H), 7.44 (t, <i>J</i> = 7.2 Hz, 1 H), 7.45–7.91 (m, 2 H), 7.69 (m, 2 H), 8.35 (s, 1 H), 9.21 (br, 1 H). [α]<sub>D</sub><sup>20</sup> = −25.24° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 508 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>30</sub>H<sub>30</sub>N<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 508.2349, found 508.2342. Purity 97.74% (<i>T</i><sub>R</sub> = 22.64 min).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i><sup>3</sup>,<i>N</i><sup>3</sup>-dimethyl-ß-alaninamide (<b>4b</b>)</h3><div class="NLM_p last">A mixture of MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1:25) was used as the eluent. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.26 (br, 6 H), 2.43 (br, 3 H), 2.58 (br, 3 H), 3.66 (dd, <i>J</i> = 11.2, 6.0 Hz, 1 H), 3.80 (d, <i>J</i> = 11.2 Hz, 1 H), 5.28 (br, 1H), 5.61 (br, 1 H), 6.92–7.04 (m, 2 H), 7.07–7.26 (m, 9 H), 7.34 (t, <i>J</i> = 7.2 Hz, 1 H), 7.47–7.55 (m, 2 H), 7.72 (br, 1 H), 8.29 (s, 1 H). [α]<sub>D</sub><sup>20</sup> = −269.04° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 522 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>31</sub>H<sub>32</sub>N<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 522.2505, found 522.2505. Purity 99.56% (<i>T</i><sub>R</sub> = 23.17 min).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 4-(Dimethylamino)-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]butanamide (<b>4c</b>)</h3><div class="NLM_p last">A mixture of MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1:30) was used as the eluent. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.90 (quinetet, <i>J</i> = 7.6 Hz, 2 H), 2.27 (s, 6 H), 2.37–2.48 (m, 4 H), 3.64 (dd, <i>J</i> = 11.2, 5.2 Hz, 1 H), 3.77 (dd, <i>J</i> = 11.2, 5.2 Hz, 1 H), 5.29 (t, <i>J</i> = 5.2 Hz, 1 H), 7.14–7.20 (m, 2 H), 7.21–7.39 (m, 8 H), 7.53–7.63 (m, 3 H), 7.79 (ddd, <i>J</i> = 8.4, 2.4, 0.8 Hz, 1 H), 7.92 (t, <i>J</i> = 1.6 Hz, 1 H), 8.27 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 536 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>32</sub>H<sub>34</sub>N<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 536.2662, found 536.2642. Purity 88.82% (<i>T</i><sub>R</sub> = 23.03 min).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 5-(Dimethylamino)-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]pentanamide (<b>4d</b>)</h3><div class="NLM_p last">A mixture of MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1:30) was used as the eluent. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.38–1.49 (m, 2 H), 1.56–1.72 (m, 2 H), 1.86 (s, 7 H), 2.02–2.19 (m, 2 H), 2.28 (t, <i>J</i> = 7.2 Hz, 2 H), 3.57 (dd, <i>J</i> = 11.2, 4.4 Hz, 1 H), 3.66 (dd, <i>J</i> = 11.2, 3.2 Hz, 1 H), 5.09–5.19 (m, 1 H), 5.83 (d, <i>J</i> = 7.2 Hz, 1 H), 7.02 (d, <i>J</i> = 7.2 Hz, 2 H), 7.13 (t, <i>J</i> = 7.2 Hz, 2 H), 7.16–7.24 (m, 6 H), 7.35 (t, <i>J</i> = 8.0 Hz, 1 H), 7.42–7.54 (m, 3 H), 7.92 (d, <i>J</i> = 5.6 Hz, 1 H), 8.28 (s, 1 H), 8.73 (br, 1 H). [α]<sub>D</sub><sup>20</sup> = −29.12° (<i>c</i> = 0.245 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 550 ([M + H]<sup>+</sup>). HRMS (ESI) calcd for C<sub>33</sub>H<sub>36</sub>N<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 550.2818, found 550.2824. Purity 97.96% (<i>T</i><sub>R</sub> = 23.37 min).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 6-(Dimethylamino)-<i>N</i>-[3-(4-{[(1<i>S</i>)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]hexanamide (<b>4e</b>)</h3><div class="NLM_p last">A mixture of MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1:30) was used as the eluent. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.20–1.44 (m, 4 H), 1.58 (quinetet, <i>J</i> = 7.2 Hz, 2 H), 2.06 (s, 6 H), 2.13 (t, <i>J</i> = 7.2 Hz, 2 H), 2.31 (t, <i>J</i> = 7.2 Hz, 2 H), 3.38–3.47 (m, 1 H), 3.54–3.62 (m, 1 H), 4.85 (t, <i>J</i> = 4.8 Hz, 1 H), 5.19 (dd, <i>J</i> = 12.4, 4.4 Hz, 1 H), 5.72 (d, <i>J</i> = 7.6 Hz, 1 H), 7.10–7.29 (m, 6 H), 7.30–7.43 (m, 3 H), 7.47–7.59 (m, 3 H), 7.74 (d, <i>J</i> = 8.8 Hz, 1 H), 7.86–7.99 (m, 1 H), 8.23–8.32 (m, 1 H), 10.03–10.15 (m, 1 H). [α]<sub>D</sub><sup>20</sup> = −302.56° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 564 ([M + H]<sup>+</sup>). Purity 94.15% (<i>T</i><sub>R</sub> = 40.18 min).</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-[3-(4-{[(1<i>S</i>)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-<i>d</i>]pyrimidin-5-yl)phenyl]-5-methylhexanamide (<b>4f</b>)</h3><div class="NLM_p last">A mixture of EtOAc/<i>n</i>-hexane (2:3) was used as the eluent. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.89 (d, <i>J</i> = 6.8 Hz, 6H), 1.30–1.20 (m, 2H), 1.77–1.50 (m, 3H), 2.33 (br, 2H), 3.78–3.68 (m, 1H), 3.92–3.82 (m, 1H), 5.35 (br. s., 1H), 5.59 (br, 1H), 7.06 (d, <i>J</i> = 7.6 Hz, 2H), 7.34–7.18 (m, 9H), 7.42 (t, <i>J</i> = 7.6 Hz, 1H), 7.82–7.52 (m, 3H), 8.37 (s, 1H). [α]<sub>D</sub><sup>20</sup> = −261.84° (<i>c</i> = 0.25 in CH<sub>2</sub>Cl<sub>2</sub>). LCMS (ESI) <i>m</i>/<i>z</i> 535 ([M + H]<sup>+</sup>), 557 ([M + Na]<sup>+</sup>). HRMS (ESI) calcd for C<sub>33</sub>H<sub>35</sub>N<sub>4</sub>O<sub>3</sub> ([M + H]<sup>+</sup>) 535.2709, found 535.2711. Purity 100.0% (<i>T</i><sub>R</sub> = 43.66 min).</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> EGFR Kinase Assay</h3><div class="NLM_p last">Wild-type and L834R mutant of human EGFR kinase domain were amplified by PCR and subcloned to pBac-PAK8-GST-EGFR-KD plasmid for generating recombinant baculovirus for protein expression in <i>Spodoptera frugiperda</i> Sf9 cells, separately. The GST fusion proteins were expressed and purified as described previously.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Kinase-Glo luminescent kinase assay was used for determining wild-type and L834R mutant EGFR kinase activity. The assay was first done at 30 °C for 2 h in a 96-well plates with a final volume of 50 μL containing 200 ng of wild-type GST-fusion proteins, 25 mM HEPES, pH 7.4, 4 mM MnCl<sub>2</sub>, 2 mM DTT, 10 mM MgCl<sub>2</sub>, 0.01% bovine serum albumin, 0.02% Triton X-100, 5 μM poly(Glu,Tyr) 4:1, 0.5 mM Na<sub>3</sub>VO<sub>4</sub>, and 10 μM ATP. After incubation, 50 μL of Kinase-Glo Plus reagent (Promega) was added and further incubated at 25 °C for 20 min. Then a 70 μL aliquot of each reaction mixture was transferred to a black mictotiter plate and measured the luminescence by a Wallac Vector 1420 multilabel counter (Perkin-Elmer).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Protein Purification and Crystallography</h3><div class="NLM_p">Co-crystal complex structure determinations were carried out as previously described.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Human EGFR kinase domain were expressed and purified by using a baculovirus/insect cell system. The amplified DNA was subcloned into pBacPAK8-MT-EGFP-GST vector to generate recombinant baculovirus for protein expression. The recombinant protein was large scale production in Hi5 insect cells. The cell pellets were suspended in tris-buffer solution (50 mM Tris-Cl pH8.0, 1 mM DTT) and lysed by sonication. Cell debris was removed by centrifugation at 19000 rpm for 30 min at 4 °C, and supernatant was collected for further purification. The protein was purified by GST affinity column by washed with 1× PBS buffer and eluted with 20 mM GSH in 50 mM Tris-Cl (pH8.0) buffer solution. The eluted protein was exchanged to PreScission protease digestion buffer (50 mM Tris-Cl, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, pH8.0) by desalting column and digested with PreScission protease (GE Healthcare) at 4 °C for 16 h. The GST tag was removed by loading the digested mixture to the second GST affinity column and recovered the fractions of flow-through. The flow-through was then buffer exchanged to final buffer [20 mM Tris-Cl (pH8.0), 100 mM sodium chloride, and 5 mM DTT] and concentrated up to 4–6 mg/mL and flash-frozen in liquid nitrogen for storage at −80 °C.</div><div class="NLM_p last">The purified EGFR kinase domain (4–6 mg/mL) was crystallized by hanging drop vapor diffusion method. The crystals were grown at 18 °C for 3–7 days. The complex crystals were obtained by soaking apo crystals in reservoir solution (1.0 M ammonium citrate tribase, pH7.0, 0.1 M Bis-Tris propane, pH 7.0) containing 0.6–1.0 mM compound. The complex crystals were immersed briefly in 14.3–22.2% glycerol in soaking drop before being flash-frozen in liquid nitrogen. Diffraction data were collected at the NSRRC (beamline BL13B1 and BL13C1) and SPring8 synchrotron facility (beamline BL12B2). The structures were solved by the molecular replacement method MOLREP<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> of the CCP4 program suit<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> using the EGFR structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>) as a search model. The structures were refined by utilizing REFMAC<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> followed by model building with program O<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and AFITT (OpenEye Scientific Software, USA). The completed structure model was optimized by using a PDB_REDO.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The final models were validated using Molprobity.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> All structural figures were generated using PyMOL (Schrödinger, USA).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41"><a href="/doi/suppl/10.1021/jm400072p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Data collection and refinement statistics for X-ray crystallography, kinase profiling of compound <b>4b</b>, overlay of EGFR/<b>4b</b> structure with JAK1 and CDK2. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400072p/suppl_file/jm400072p_si_001.pdf">jm400072p_si_001.pdf (1.0 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ8">4JQ8</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JR3">4JR3</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JRV">4JRV</a>.</p><div class="testing" data-doi="10.1021/jm400072p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hsing-Pang Hsieh</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5d2e282434333a1d33352f3473322f3a73292a7d352d352e3438351d33352f3473322f3a73292a"><span class="__cf_email__" data-cfemail="9feceae6f6f1f8dff1f7edf6b1f0edf8b1ebe8">[email protected]</span> <span class="__cf_email__" data-cfemail="442c342c372d212c042a2c362d6a2b36236a3033">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Su-Ying Wu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2a595f5343444d6a444258430445584d045e5d0a425a4259434f426a444258430445584d045e5d"><span class="__cf_email__" data-cfemail="61121418080f06210f0913084f0e13064f1516">[email protected]</span> <span class="__cf_email__" data-cfemail="9ff7eff7ecf6faf7dff1f7edf6b1f0edf8b1ebe8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Hui Peng</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui-Yi Shiao</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chih-Hsiang Tu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span>; 
    <span class="hlFld-Affiliation affiliation">Institute of Bioinformatics
and Structural Biology, National Tsing Hua University, 101, Sect.
2, Guangfu Road, Hsinchu 300, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pang-Min Liu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Tsu-An Hsu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Prashanth Kumar Amancha</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian-Sung Wu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohane Selvaraj Coumar</span> - <span class="hlFld-Affiliation affiliation">Centre for Bioinformatics, School
of Life Sciences, Pondicherry University, Kalapet, Puducherry 605014,
India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun-Hwa Chen</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sing-Yi Wang</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen-Hsing Lin</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hsu-Yi Sun</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu-Sheng Chao</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology and
Pharmaceutical Research, National Health Research Institutes, 35 Keyan
Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ping-Chiang Lyu</span> - <span class="hlFld-Affiliation affiliation">Institute of Bioinformatics
and Structural Biology, National Tsing Hua University, 101, Sect.
2, Guangfu Road, Hsinchu 300, Taiwan, ROC</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>These authors contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d49e3389-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Grant support was from the National Health Research Institute, Taiwan, ROC, and the National Science Council (grant no. NSC-101-2321-B-400-005 for Drs. Y.S.C. and H.P.H., NSC-101-2113-M-400-002-MY4 for H.P.H., and NSC 99-2113-M-400-002-MY3 for H.Y.S.). We thank the staff of beamline BL13B1and BL13C1 at National Synchrotron Radiation Research Centre (NSRRC), Taiwan, and BL12B2 at SPring-8, Japan, for technical assistance. We also thank Mark Swofford for helping with the English editing.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i45" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i45"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i46" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i46"> Abbreviations Used</h2><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">Asp-Phe-Gly</p></td></tr><tr><td class="NLM_term">TKIs</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr><tr><td class="NLM_term">ILD</td><td class="NLM_def"><p class="first last">interstitial lung disease</p></td></tr><tr><td class="NLM_term">STK10</td><td class="NLM_def"><p class="first last">serine/threonine kinase 10</p></td></tr><tr><td class="NLM_term">EPHA3</td><td class="NLM_def"><p class="first last">erythropoietin-producing human hepatocellular carcinoma receptor A3</p></td></tr><tr><td class="NLM_term">CDC7</td><td class="NLM_def"><p class="first last">cell division cycle 7-related protein kinase</p></td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr><tr><td class="NLM_term">CDK2</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase 2</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 71 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0li5riyCz0u_Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through the “gatekeeper door”: exploiting the active kinase conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2681</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+the+%E2%80%9Cgatekeeper+door%E2%80%9D%3A+exploiting+the+active+kinase+conformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520the%2520%25E2%2580%259Cgatekeeper%2520door%25E2%2580%259D%253A%2520exploiting%2520the%2520active%2520kinase%2520conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2681%26epage%3D2694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0li5riyCz0u_Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Huse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">The conformational plasticity of protein kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2FS0092-8674%2802%2900741-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12015977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=275-282&author=M.+Huseauthor=J.+Kuriyan&title=The+conformational+plasticity+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The conformational plasticity of protein kinases</span></div><div class="casAuthors">Huse, Morgan; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-282</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 48 refs.  Protein kinases operate in a large no. of distinct signaling pathways, where the tight regulation of their catalytic activity is crucial to the development and maintenance of eukaryotic organisms.  The catalytic domains of different kinases adopt strikingly similar structures when they are active.  By contrast, crystal structures of inactive kinases have revealed a marked plasticity in the kinase domain that allows the adoption of distinct conformations in response to interactions with specific regulatory domains or proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJrn7F3h4ej7Vg90H21EOLACvtfcHk0liDcsAWuPrcLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D&md5=cd56edae94ad239f2ce7a5d6c8930cbb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900741-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900741-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuse%26aufirst%3DM.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DThe%2520conformational%2520plasticity%2520of%2520protein%2520kinases%26jtitle%3DCell%26date%3D2002%26volume%3D109%26spage%3D275%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Nagar, B.</span><span> </span><span class="NLM_article-title">c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)</span> <span class="citation_source-journal">J. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">1518S</span><span class="NLM_x">–</span> <span class="NLM_lpage">1523S</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1093%2Fjn%2F137.6.1518S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=17513418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1elur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2007&pages=1518S-1523S&author=B.+Nagar&title=c-Abl+tyrosine+kinase+and+inhibition+by+the+cancer+drug+imatinib+%28Gleevec%2FSTI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)</span></div><div class="casAuthors">Nagar, Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutrition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">6S-1</span>),
    <span class="NLM_cas:pages">1518S-1523S</span>CODEN:
                <span class="NLM_cas:coden">JONUAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-3166</span>.
    
            (<span class="NLM_cas:orgname">American Society for Nutrition</span>)
        </div><div class="casAbstract">The search for specific protein kinase inhibitors is an intense area of research because of the potential for drug development.  The small-mol. inhibitor imatinib (Gleevec/STI-571) can specifically inactivate the tyrosine kinase c-Abl, whose normal mechanism of autoinhibition is disrupted in chronic myelogenous leukemia.  Crystallog. anal. of c-Abl reveals that imatinib recognizes a distinct inactive conformation of the Abl kinase domain that relies on the mechanism of autoinhibition achieved in the context of a larger fragment of the protein.  This mechanism is distinct from that seen in the related Src family kinases, where autoinhibition is achieved through the internal engagement of a C-terminal phosphotyrosine residue by the Src homol. 2 domain (SH2) domain.  Notably, this phosphotyrosine residue is lacking in c-Abl, where instead autoinhibition is mediated by an interaction between the kinase domain and the N-terminal myristoyl modification.  Within the framework of these 2 distinct modes of autoinhibition, the SH3-SH2 unit is structurally conserved between Abl and Src, leading to large conformational differences in their kinase domains.  These differences help explain the ability of imatinib to preferentially inhibit Abl over Src.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbSjfYUuL1FLVg90H21EOLACvtfcHk0liDcsAWuPrcLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1elur4%253D&md5=8c11f5f4abed3ab4b86ad99158ef0d8d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fjn%2F137.6.1518S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjn%252F137.6.1518S%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26atitle%3Dc-Abl%2520tyrosine%2520kinase%2520and%2520inhibition%2520by%2520the%2520cancer%2520drug%2520imatinib%2520%2528Gleevec%252FSTI-571%2529%26jtitle%3DJ.%2520Nutr.%26date%3D2007%26volume%3D137%26spage%3D1518S%26epage%3D1523S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Hubbard, S. R.</span><span> </span><span class="NLM_article-title">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5572</span><span class="NLM_x">–</span> <span class="NLM_lpage">5581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1093%2Femboj%2F16.18.5572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=9312016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFWmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=5572-5581&author=S.+R.+Hubbard&title=Crystal+structure+of+the+activated+insulin+receptor+tyrosine+kinase+in+complex+with+peptide+substrate+and+ATP+analog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span></div><div class="casAuthors">Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5572-5581</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The crystal structure of the phosphorylated, activated form of insulin receptor tyrosine kinase (I) in complex with an 18-residue peptide substrate (KKKLPATGDYMNMSPVGD), and the nonhydrolyzable ATP analog, AMP-PNP, was detd. at 1.9 Å resoln.  The activation loop (A-loop) of I undergoes a major conformational change upon autophosphorylation of Tyr-1158, Tyr-1162, and Tyr-1163 within the loop, resulting in unrestricted access of ATP and protein substrates to the I active site.  Phosphorylated Tyr-1163 (pTyr-1163) was the key phospho-Tyr group in stabilizing the conformation of the tris-phosphorylated A-loop, whereas pTyr-1158 was completely solvent-exposed, suggesting an availability for interaction with downstream signaling proteins.  The YMXM-contg. peptide substrate bound as a short anti-parallel β-strand to the C-terminal end of the A-loop, with the Met side-chains occupying 2 hydrophobic pockets on the C-terminal lobe of I.  The structure thus reveals the mol. basis for insulin receptor activation via autophosphorylation, and provides insights into I substrate specificity and the mechanism of phosphotransfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlJGdy9gorfbVg90H21EOLACvtfcHk0liDcsAWuPrcLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFWmt74%253D&md5=99c1865418541c085220185310b7b533</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.18.5572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.18.5572%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520the%2520activated%2520insulin%2520receptor%2520tyrosine%2520kinase%2520in%2520complex%2520with%2520peptide%2520substrate%2520and%2520ATP%2520analog%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D5572%26epage%3D5581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, W. A.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">746</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2F372746a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=7997262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1994&pages=746-754&author=S.+R.+Hubbardauthor=L.+Weiauthor=L.+Ellisauthor=W.+A.+Hendrickson&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+human+insulin+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span></div><div class="casAuthors">Hubbard, Stevan R.; Wei, Lei; Ellis, Leland; Hendrickson, Wayne A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6508</span>),
    <span class="NLM_cas:pages">746-54</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The x-ray crystal structure of the tyrosine kinase domain of the human insulin receptor has been detd. by multiwavelength anomalous diffraction phasing and refined to 2.1 Å resoln.  The structure reveals the determinants of substrate preference for tyrosine rather than serine or threonine and a novel autoinhibition mechanism whereby one of the tyrosines that is autophosphorylated in response to insulin, Tyr 1162, is bound in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp222kk0byoTrVg90H21EOLACvtfcHk0ljPGU1xnZb4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D&md5=ad60bacc76a642b2957c55ff82274cab</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F372746a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F372746a0%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520human%2520insulin%2520receptor%26jtitle%3DNature%26date%3D1994%26volume%3D372%26spage%3D746%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Sicheri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moarefi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the Src family tyrosine kinase Hck</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">602</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2F385602a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=9024658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2sXht1ymtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=1997&pages=602-609&author=F.+Sicheriauthor=I.+Moarefiauthor=J.+Kuriyan&title=Crystal+structure+of+the+Src+family+tyrosine+kinase+Hck"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the Src family tyrosine kinase Hck</span></div><div class="casAuthors">Sicheri, Frank; Moarefi, Ismail; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">6617</span>),
    <span class="NLM_cas:pages">602-609</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The crystal structure of the hematopoietic cell kinase Hck has been detd. at 2.6/2.9 Å resoln.  Inhibition of enzymic activity is a consequence of intramol. interactions of the enzyme's Src-homol. domains SH2 and SH3, with concomitant displacement of elements of the catalytic domain.  The conformation of the active site has similarities with that of inactive cyclin-dependent protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdo3t4KV6jLVg90H21EOLACvtfcHk0ljPGU1xnZb4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1ymtLs%253D&md5=5703b01ea960313345d43e0f8047ffcf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2F385602a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F385602a0%26sid%3Dliteratum%253Aachs%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DMoarefi%26aufirst%3DI.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520Src%2520family%2520tyrosine%2520kinase%2520Hck%26jtitle%3DNature%26date%3D1997%26volume%3D385%26spage%3D602%26epage%3D609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Common and distinct elements in cellular signaling via EGF and FGF receptors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">1506</span><span class="NLM_x">–</span> <span class="NLM_lpage">1507</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2004&pages=1506-1507&author=J.+Schlessinger&title=Common+and+distinct+elements+in+cellular+signaling+via+EGF+and+FGF+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCommon%2520and%2520distinct%2520elements%2520in%2520cellular%2520signaling%2520via%2520EGF%2520and%2520FGF%2520receptors%26jtitle%3DScience%26date%3D2004%26volume%3D306%26spage%3D1506%26epage%3D1507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G.</span><span> </span><span class="NLM_article-title">ErbB receptors and signaling pathways in cancer</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.ceb.2008.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19208461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVClurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=177-184&author=N.+E.+Hynesauthor=G.+MacDonald&title=ErbB+receptors+and+signaling+pathways+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">ErbB receptors and signaling pathways in cancer</span></div><div class="casAuthors">Hynes, Nancy E.; MacDonald, Gwen</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-184</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ErbB receptor tyrosine kinases play important roles in normal physiol. and in cancer.  Epidermal growth factor receptor (EGFR) and ErbB2 in particular are mutated in many epithelial tumors, and clin. studies suggest that they play roles in cancer development and progression.  These receptors were intensely studied, not only to understand the mechanisms underlying their oncogenic potential, but also to exploit them as therapeutic targets.  ErbB receptors activate a multiplicity of intracellular pathways via their ability to interact with numerous signal transducers.  Furthermore, there are now many ErbB-targeted inhibitors used in the clinic.  In this review we will conc. on breast tumors with ERBB2 gene amplification/receptor overexpression and non-small cell lung cancer (NSCLC) with activating EGFR mutations.  We will discuss data showing the important role that the PI3K/Akt pathway plays, not only in cancer development, but also in response to targeted therapies.  Finally, mechanisms contributing to resistance to ErbB-targeted therapeutics will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0lju0mdtYpbVg90H21EOLACvtfcHk0ljPGU1xnZb4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVClurc%253D&md5=217703dc2eff6a8157ce74a7c100a3fe</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2008.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2008.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DMacDonald%26aufirst%3DG.%26atitle%3DErbB%2520receptors%2520and%2520signaling%2520pathways%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D177%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ernst, E.</span><span> </span><span class="NLM_article-title">Mistletoe for cancer?</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=9-11&author=E.+Ernst&title=Mistletoe+for+cancer%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DE.%26atitle%3DMistletoe%2520for%2520cancer%253F%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D9%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Klapper, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschbaum, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sela, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarden, Y.</span><span> </span><span class="NLM_article-title">Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2000&pages=25-79&author=L.+N.+Klapperauthor=M.+H.+Kirschbaumauthor=M.+Selaauthor=Y.+Yarden&title=Biochemical+and+clinical+implications+of+the+ErbB%2FHER+signaling+network+of+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlapper%26aufirst%3DL.%2BN.%26aulast%3DKirschbaum%26aufirst%3DM.%2BH.%26aulast%3DSela%26aufirst%3DM.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DBiochemical%2520and%2520clinical%2520implications%2520of%2520the%2520ErbB%252FHER%2520signaling%2520network%2520of%2520growth%2520factor%2520receptors%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2000%26volume%3D77%26spage%3D25%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0li3eE-4dLggzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Å resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0li3eE-4dLggzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prichard, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasser, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekele, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. N.</span><span> </span><span class="NLM_article-title">Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F1078-0432.CCR-05-1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=16428506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=600-607&author=S.+Kimauthor=C.+N.+Prichardauthor=M.+N.+Younesauthor=Y.+D.+Yaziciauthor=S.+A.+Jasserauthor=B.+N.+Bekeleauthor=J.+N.+Myers&title=Cetuximab+and+irinotecan+interact+synergistically+to+inhibit+the+growth+of+orthotopic+anaplastic+thyroid+carcinoma+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice</span></div><div class="casAuthors">Kim, Seungwon; Prichard, Christopher N.; Younes, Maher N.; Yazici, Yasemin D.; Jasser, Samar A.; Bekele, B. Nebiyou; Myers, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">600-607</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic thyroid carcinoma (ATC) remains one of the most lethal known human cancers.  Targeted mol. therapy with cetuximab, a monoclonal antibody against epidermal growth factor receptor, offers new treatment potentials for patient with ATC.  Cetuximab has also been reported to have synergistic effects when combined with irinotecan, a topoisomerase inhibitor.  Therefore, we hypothesized that cetuximab and irinotecan would be effective in inhibiting the growth and progression of ATC in a murine orthotopic model.  Exptl. Design: The in vitro antiproliferative effects of cetuximab and irinotecan on ATC cell line ARO were examd.  We also studied the in vivo effects of cetuximab and irinotecan on the growth, invasion, and metastasis of orthotopic ATC tumors in nude mice.  The in vivo antitumor efficacy of cetuximab/irinotecan combination was also compared with that of doxorubicin.  Results: Cetuximab alone did not show any antiproliferative or proapoptotic effect on this cell line.  However, when combined with irinotecan, cetuximab potentiated the in vitro antiproliferative and proapoptotic effect of irinotecan.  Cetuximab, irinotecan, and cetuximab/irinotecan combination resulted in 77%, 79%, and 93% in vivo inhibition of tumor growth, resp.  Incidences of lymph node metastasis, laryngeal invasion, and tumor microvessel d. were also significantly decreased in these treatment groups.  Furthermore, the cetuximab/irinotecan combination was significantly more effective than doxorubicin in inhibiting the growth of orthotopic ATC xenografts.  Conclusions: Combination therapy with cetuximab/irinotecan inhibits the growth and progression of orthotopic ATC xenografts in nude mice.  Given the lack of curative options for patients with ATC, combination therapy with cetuximab and irinotecan treatment warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsHzVhsFHwebVg90H21EOLACvtfcHk0li3eE-4dLggzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlKgsA%253D%253D&md5=90f0a52d3c65268632c168a4cb4b633c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1325%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPrichard%26aufirst%3DC.%2BN.%26aulast%3DYounes%26aufirst%3DM.%2BN.%26aulast%3DYazici%26aufirst%3DY.%2BD.%26aulast%3DJasser%26aufirst%3DS.%2BA.%26aulast%3DBekele%26aufirst%3DB.%2BN.%26aulast%3DMyers%26aufirst%3DJ.%2BN.%26atitle%3DCetuximab%2520and%2520irinotecan%2520interact%2520synergistically%2520to%2520inhibit%2520the%2520growth%2520of%2520orthotopic%2520anaplastic%2520thyroid%2520carcinoma%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D600%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averbuch, S. D.</span><span> </span><span class="NLM_article-title">ZD1839 (‘Iressa’) as an anticancer agent</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=33-40&author=J.+Baselgaauthor=S.+D.+Averbuch&title=ZD1839+%28%E2%80%98Iressa%E2%80%99%29+as+an+anticancer+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26atitle%3DZD1839%2520%2528%25E2%2580%2598Iressa%25E2%2580%2599%2529%2520as%2520an%2520anticancer%2520agent%26jtitle%3DDrugs%26date%3D2000%26volume%3D60%26spage%3D33%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0ljhZvnpQxy1Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12467226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=85-94&author=D.+W.+Rusnakauthor=K.+Lackeyauthor=K.+Affleckauthor=E.+R.+Woodauthor=K.+J.+Alligoodauthor=N.+Rhodesauthor=B.+R.+Keithauthor=D.+M.+Murrayauthor=W.+B.+Knightauthor=R.+J.+Mullinauthor=T.+M.+Gilmer&title=The+effects+of+the+novel%2C+reversible+epidermal+growth+factor+receptor%2FErbB-2+tyrosine+kinase+inhibitor%2C+GW2016%2C+on+the+growth+of+human+normal+and+tumor-derived+cell+lines+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span></div><div class="casAuthors">Rusnak, David W.; Lackey, Karen; Affleck, Karen; Wood, Edgar R.; Alligood, Krystal J.; Rhodes, Nelson; Keith, Barry R.; Murray, Doris M.; Knight, W. Blaine; Mullin, Robert J.; Gilmer, Tona M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) and ErbB-2 transmembrane tyrosine kinases are currently being targeted by various mechanisms in the treatment of cancer.  GW2016 is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, resp.  This report describes the efficacy in cell growth assays of GW2016 on human tumor cell lines overexpressing either EGFR or ErbB-2: HN5 (head and neck), A-431 (vulva), BT474 (breast), CaLu-3 (lung), and N87 (gastric).  Normal human foreskin fibroblasts, nontumorigenic epithelial cells (HB4a), and nonoverexpressing tumor cells (MCF-7 and T47D) were tested as neg. controls.  After 3 days of compd. exposure, av. IC50 values for growth inhibition in the EGFR- and ErbB-2-overexpressing tumor cell lines were <0.16 μM.  The av. selectivity for the tumor cells vs. the human foreskin fibroblast cell line was 100-fold.  Inhibition of EGFR and ErbB-2 receptor autophosphorylation and phosphorylation of the downstream modulator, AKT, was verified by Western blot anal. in the BT474 and HN5 cell lines.  As a measure of cytotoxicity vs. growth arrest, the HN5 and BT474 cells were assessed in an outgrowth assay after a transient exposure to GW2016.  The cells were treated for 3 days in five concns. of GW2016, and cell growth was monitored for an addnl. 12 days after removal of the compd.  In each of these tumor cell lines, concns. of GW2016 were reached where outgrowth did not occur.  Furthermore, growth arrest and cell death were obsd. in parallel expts., as detd. by bromodeoxyuridine incorporation and propidium iodide staining.  GW2016 treatment inhibited tumor xenograft growth of the HN5 and BT474 cells in a dose-responsive manner at 30 and 100 mg/kg orally, twice daily, with complete inhibition of tumor growth at the higher dose.  Together, these results indicate that GW2016 achieves excellent potency on tumor cells with selectivity for tumor vs. normal cells and suggest that GW2016 has value as a therapy for patients with tumors overexpressing either EGFR or ErbB-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5OJ41zsWu6rVg90H21EOLACvtfcHk0ljhZvnpQxy1Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D&md5=64fd8cadce83eda3b9b82ab50f1e57b0</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DMurray%26aufirst%3DD.%2BM.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DThe%2520effects%2520of%2520the%2520novel%252C%2520reversible%2520epidermal%2520growth%2520factor%2520receptor%252FErbB-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520GW2016%252C%2520on%2520the%2520growth%2520of%2520human%2520normal%2520and%2520tumor-derived%2520cell%2520lines%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2001%26volume%3D1%26spage%3D85%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0ljhZvnpQxy1Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Yokoi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaker, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebhun, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3716</span><span class="NLM_x">–</span> <span class="NLM_lpage">3725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3716-3725&author=K.+Yokoiauthor=P.+H.+Thakerauthor=S.+Yaziciauthor=R.+R.+Rebhunauthor=D.+H.+Namauthor=J.+Heauthor=S.+J.+Kimauthor=J.+L.+Abbruzzeseauthor=S.+R.+Hamiltonauthor=I.+J.+Fidler&title=Dual+inhibition+of+epidermal+growth+factor+receptor+and+vascular+endothelial+growth+factor+receptor+phosphorylation+by+AEE788+reduces+growth+and+metastasis+of+human+colon+carcinoma+in+an+orthotopic+nude+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DYazici%26aufirst%3DS.%26aulast%3DRebhun%26aufirst%3DR.%2BR.%26aulast%3DNam%26aufirst%3DD.%2BH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DHamilton%26aufirst%3DS.%2BR.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DDual%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520phosphorylation%2520by%2520AEE788%2520reduces%2520growth%2520and%2520metastasis%2520of%2520human%2520colon%2520carcinoma%2520in%2520an%2520orthotopic%2520nude%2520mouse%2520model%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3716%26epage%3D3725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6186</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F1078-0432.CCR-06-0642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=17062696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6186-6193&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=C.+Yuauthor=F.+R.+Luoauthor=S.+Oppenheimerauthor=H.+Zhangauthor=R.+A.+Smyklaauthor=H.+Mastalerzauthor=B.+E.+Finkauthor=J.+T.+Huntauthor=A.+V.+Gavaiauthor=G.+D.+Vite&title=Preclinical+antitumor+activity+of+BMS-599626%2C+a+pan-HER+kinase+inhibitor+that+inhibits+HER1%2FHER2+homodimer+and+heterodimer+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling</span></div><div class="casAuthors">Wong, Tai W.; Lee, Francis Y.; Yu, Chiang; Luo, Feng R.; Oppenheimer, Simone; Zhang, Hongjian; Smykla, Richard A.; Mastalerz, Harold; Fink, Brian E.; Hunt, John T.; Gavai, Ashvinikumar V.; Vite, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6186-6193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The studies described here are intended to characterize the ability of BMS-599626, a small-mol. inhibitor of the human epidermal growth factor receptor (HER) kinase family, to modulate signaling and growth of tumor cells that depend on HER1 and/or HER2.  Exptl. Design: The potency and selectivity of BMS-599626 were assessed in biochem. assays using recombinant protein kinases, as well as in cell proliferation assays using tumor cell lines with varying degrees of dependence on HER1 or HER2 signaling.  Modulation of receptor signaling was detd. in cell assays by Western blot analyses of receptor autophosphorylation and downstream signaling.  The ability of BMS-599626 to inhibit receptor heterodimer signaling in tumor cells was studied by receptor coimmunopptn.  Antitumor activity of BMS-599626 was evaluated using a no. of different xenograft models that represent a spectrum of human tumors with HER1 or HER2 overexpression.  Results: BMS-599626 inhibited HER1 and HER2 with IC50 of 20 and 30 nmol/L, resp., and was highly selective when tested against a broad panel of diverse protein kinases.  Biochem. studies suggested that BMS-599626 inhibited HER1 and HER2 through distinct mechanisms.  BMS-599626 abrogated HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 μmol/L.  BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors.  In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling.  BMS-599626 had antitumor activity in models that overexpress HER1 (GEO), as well as in models that have HER2 gene amplification (KPL4) or overexpression (Sal2), and there was good correlation between the inhibition of receptor signaling and antitumor activity.  Conclusions: BMS-599626 is a highly selective and potent inhibitor of HER1 and HER2 kinases and inhibits tumor cell proliferation through modulation of receptor signaling.  BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an addnl. mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth.  The preclin. data support the advancement of BMS-599626 into clin. development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgsCF6GDMPbVg90H21EOLACvtfcHk0lihiF20OrguSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK&md5=a8350e2eb304a091fa82f1159e44c119</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0642%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmykla%26aufirst%3DR.%2BA.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DGavai%26aufirst%3DA.%2BV.%26aulast%3DVite%26aufirst%3DG.%2BD.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-599626%252C%2520a%2520pan-HER%2520kinase%2520inhibitor%2520that%2520inhibits%2520HER1%252FHER2%2520homodimer%2520and%2520heterodimer%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6186%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span> </span><span class="NLM_article-title">Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">18756</span><span class="NLM_x">–</span> <span class="NLM_lpage">18765</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1074%2Fjbc.M110.206193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=21454582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=18756-18765&author=K.+Aertgeertsauthor=R.+Skeneauthor=J.+Yanoauthor=B.+C.+Sangauthor=H.+Zouauthor=G.+Snellauthor=A.+Jenningsauthor=K.+Iwamotoauthor=N.+Habukaauthor=A.+Hirokawaauthor=T.+Ishikawaauthor=T.+Tanakaauthor=H.+Mikiauthor=Y.+Ohtaauthor=S.+Sogabe&title=Structural+analysis+of+the+mechanism+of+inhibition+and+allosteric+activation+of+the+kinase+domain+of+HER2+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein</span></div><div class="casAuthors">Aertgeerts, Kathleen; Skene, Robert; Yano, Jason; Sang, Bi-Ching; Zou, Hua; Snell, Gyorgy; Jennings, Andy; Iwamoto, Keiji; Habuka, Noriyuki; Hirokawa, Aki; Ishikawa, Tomoyasu; Tanaka, Toshimasa; Miki, Hiroshi; Ohta, Yoshikazu; Sogabe, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">18756-18765</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is implicated in many human cancers, and HER2 expression is predictive of human disease recurrence and prognosis.  Small mol. kinase inhibitors of EGFR and of both HER2 and EGFR have received approval for the treatment of cancer.  We present the first high resoln. crystal structure of the kinase domain of HER2 in complex with a selective inhibitor to understand protein activation, inhibition, and function at the mol. level.  HER2 kinase domain crystallizes as a dimer and suggests evidence for an allosteric mechanism of activation comparable with previously reported activation mechanisms for EGFR and HER4.  A unique Gly-rich region in HER2 following the α-helix C is responsible for increased conformational flexibility within the active site and could explain the low intrinsic catalytic activity previously reported for HER2.  In addn., we solved the crystal structure of the kinase domain of EGFR in complex with a HER2/EGFR dual inhibitor (TAK-285).  Comparison with previously reported inactive and active EGFR kinase domain structures gave insight into the mechanism of HER2 and EGFR inhibition and may help guide the design and development of new cancer drugs with improved potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomtAlJ0FGUX7Vg90H21EOLACvtfcHk0lihiF20OrguSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL0%253D&md5=c7897f5363d6452f7b60a8ced0f2bc30</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.206193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.206193%26sid%3Dliteratum%253Aachs%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DHirokawa%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DSogabe%26aufirst%3DS.%26atitle%3DStructural%2520analysis%2520of%2520the%2520mechanism%2520of%2520inhibition%2520and%2520allosteric%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520HER2%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D18756%26epage%3D18765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oorui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-<i>d</i>]pyrimidine scaffold</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8030</span><span class="NLM_x">–</span> <span class="NLM_lpage">8050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2008634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8030-8050&author=T.+Ishikawaauthor=M.+Setoauthor=H.+Bannoauthor=Y.+Kawakitaauthor=M.+Ooruiauthor=T.+Taniguchiauthor=Y.+Ohtaauthor=T.+Tamuraauthor=A.+Nakayamaauthor=H.+Mikiauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=N.+Habukaauthor=S.+Sogabeauthor=J.+Yanoauthor=K.+Aertgeertsauthor=K.+Kamiyama&title=Design+and+synthesis+of+novel+human+epidermal+growth+factor+receptor+2+%28HER2%29%2Fepidermal+growth+factor+receptor+%28EGFR%29+dual+inhibitors+bearing+a+pyrrolo%5B3%2C2-d%5Dpyrimidine+scaffold"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold</span></div><div class="casAuthors">Ishikawa, Tomoyasu; Seto, Masaki; Banno, Hiroshi; Kawakita, Youichi; Oorui, Mami; Taniguchi, Takahiko; Ohta, Yoshikazu; Tamura, Toshiya; Nakayama, Akiko; Miki, Hiroshi; Kamiguchi, Hidenori; Tanaka, Toshimasa; Habuka, Noriyuki; Sogabe, Satoshi; Yano, Jason; Aertgeerts, Kathleen; Kamiyama, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8030-8050</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer.  To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivs., e.g. I, capable of fitting into the receptors' ATP binding site.  Among the prepd. compds., I showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity.  The X-ray cocrystal structures of I with both HER2 and EGFR demonstrated that I interacts with the expected residues in their resp. ATP pockets.  Furthermore, reflecting its good oral bioavailability, I exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models.  On the basis of these findings, we report I (TAK-285) as a promising candidate for clin. development as a novel HER2/EGFR dual kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QtqAj6idYrVg90H21EOLACvtfcHk0liCBFpnxB_QJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M&md5=ce030ac133a1c0ff7cb78b269ff85987</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm2008634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008634%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DBanno%26aufirst%3DH.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DOorui%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DKamiyama%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252Fepidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520dual%2520inhibitors%2520bearing%2520a%2520pyrrolo%255B3%252C2-d%255Dpyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8030%26epage%3D8050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+HER-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0liCBFpnxB_QJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520HER-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U S A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liCBFpnxB_QJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U%2520S%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lhZLnJ2RmiVVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Eskens, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mom, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amelsberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fsj.bjc.6604108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=18026190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=80-85&author=F.+A.+Eskensauthor=C.+H.+Momauthor=A.+S.+Plantingauthor=J.+A.+Gietemaauthor=A.+Amelsbergauthor=H.+Huismanauthor=L.+van+Doornauthor=H.+Burgerauthor=P.+Stopferauthor=J.+Verweijauthor=E.+G.+de+Vries&title=A+phase+I+dose+escalation+study+of+BIBW+2992%2C+an+irreversible+dual+inhibitor+of+epidermal+growth+factor+receptor+1+%28EGFR%29+and+2+%28HER2%29+tyrosine+kinase+in+a+2-week+on%2C+2-week+off+schedule+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clin. activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992.  An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was explored.  Thirty-eight patients were enrolled.  Dose levels were 10, 20, 30, 45, 70, 85, and 100 mg.  At 100 mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhea despite treatment with loperamide) occurred in two patients.  In the next-lower dose of 70 mg, DLT (grade 3 fatigue and ALAT elevation) occurred in one of six patients.  An intermediate dose level of 85 mg was studied.  Here DLT occurred in two patients (grade 3 diarrhea despite treatment and grade 2 diarrhea lasting more than 7 days despite treatment).  An addnl. 12 patients were treated at 70 mg.  BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose proportionality.  Pharmacodynamics anal. in skin biopsies did not show significant changes in EGFR-assocd. biomarkers.  However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was obsd.  No partial or complete responses were obsd., stable disease lasting more than four cycles was seen in seven patients.  The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD.  British Journal of Cancer (2008) 98, 80-85. doi:10.1038/sj.bjc.6604108 www.bjcancer.com Published online 20 Nov. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZL8pTnjAwrVg90H21EOLACvtfcHk0lhZLnJ2RmiVVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D&md5=96a0be31145bf1691640109d69ff5dc0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604108%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%26aulast%3DMom%26aufirst%3DC.%2BH.%26aulast%3DPlanting%26aufirst%3DA.%2BS.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26aulast%3DAmelsberg%26aufirst%3DA.%26aulast%3DHuisman%26aufirst%3DH.%26aulast%3Dvan%2BDoorn%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%2520dual%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%25201%2520%2528EGFR%2529%2520and%25202%2520%2528HER2%2529%2520tyrosine%2520kinase%2520in%2520a%25202-week%2520on%252C%25202-week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraemer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1124%2Fjpet.112.197756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22888144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=342-350&author=F.+Solcaauthor=G.+Dahlauthor=A.+Zoephelauthor=G.+Baderauthor=M.+Sandersonauthor=C.+Kleinauthor=O.+Kraemerauthor=F.+Himmelsbachauthor=E.+Haaksmaauthor=G.+R.+Adolf&title=Target+Binding+Properties+and+Cellular+Activity+of+Afatinib+%28BIBW+2992%29%2C+an+Irreversible+ErbB+Family+Blocker"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span></div><div class="casAuthors">Solca, Flavio; Dahl, Goeran; Zoephel, Andreas; Bader, Gerd; Sanderson, Michael; Klein, Christian; Kraemer, Oliver; Himmelsbach, Frank; Haaksma, Eric; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers.  Several targeted drugs have been developed, including antibodies and small-mol. kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions.  Understanding the precise pharmacol. properties of these compds. is important for optimal use in clin. practice.  Afatinib [BIBW 2992; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide] is an ATP-competitive anilinoquinazoline deriv. harboring a reactive acrylamide group.  It was designed to covalently bind and irreversibly block enzymically active ErbB receptor family members.  Here, we show by X-ray crystallog. the covalent binding of afatinib to wild-type epidermal growth factor receptor (EGFR) and by mass spectrometry the covalent interaction with EGFR, EGFRL858R/T790M, human epidermal growth factor receptor 2 (HER2), and ErbB-4.  Afatinib potently inhibits the enzymatic activity of ErbB-4 (EC50 = 1 nM) and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concns. below 100 nM.  N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butanamide (BI 37781), a close analog of afatinib lacking the acrylamide group and thus incapable of covalent bond formation, had similar potency on cells driven by EGFR or EGFRL858R, but less or no detectable activity on cells expressing EGFRL858R/T790M HER2 or ErbB-4.  These results stress the importance of the acrylamide group and show that afatinib differs from approved ErbB targeting agents by irreversibly inhibiting the kinase activity of all ErbB family members.  They provide a mechanistic rationale for the distinct pharmacol. features of this compd. and explain the clin. activity seen in some patients who are resistant to antibody or kinase inhibitor therapy because of secondary mutations or ErbB receptor "reprogramming.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofXgQqaKXv-bVg90H21EOLACvtfcHk0lgOPPkTyMSeKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE&md5=4a57df32abe8101f287fc6251f63f92d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.197756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.197756%26sid%3Dliteratum%253Aachs%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DKraemer%26aufirst%3DO.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DTarget%2520Binding%2520Properties%2520and%2520Cellular%2520Activity%2520of%2520Afatinib%2520%2528BIBW%25202992%2529%252C%2520an%2520Irreversible%2520ErbB%2520Family%2520Blocker%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D342%26epage%3D350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1978</span><span class="NLM_x">–</span> <span class="NLM_lpage">1987</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F1535-7163.MCT-11-0730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22761403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1978-1987&author=O.+Kalousauthor=D.+Conklinauthor=A.+J.+Desaiauthor=N.+A.+O%E2%80%99Brienauthor=C.+Gintherauthor=L.+Andersonauthor=D.+J.+Cohenauthor=C.+D.+Brittenauthor=I.+Taylorauthor=J.+G.+Christensenauthor=D.+J.+Slamonauthor=R.+S.+Finn&title=Dacomitinib+%28PF-00299804%29%2C+an+irreversible+Pan-HER+inhibitor%2C+inhibits+proliferation+of+HER2-amplified+breast+cancer+cell+lines+resistant+to+trastuzumab+and+lapatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib</span></div><div class="casAuthors">Kalous, Ondrej; Conklin, Dylan; Desai, Amrita J.; O'Brien, Neil A.; Ginther, Charles; Anderson, Lee; Cohen, David J.; Britten, Carolyn D.; Taylor, Ian; Christensen, James G.; Slamon, Dennis J.; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1978-1987</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies.  Trastuzumab and lapatinib are std. treatments for HER2-amplified breast cancer, but a significant no. of patients do not respond or develop resistance to these drugs.  Here we evaluate the in vitro activity of dacomitinib (PF-00299804), an irreversible small mol. pan-HER inhibitor, in a large panel of human breast cancer cell lines with variable expression of the HER family receptors and ligands, and with variable sensitivity to trastuzumab and lapatinib.  Forty-seven human breast cancer and immortalized breast epithelial lines representing the known mol. subgroups of breast cancer were treated with dacomitinib to det. IC50 values.  HER2-amplified lines were far more likely to respond to dacomitinib than nonamplified lines (RR, 3.39; P < 0.0001).  Furthermore, HER2 mRNA and protein expression were quant. assocd. with response.  Dacomitinib reduced the phosphorylation of HER2, EGFR, HER4, AKT, and ERK in the majority of sensitive lines.  Dacomitinib exerted its antiproliferative effect through a combined G0-G1 arrest and an induction of apoptosis.  Dacomitinib inhibited growth in several HER2-amplified lines with de novo and acquired resistance to trastuzumab.  Dacomitinib maintained a high activity in lines with acquired resistance to lapatinib.  This study identifies HER2-amplified breast cancer lines as most sensitive to the antiproliferative effect of dacomitinib and provides a strong rationale for its clin. testing in HER2-amplified breast cancers resistant to trastuzumab and lapatinib.  Mol Cancer Ther; 11(9); 1978-87. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp55-QHIJqDk7Vg90H21EOLACvtfcHk0lgOPPkTyMSeKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI&md5=b2b0677cbecb66e1e629742adffb0782</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0730%26sid%3Dliteratum%253Aachs%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DDacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520Pan-HER%2520inhibitor%252C%2520inhibits%2520proliferation%2520of%2520HER2-amplified%2520breast%2520cancer%2520cell%2520lines%2520resistant%2520to%2520trastuzumab%2520and%2520lapatinib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1978%26epage%3D1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seog Heo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbot, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span> </span><span class="NLM_article-title">Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3337</span><span class="NLM_x">–</span> <span class="NLM_lpage">3344</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1200%2FJCO.2011.40.9433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22753918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3337-3344&author=S.+S.+Ramalingamauthor=F.+Blackhallauthor=M.+Krzakowskiauthor=C.+H.+Barriosauthor=K.+Parkauthor=I.+Boverauthor=D.+Seog+Heoauthor=R.+Rosellauthor=D.+C.+Talbotauthor=R.+Frankauthor=S.+P.+Letrentauthor=A.+Ruiz-Garciaauthor=I.+Taylorauthor=J.+Q.+Liangauthor=A.+K.+Campbellauthor=J.+O%E2%80%99Connellauthor=M.+Boyer&title=Randomized+phase+II+study+of+dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-human+epidermal+growth+factor+receptor+inhibitor%2C+versus+erlotinib+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of dacomitinib (PF-00299804), and irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Blackhall, Fiona; Krzakowski, Maciej; Barrios, Carlos H.; Park, Keunchil; Bover, Isabel; Heo, Dae Seog; Rosell, Rafael; Talbot, Denis C.; Frank, Richard; Letrent, Stephen P.; Ruiz-Garcia, Ana; Taylor, Ian; Liang, Jane Q.; Campbell, Alicyn K.; O'Connell, Joseph; Boyer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3337-3344</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR1/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).  Patients and Methods Patients with NSCLC, Eastern Cooperative Oncol. Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily.  Results One hundred eighty-eight patients were randomly assigned.  Treatment arms were balanced for most clin. and mol. characteristics.  Median progression-free survival (PFS; primary end point) was 2.86 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (hazard ratio [HR] = 0.66; 95% CI, 0.47 to 0.91; two-sided P = .012); in patients with KRAS wild-type tumors, median PFS was 3.71 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (HR = 0.55; 95% CI, 0.35 to 0.85; two-sided P = .006); and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 mo for patients treated with dacomitinib and 1.84 mo for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37 to 0.99; two-sided P = .043).  Median overall survival was 9.53 mo for patients treated with dacomitinib and 7.44 mo for patients treated with erlotinib (HR = 0.80; 95% CI, 0.56 to 1.13; two-sided P = .205).  Adverse event-related discontinuations were uncommon in both arms.  Common treatment-related adverse events were dermatol. and gastrointestinal, predominantly grade 1 to 2, and more frequent with dacomitinib.  Conclusion Dacomitinib demonstrated significantly improved PFS vs. erlotinib, with acceptable toxicity.  PFS benefit was obsd. in most clin. and mol. subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHl-bReesXsbVg90H21EOLACvtfcHk0li4l7BiKvBWhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK&md5=bdc76102e0ae37fb3f5307c285f952d4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.9433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.9433%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DKrzakowski%26aufirst%3DM.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DSeog%2BHeo%26aufirst%3DD.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTalbot%26aufirst%3DD.%2BC.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DLetrent%26aufirst%3DS.%2BP.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DJ.%2BQ.%26aulast%3DCampbell%26aufirst%3DA.%2BK.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DM.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-human%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520versus%2520erlotinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3337%26epage%3D3344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Chang, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C. J.</span><span> </span><span class="NLM_article-title">Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.cllc.2012.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22607779" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=55-61&author=S.+C.+Changauthor=C.+Y.+Changauthor=S.+J.+Changauthor=M.+K.+Yuanauthor=Y.+C.+Laiauthor=Y.+C.+Liuauthor=C.+Y.+Chenauthor=L.+C.+Kuoauthor=C.+J.+Yu&title=Gefitinib-Related+Interstitial+Lung+Disease+in+Taiwanese+Patients+With+Non-Small-Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2012.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2012.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DChang%26aufirst%3DS.%2BJ.%26aulast%3DYuan%26aufirst%3DM.%2BK.%26aulast%3DLai%26aufirst%3DY.%2BC.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DKuo%26aufirst%3DL.%2BC.%26aulast%3DYu%26aufirst%3DC.%2BJ.%26atitle%3DGefitinib-Related%2520Interstitial%2520Lung%2520Disease%2520in%2520Taiwanese%2520Patients%2520With%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2012%26volume%3D14%26spage%3D55%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Widakowich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro, G.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Azambuja, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awada, A.</span><span> </span><span class="NLM_article-title">Review: side effects of approved molecular targeted therapies in solid cancers</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1443</span><span class="NLM_x">–</span> <span class="NLM_lpage">1455</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1634%2Ftheoncologist.12-12-1443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=18165622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslSntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1443-1455&author=C.+Widakowichauthor=G.+de+Castroauthor=E.+de+Azambujaauthor=P.+Dinhauthor=A.+Awada&title=Review%3A+side+effects+of+approved+molecular+targeted+therapies+in+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Review: side effects of approved molecular targeted therapies in solid cancers</span></div><div class="casAuthors">Widakowich, Christian; de Castro, Gilberto, Jr.; de Azambuja, Evandro; Dinh, Phuong; Awada, Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1443-1455</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Major advances have been achieved in the field of biol. based therapies for cancer in the last few years, and some of the recently approved mol.-targeted therapies are now being used in daily clin. practice.  These mol. targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function.  In general, targeted mol. therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities.  In this article, we review the toxicity and safety of various small mols. and monoclonal antibodies used in solid tumors, with discussion of the pathophysiol., correlation with response, and strategies for prevention and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQLiiHG_Az7Vg90H21EOLACvtfcHk0li4l7BiKvBWhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslSntb8%253D&md5=56e9026df40a921510114079777e84b7</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-12-1443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-12-1443%26sid%3Dliteratum%253Aachs%26aulast%3DWidakowich%26aufirst%3DC.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26aulast%3Dde%2BAzambuja%26aufirst%3DE.%26aulast%3DDinh%26aufirst%3DP.%26aulast%3DAwada%26aufirst%3DA.%26atitle%3DReview%253A%2520side%2520effects%2520of%2520approved%2520molecular%2520targeted%2520therapies%2520in%2520solid%2520cancers%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1443%26epage%3D1455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Castellino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borts, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowers, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLauchlin, C.</span><span> </span><span class="NLM_article-title">Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=139-150&author=S.+Castellinoauthor=M.+O%E2%80%99Maraauthor=K.+Kochauthor=D.+J.+Bortsauthor=G.+D.+Bowersauthor=C.+MacLauchlin&title=Human+metabolism+of+lapatinib%2C+a+dual+kinase+inhibitor%3A+implications+for+hepatotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCastellino%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Mara%26aufirst%3DM.%26aulast%3DKoch%26aufirst%3DK.%26aulast%3DBorts%26aufirst%3DD.%2BJ.%26aulast%3DBowers%26aufirst%3DG.%2BD.%26aulast%3DMacLauchlin%26aufirst%3DC.%26atitle%3DHuman%2520metabolism%2520of%2520lapatinib%252C%2520a%2520dual%2520kinase%2520inhibitor%253A%2520implications%2520for%2520hepatotoxicity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D139%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span> </span><span class="NLM_article-title">Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC</span> <span class="citation_source-journal">Curr. Treat. Options Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1007%2Fs11864-012-0204-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22833206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A280%3ADC%252BC38fjtV2jsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=516-526&author=C.+M.+Lovlyauthor=L.+Horn&title=Strategies+for+Overcoming+EGFR+Resistance+in+the+Treatment+of+Advanced-Stage+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC</span></div><div class="casAuthors">Lovly Christine M; Horn Leora</div><div class="citationInfo"><span class="NLM_cas:title">Current treatment options in oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">516-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OPINION STATEMENT:  Patients whose tumors harbor somatic-activating mutations within the epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of lung cancers with increased sensitivity to the EGFR tyrosine kinase inhibitors (TKIs), including the "first-generation" reversible inhibitors, erlotinib and gefitinib, and the "second-generation" irreversible inhibitors, afatinib and dacomitinib.  Several, large, phase III studies have shown already that patients with EGFR-mutant tumors display radiographic response rates of >60 % and improved progression free survival (PFS) when treated with an EGFR TKI compared with chemotherapy.  Unfortunately, despite these initial responses, patients inevitably develop progressive disease, a concept referred to clinically as acquired resistance.  Novel strategies are needed to delay or overcome acquired resistance to EGFR TKIs.  These strategies include second-generation EGFR inhibitors, rationale combinations of targeted small molecule inhibitors and/or monoclonal antibodies, and addition of traditional cytotoxic chemotherapy to EGFR TKI therapy at the time of progression.  Unfortunately, to date, there is no genotype-specific standard of care, and enrollment of patients with acquired resistance to EGFR TKIs into clinical trials specifically addressed at overcoming resistance is paramount to continue to advance the field and to improve outcomes for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDoPP1h2yk22yYR5VtavbzfW6udTcc2eZX_ipgGJ-eDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fjtV2jsA%253D%253D&md5=120951d5f7ddca457581fc3421bca772</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs11864-012-0204-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11864-012-0204-6%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHorn%26aufirst%3DL.%26atitle%3DStrategies%2520for%2520Overcoming%2520EGFR%2520Resistance%2520in%2520the%2520Treatment%2520of%2520Advanced-Stage%2520NSCLC%26jtitle%3DCurr.%2520Treat.%2520Options%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D516%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, H.</span><span> </span><span class="NLM_article-title">Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">475</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=466-475&author=N.+Yamamotoauthor=M.+Honmaauthor=H.+Suzuki&title=Off-target+serine%2Fthreonine+kinase+10+inhibition+by+erlotinib+enhances+lymphocytic+activity+leading+to+severe+skin+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DHonma%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DOff-target%2520serine%252Fthreonine%2520kinase%252010%2520inhibition%2520by%2520erlotinib%2520enhances%2520lymphocytic%2520activity%2520leading%2520to%2520severe%2520skin%2520disorders%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D466%26epage%3D475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0lg7V0wV_RIYEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leou, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittimalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span> </span><span class="NLM_article-title">Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4988</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.+Y.+Chuauthor=C.+W.+Linauthor=H.+Y.+Shiaoauthor=Y.+L.+Hoauthor=R.+Reddyauthor=W.+H.+Linauthor=C.+H.+Chenauthor=Y.+H.+Pengauthor=J.+S.+Leouauthor=T.+W.+Lienauthor=C.+T.+Huangauthor=M.+Y.+Fangauthor=S.+H.+Wuauthor=J.+S.+Wuauthor=S.+K.+Chittimallaauthor=J.+S.+Songauthor=J.+T.+Hsuauthor=S.+Y.+Wuauthor=C.+C.+Liaoauthor=Y.+S.+Chaoauthor=H.+P.+Hsieh&title=Fast-forwarding+hit+to+lead%3A+aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Chu, Chang-Ying; Lin, Cheng-Wei; Shiao, Hui-Yi; Ho, Yun-Lung; Reddy, Randheer; Lin, Wen-Hsing; Chen, Chun-Hwa; Peng, Yi-Hui; Leou, Jiun-Shyang; Lien, Tzu-Wen; Huang, Chin-Ting; Fang, Ming-Yu; Wu, Szu-Huei; Wu, Jian-Sung; Chittimalla, Santhosh Kumar; Song, Jen-Shin; Hsu, John T.-A.; Wu, Su-Ying; Liao, Chun-Chen; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4980-4988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Furanopyrimidines such as I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] are prepd. as Aurora A kinase and epidermal growth factor receptor (EGFR) inhibitors by prepn. of a combinatorial library of approx. 350 furanopyridines and optimization of the inhibitors found from the library.  The initial hit compd. I (R = HOCH2CH2; R1 = Ph) was modified to better fit the back pocket to produce the potent Aurora A kinase inhibitor I (R = 4-PhNHCONHC6H4; R1 = Ph) with submicromolar antiproliferative activity in the HCT-116 human colon cancer cell line.  On the basis of docking studies with EGFR hit I [R = (S)-HOCH2CHPh; R1 = Ph], introduction of an acrylamide Michael acceptor group led to I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4], which inhibited both the wild and mutant EGFR kinases and also showed antiproliferative activity in the gefitinib-resistant HCC827 human lung cancer cells.  The X-ray cocrystal structures of I (R = HOCH2CH2, 4-PhNHCONHC6H4; R1 = Ph) bound to Aurora A kinase and the crystal structure of I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] bound to EGFR confirmed their hypothesized binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCOPMtJ1xilrVg90H21EOLACvtfcHk0lhHeDsriEObSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D&md5=8064e99d8d31603c7186b5fa33e019a6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DShiao%26aufirst%3DH.%2BY.%26aulast%3DHo%26aufirst%3DY.%2BL.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DLeou%26aufirst%3DJ.%2BS.%26aulast%3DLien%26aufirst%3DT.%2BW.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DFang%26aufirst%3DM.%2BY.%26aulast%3DWu%26aufirst%3DS.%2BH.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DChittimalla%26aufirst%3DS.%2BK.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DC.%2BC.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DFast-forwarding%2520hit%2520to%2520lead%253A%2520aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Huang, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. F.</span><span> </span><span class="NLM_article-title">High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">8195</span><span class="NLM_x">–</span> <span class="NLM_lpage">8203</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F1078-0432.CCR-04-1245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15623594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGjsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=8195-8203&author=S.+F.+Huangauthor=H.+P.+Liuauthor=L.+H.+Liauthor=Y.+C.+Kuauthor=Y.+N.+Fuauthor=H.+Y.+Tsaiauthor=Y.+T.+Chenauthor=Y.+F.+Linauthor=W.+C.+Changauthor=H.+P.+Kuoauthor=Y.+C.+Wuauthor=Y.+R.+Chenauthor=S.+F.+Tsai&title=High+frequency+of+epidermal+growth+factor+receptor+mutations+with+complex+patterns+in+non-small+cell+lung+cancers+related+to+gefitinib+responsiveness+in+Taiwan"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan</span></div><div class="casAuthors">Huang, Shiu-Feng; Liu, Hui-Ping; Li, Ling-Hui; Ku, Yuan-Chieh; Fu, Yu-Ning; Tsai, Hsien-Yu; Chen, Ya-Ting; Lin, Yung-Feng; Chang, Wen-Cheng; Kuo, Han-Pin; Wu, Yi-Cheng; Chen, Yi-Rong; Tsai, Shih-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8195-8203</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutations related to gefitinib responsiveness in non-small cell lung cancer have been found recently.  Detection of EGFR mutations has become an important issue for therapeutic decision-making in non-small cell lung cancer.  Mutational anal. of the kinase domain of EGFR coding sequence was done on 101 fresh frozen tumor tissues from patients without prior gefitinib treatment and 16 paraffin-embedded tumor tissues from patients treated with gefitinib.  Detection of phosphorylated EGFR by immunoblot was also done on frozen tumor tissues.  The 101 non-small cell lung cancer tumor specimens include 69 adenocarcinomas, 24 squamous cell carcinomas, and 8 other types of non-small cell lung cancers.  Mutation(s) in the kinase domain (exon 18 to exon 21) of the EGFR gene were identified in 39 patients.  All of the mutations occurred in adenocarcinoma, except one that was in an adenosquamous carcinoma.  The mutation rate in adenocarcinoma was 55% (38 of 69).  For the 16 patients treated with gefitinib, 7 of the 9 responders had EGFR mutations, and only 1 of the 7 nonresponders had mutations, which included a nonsense mutation.  The mutations seem to be complex in that altogether 23 different mutations were obsd., and 9 tumors carried 2 mutations.  Data from our study would predict a higher gefitinib response rate in lung adenocarcinoma patients in Chinese and, possibly, other East Asian populations.  The tight assocn. with adenocarcinoma and the high frequency of mutations raise the possibility that EGFR mutations play an important role in the tumorigenesis of adenocarcinoma of lung, esp. in East Asians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQvlewXRMI67Vg90H21EOLACvtfcHk0lhHeDsriEObSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGjsrjK&md5=4908f9d05ea8bb425c1a35f7848964d0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1245%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.%2BF.%26aulast%3DLiu%26aufirst%3DH.%2BP.%26aulast%3DLi%26aufirst%3DL.%2BH.%26aulast%3DKu%26aufirst%3DY.%2BC.%26aulast%3DFu%26aufirst%3DY.%2BN.%26aulast%3DTsai%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DLin%26aufirst%3DY.%2BF.%26aulast%3DChang%26aufirst%3DW.%2BC.%26aulast%3DKuo%26aufirst%3DH.%2BP.%26aulast%3DWu%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BR.%26aulast%3DTsai%26aufirst%3DS.%2BF.%26atitle%3DHigh%2520frequency%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520with%2520complex%2520patterns%2520in%2520non-small%2520cell%2520lung%2520cancers%2520related%2520to%2520gefitinib%2520responsiveness%2520in%2520Taiwan%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D8195%26epage%3D8203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lhHeDsriEObSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Lawrence, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pireddu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gevariya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozcan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elias, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schonbrunn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, N. J.</span><span> </span><span class="NLM_article-title">Development of <i>o</i>-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7392</span><span class="NLM_x">–</span> <span class="NLM_lpage">7416</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300334d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7392-7416&author=H.+R.+Lawrenceauthor=M.+P.+Martinauthor=Y.+Luoauthor=R.+Piredduauthor=H.+Yangauthor=H.+Gevariyaauthor=S.+Ozcanauthor=J.+Y.+Zhuauthor=R.+Kendigauthor=M.+Rodriguezauthor=R.+Eliasauthor=J.+Q.+Chengauthor=S.+M.+Sebtiauthor=E.+Schonbrunnauthor=N.+J.+Lawrence&title=Development+of+o-chlorophenyl+substituted+pyrimidines+as+exceptionally+potent+aurora+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Development of o-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors</span></div><div class="casAuthors">Lawrence, Harshani R.; Martin, Mathew P.; Luo, Yunting; Pireddu, Roberta; Yang, Hua; Gevariya, Harsukh; Ozcan, Sevil; Zhu, Jin-Yi; Kendig, Robert; Rodriguez, Mercedes; Elias, Roy; Cheng, Jin Q.; Sebti, Said M.; Schonbrunn, Ernst; Lawrence, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7392-7416</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The o-carboxylic acid substituted bisanilinopyrimidine I was identified as a potent hit (Aurora A IC50 = 6.1 ± 1.0 nM) from inhouse screening.  Detailed structure-activity relationship (SAR) studies indicated that polar substituents at the para position of the B-ring are crit. for potent activity.  X-ray crystallog. studies revealed that compd. I is a type I inhibitor that binds the Aurora kinase active site in a DFG-in conformation.  Structure-activity guided replacement of the A-ring carboxylic acid with halogens and incorporation of fluorine at the pyrimidine 5-position led to highly potent inhibitors of Aurora A that bind in a DFG-out conformation.  B-Ring modifications were undertaken to improve the soly. and cell permeability.  Compds. such as II with water-solubilizing moieties at the para position of the B-ring inhibited the autophosphorylation of Aurora A in MDA-MB-468 breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeJbI5uTT-4bVg90H21EOLACvtfcHk0ljP5CbEummCZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhsrfN&md5=8158e18d9d2a26dfce7a831a353f333c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm300334d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300334d%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DPireddu%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DGevariya%26aufirst%3DH.%26aulast%3DOzcan%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DKendig%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DElias%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DJ.%2BQ.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DSchonbrunn%26aufirst%3DE.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26atitle%3DDevelopment%2520of%2520o-chlorophenyl%2520substituted%2520pyrimidines%2520as%2520exceptionally%2520potent%2520aurora%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7392%26epage%3D7416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghate, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span> </span><span class="NLM_article-title">X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5217</span><span class="NLM_x">–</span> <span class="NLM_lpage">5220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5217-5220&author=A.+Kuglstatterauthor=M.+Ghateauthor=S.+Tsingauthor=A.+G.+Villasenorauthor=D.+Shawauthor=J.+W.+Barnettauthor=M.+F.+Browner&title=X-ray+crystal+structure+of+JNK2+complexed+with+the+p38alpha+inhibitor+BIRB796%3A+insights+into+the+rational+design+of+DFG-out+binding+MAP+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DGhate%26aufirst%3DM.%26aulast%3DTsing%26aufirst%3DS.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26atitle%3DX-ray%2520crystal%2520structure%2520of%2520JNK2%2520complexed%2520with%2520the%2520p38alpha%2520inhibitor%2520BIRB796%253A%2520insights%2520into%2520the%2520rational%2520design%2520of%2520DFG-out%2520binding%2520MAP%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5217%26epage%3D5220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nature Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0ljP5CbEummCZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNature%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Alevy, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roswit, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heier, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holtzman, M. J.</span><span> </span><span class="NLM_article-title">IL-13-induced airway mucus production is attenuated by MAPK13 inhibition</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">4555</span><span class="NLM_x">–</span> <span class="NLM_lpage">4568</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=4555-4568&author=Y.+G.+Alevyauthor=A.+C.+Patelauthor=A.+G.+Romeroauthor=D.+A.+Patelauthor=J.+Tuckerauthor=W.+T.+Roswitauthor=C.+A.+Millerauthor=R.+F.+Heierauthor=D.+E.+Byersauthor=T.+J.+Brettauthor=M.+J.+Holtzman&title=IL-13-induced+airway+mucus+production+is+attenuated+by+MAPK13+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlevy%26aufirst%3DY.%2BG.%26aulast%3DPatel%26aufirst%3DA.%2BC.%26aulast%3DRomero%26aufirst%3DA.%2BG.%26aulast%3DPatel%26aufirst%3DD.%2BA.%26aulast%3DTucker%26aufirst%3DJ.%26aulast%3DRoswit%26aufirst%3DW.%2BT.%26aulast%3DMiller%26aufirst%3DC.%2BA.%26aulast%3DHeier%26aufirst%3DR.%2BF.%26aulast%3DByers%26aufirst%3DD.%2BE.%26aulast%3DBrett%26aufirst%3DT.%2BJ.%26aulast%3DHoltzman%26aufirst%3DM.%2BJ.%26atitle%3DIL-13-induced%2520airway%2520mucus%2520production%2520is%2520attenuated%2520by%2520MAPK13%2520inhibition%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D4555%26epage%3D4568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranjitkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasap, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maly, D. J.</span><span> </span><span class="NLM_article-title">Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2384</span><span class="NLM_x">–</span> <span class="NLM_lpage">2392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F0008-5472.CAN-08-3953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19276351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFyqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2384-2392&author=M.+A.+Seeligerauthor=P.+Ranjitkarauthor=C.+Kasapauthor=Y.+Shanauthor=D.+E.+Shawauthor=N.+P.+Shahauthor=J.+Kuriyanauthor=D.+J.+Maly&title=Equally+potent+inhibition+of+c-Src+and+Abl+by+compounds+that+recognize+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations</span></div><div class="casAuthors">Seeliger, Markus A.; Ranjitkar, Pratistha; Kasap, Corynn; Shan, Yibing; Shaw, David E.; Shah, Neil P.; Kuriyan, John; Maly, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2384-2392</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Imatinib is an inhibitor of the Abl tyrosine kinase domain that is effective in the treatment of chronic myelogenic leukemia.  Although imatinib binds tightly to the Abl kinase domain, its affinity for the closely related kinase domain of c-Src is at least 2,000-fold lower.  Imatinib recognition requires a specific inactive conformation of the kinase domain, in which a conserved Asp-Phe-Gly (DFG) motif is flipped with respect to the active conformation.  The inability of c-Src to readily adopt this flipped DFG conformation was thought to underlie the selectivity of imatinib for Abl over c-Src.  Here, we present a series of inhibitors (DSA compds.) that are based on the core scaffold of imatinib but which bind with equally high potency to c-Src and Abl.  The DSA compds. bind to c-Src in the DFG-flipped conformation, as confirmed by crystal structures and kinetic anal.  The origin of the high affinity of these compds. for c-Src is suggested by the fact that they also inhibit clin. relevant Abl variants bearing mutations in a structural element, the P-loop, that normally interacts with the phosphate groups of ATP but is folded over a substructure of imatinib in Abl.  Importantly, several of the DSA compds. block the growth of Ba/F3 cells harboring imatinib-resistant BCR-ABL mutants, including the Thr315Ile "gatekeeper" mutation, but do not suppress the growth of parental Ba/F3 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjllvXItGitrVg90H21EOLACvtfcHk0lgNf7DgoEAn0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFyqtb0%253D&md5=d6e719acb5b216c073d79c242d15f587</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-3953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-3953%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DRanjitkar%26aufirst%3DP.%26aulast%3DKasap%26aufirst%3DC.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DEqually%2520potent%2520inhibition%2520of%2520c-Src%2520and%2520Abl%2520by%2520compounds%2520that%2520recognize%2520inactive%2520kinase%2520conformations%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D2384%26epage%3D2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=17355866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Caoauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=c-Src+binds+to+the+cancer+drug+imatinib+with+an+inactive+Abl%2Fc-Kit+conformation+and+a+distributed+thermodynamic+penalty"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span></div><div class="casAuthors">Seeliger, Markus A.; Nagar, Bhushan; Frank, Filipp; Cao, Xiaoxian; Henderson, M. Nidanie; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-311</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor.  Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src.  The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl•imatinib and c-Kit•imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases.  Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodn. penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure.  Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2SQGjjXdg1LVg90H21EOLACvtfcHk0lgNf7DgoEAn0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D&md5=ddfbcf06d91b408ca5fb25af9774c334</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520imatinib%2520with%2520an%2520inactive%2520Abl%252Fc-Kit%2520conformation%2520and%2520a%2520distributed%2520thermodynamic%2520penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26spage%3D299%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Hodous, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaffee, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span> </span><span class="NLM_article-title">Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2886</span><span class="NLM_x">–</span> <span class="NLM_lpage">2889</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2886-2889&author=B.+L.+Hodousauthor=S.+D.+Geuns-Meyerauthor=P.+E.+Hughesauthor=B.+K.+Albrechtauthor=S.+Bellonauthor=S.+Caenepeelauthor=V.+J.+Ceeauthor=S.+C.+Chaffeeauthor=M.+Emeryauthor=J.+Fretlandauthor=P.+Gallantauthor=Y.+Guauthor=R.+E.+Johnsonauthor=J.+L.+Kimauthor=A.+M.+Longauthor=M.+Morrisonauthor=P.+R.+Olivieriauthor=V.+F.+Patelauthor=A.+Polverinoauthor=P.+Roseauthor=L.+Wangauthor=H.+Zhao&title=Synthesis%2C+structural+analysis%2C+and+SAR+studies+of+triazine+derivatives+as+potent%2C+selective+Tie-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%2BD.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DR.%2BE.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DP.%2BR.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DRose%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DSynthesis%252C%2520structural%2520analysis%252C%2520and%2520SAR%2520studies%2520of%2520triazine%2520derivatives%2520as%2520potent%252C%2520selective%2520Tie-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2886%26epage%3D2889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Hodous, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaffee, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tempest, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span> </span><span class="NLM_article-title">Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061107l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=611-626&author=B.+L.+Hodousauthor=S.+D.+Geuns-Meyerauthor=P.+E.+Hughesauthor=B.+K.+Albrechtauthor=S.+Bellonauthor=J.+Breadyauthor=S.+Caenepeelauthor=V.+J.+Ceeauthor=S.+C.+Chaffeeauthor=A.+Coxonauthor=M.+Emeryauthor=J.+Fretlandauthor=P.+Gallantauthor=Y.+Guauthor=D.+Hoffmanauthor=R.+E.+Johnsonauthor=R.+Kendallauthor=J.+L.+Kimauthor=A.+M.+Longauthor=M.+Morrisonauthor=P.+R.+Olivieriauthor=V.+F.+Patelauthor=A.+Polverinoauthor=P.+Roseauthor=P.+Tempestauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=H.+Zhao&title=Evolution+of+a+highly+selective+and+potent+2-%28pyridin-2-yl%29-1%2C3%2C5-triazine+Tie-2+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm061107l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061107l%26sid%3Dliteratum%253Aachs%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%2BD.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BE.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DP.%2BR.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DRose%26aufirst%3DP.%26aulast%3DTempest%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DEvolution%2520of%2520a%2520highly%2520selective%2520and%2520potent%25202-%2528pyridin-2-yl%2529-1%252C3%252C5-triazine%2520Tie-2%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D611%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Hughes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elustondo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fonzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroux, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snijders, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherepanov, P.</span><span> </span><span class="NLM_article-title">Crystal structure of human CDC7 kinase in complex with its activator DBF4</span> <span class="citation_source-journal">Nature Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1101</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fnsmb.2404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=23064647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1101-1107&author=S.+Hughesauthor=F.+Elustondoauthor=A.+Di+Fonzoauthor=F.+G.+Lerouxauthor=A.+C.+Wongauthor=A.+P.+Snijdersauthor=S.+J.+Matthewsauthor=P.+Cherepanov&title=Crystal+structure+of+human+CDC7+kinase+in+complex+with+its+activator+DBF4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human CDC7 kinase in complex with its activator DBF4</span></div><div class="casAuthors">Hughes, Siobhan; Elustondo, Frederic; Di Fonzo, Andrea; Leroux, Frederic G.; Wong, Ai C.; Snijders, Ambrosius P.; Matthews, Stephen J.; Cherepanov, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1101-1107</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CDC7 is a serine/threonine kinase that is essential for the initiation of eukaryotic DNA replication.  CDC7 kinase activity is controlled by its activator, DBF4 protein.  Here, the authors present crystal structures of human CDC7-DBF4 in complex with a nucleotide or ATP-competing small mols., revealing the active and inhibited forms of the kinase, resp.  DBF4 wraps around CDC7, burying ∼6000 Å2 of hydrophobic mol. surface in a bipartite interface.  The effector domain of DBF4, contg. conserved motif C, was essential and sufficient to support CDC7 kinase activity by binding to the kinase N-terminal lobe and stabilizing its canonical αC helix.  DBF4 motif M latched onto the C-terminal lobe of the kinase, acting as a tethering domain.  Thus, these results elucidate the structural basis for binding to and activation of CDC7 by DBF4 and provide a framework for the design of more potent and specific CDC7 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogBhfM_xlMUrVg90H21EOLACvtfcHk0liydcDEJgT8CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rs7bJ&md5=7fc035d6838590b31d21d59920477a40</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2404%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DS.%26aulast%3DElustondo%26aufirst%3DF.%26aulast%3DDi%2BFonzo%26aufirst%3DA.%26aulast%3DLeroux%26aufirst%3DF.%2BG.%26aulast%3DWong%26aufirst%3DA.%2BC.%26aulast%3DSnijders%26aufirst%3DA.%2BP.%26aulast%3DMatthews%26aufirst%3DS.%2BJ.%26aulast%3DCherepanov%26aufirst%3DP.%26atitle%3DCrystal%2520structure%2520of%2520human%2520CDC7%2520kinase%2520in%2520complex%2520with%2520its%2520activator%2520DBF4%26jtitle%3DNature%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1101%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Echalier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camasses, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodimont, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheinerman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasinska, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D.</span><span> </span><span class="NLM_article-title">An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1028</span><span class="NLM_x">–</span> <span class="NLM_lpage">1040</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.chembiol.2012.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22921070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kku7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1028-1040&author=A.+Echalierauthor=E.+Cotauthor=A.+Camassesauthor=E.+Hodimontauthor=F.+Hohauthor=P.+Jayauthor=F.+Sheinermanauthor=L.+Krasinskaauthor=D.+Fisher&title=An+integrated+chemical+biology+approach+provides+insight+into+Cdk2+functional+redundancy+and+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Chemical Biology Approach Provides Insight into Cdk2 Functional Redundancy and Inhibitor Sensitivity</span></div><div class="casAuthors">Echalier, Aude; Cot, Emilie; Camasses, Alain; Hodimont, Elsie; Hoh, Francois; Jay, Philippe; Sheinerman, Felix; Krasinska, Liliana; Fisher, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1028-1040</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cdk2 promotes DNA replication and is a promising cancer therapeutic target, but its functions appear redundant with Cdk1, an essential Cdk affected by most Cdk2 inhibitors.  Here, we present an integrated multidisciplinary approach to address Cdk redundancy.  Math. modeling of enzymol. data predicted conditions allowing selective chem. Cdk2 inhibition.  Together with expts. in Xenopus egg exts., this supports a rate-limiting role for Cdk2 in DNA replication.  To confirm this we designed inhibitor-resistant (ir)-Cdk2 mutants using a novel bioinformatics approach.  Bypassing inhibition with ir-Cdk2 or with Cdk1 shows that Cdk2 is rate-limiting for replication in this system because Cdk1 is insufficiently active.  Addnl., crystal structures and kinetics reveal alternative binding modes of Cdk1-selective and Cdk2-selective inhibitors and mechanisms of Cdk2 inhibitor resistance.  Our approach thus provides insight into structure, functions, and biochem. of a cyclin-dependent kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRa9UiVuPpOLVg90H21EOLACvtfcHk0liydcDEJgT8CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kku7zN&md5=d134c52fd1ad5442e07bec46a3edd9be</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DCot%26aufirst%3DE.%26aulast%3DCamasses%26aufirst%3DA.%26aulast%3DHodimont%26aufirst%3DE.%26aulast%3DHoh%26aufirst%3DF.%26aulast%3DJay%26aufirst%3DP.%26aulast%3DSheinerman%26aufirst%3DF.%26aulast%3DKrasinska%26aufirst%3DL.%26aulast%3DFisher%26aufirst%3DD.%26atitle%3DAn%2520integrated%2520chemical%2520biology%2520approach%2520provides%2520insight%2520into%2520Cdk2%2520functional%2520redundancy%2520and%2520inhibitor%2520sensitivity%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1028%26epage%3D1040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Hole, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E.</span><span> </span><span class="NLM_article-title">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+Structural+and+Functional+Studies+of+4-%28Thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+Inhibitors+Suggest+the+Basis+for+Isotype+Selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520Structural%2520and%2520Functional%2520Studies%2520of%25204-%2528Thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520Inhibitors%2520Suggest%2520the%2520Basis%2520for%2520Isotype%2520Selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Lafleur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevado, C.</span><span> </span><span class="NLM_article-title">Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301187e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=84-96&author=K.+Lafleurauthor=J.+Dongauthor=D.+Huangauthor=A.+Caflischauthor=C.+Nevado&title=Optimization+of+inhibitors+of+the+tyrosine+kinase+EphB4.+2.+Cellular+potency+improvement+and+binding+mode+validation+by+X-ray+crystallography"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Inhibitors of the Tyrosine Kinase EphB4. 2. Cellular Potency Improvement and Binding Mode Validation by X-ray Crystallography</span></div><div class="casAuthors">Lafleur, Karine; Dong, Jing; Huang, Danzhi; Caflisch, Amedeo; Nevado, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-96</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the tyrosine kinase erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) is an effective strategy for the treatment of solid tumors.  We have previously reported a low nanomolar ATP-competitive inhibitor of EphB4 discovered in silico by fragment-based high-throughput docking combined with explicit solvent mol. dynamics simulations.  Here we present a second generation of EphB4 inhibitors that show high inhibitory potency in both enzymic and cell-based assays while preserving the appealing selectivity profile exhibited by the parent compd.  In addn., respectable levels of antiproliferative activity for these compds. have been obtained.  Finally, the binding mode predicted by docking and mol. dynamics simulations is validated by solving the crystal structures of three members of this chem. class in complex with the EphA3 tyrosine kinase whose ATP-binding site is essentially identical to that of EphB4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbStxb4nLqLbVg90H21EOLACvtfcHk0liydcDEJgT8CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurzJ&md5=219d526caaa60798b7c9fe0bb88a48fa</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm301187e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301187e%26sid%3Dliteratum%253Aachs%26aulast%3DLafleur%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DNevado%26aufirst%3DC.%26atitle%3DOptimization%2520of%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%25202.%2520Cellular%2520potency%2520improvement%2520and%2520binding%2520mode%2520validation%2520by%2520X-ray%2520crystallography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D84%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Tsuhako, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koltun, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aay, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcalas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franzini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaharia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">The design, synthesis, and biological evaluation of PIM kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3732</span><span class="NLM_x">–</span> <span class="NLM_lpage">3738</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3732-3738&author=A.+L.+Tsuhakoauthor=D.+S.+Brownauthor=E.+S.+Koltunauthor=N.+Aayauthor=A.+Arcalasauthor=V.+Chanauthor=H.+Duauthor=S.+Engstauthor=M.+Franziniauthor=A.+Galanauthor=P.+Huangauthor=S.+Johnstonauthor=B.+Kaneauthor=M.+H.+Kimauthor=A.+D.+Lairdauthor=R.+Linauthor=L.+Mockauthor=I.+Nganauthor=M.+Packauthor=G.+Stottauthor=T.+J.+Stoutauthor=P.+Yuauthor=C.+Zahariaauthor=W.+Zhangauthor=P.+Zhouauthor=J.+M.+Nussauthor=P.+C.+Kearneyauthor=W.+Xu&title=The+design%2C+synthesis%2C+and+biological+evaluation+of+PIM+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsuhako%26aufirst%3DA.%2BL.%26aulast%3DBrown%26aufirst%3DD.%2BS.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DArcalas%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DDu%26aufirst%3DH.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DFranzini%26aufirst%3DM.%26aulast%3DGalan%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DKane%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DNgan%26aufirst%3DI.%26aulast%3DPack%26aufirst%3DM.%26aulast%3DStott%26aufirst%3DG.%26aulast%3DStout%26aufirst%3DT.%2BJ.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DZaharia%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DKearney%26aufirst%3DP.%2BC.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DThe%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520PIM%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3732%26epage%3D3738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4054</span><span class="NLM_x">–</span> <span class="NLM_lpage">4058</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.bmcl.2011.04.124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=21636270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4054-4058&author=S.+T.+Stabenauthor=M.+Siuauthor=R.+Goldsmithauthor=A.+G.+Oliveroauthor=S.+Doauthor=D.+J.+Burdickauthor=T.+P.+Heffronauthor=J.+Dotsonauthor=D.+P.+Sutherlinauthor=B.+Y.+Zhuauthor=V.+Tsuiauthor=H.+Leauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=L.+Rougeauthor=D.+Sampathauthor=S.+Siderisauthor=C.+Wiesmannauthor=P.+Wu&title=Structure-based+design+of+thienobenzoxepin+inhibitors+of+PI3-kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span></div><div class="casAuthors">Staben, Steven T.; Siu, Michael; Goldsmith, Richard; Olivero, Alan G.; Do, Steven; Burdick, Daniel J.; Heffron, Timothy P.; Dotson, Jenna; Sutherlin, Daniel P.; Zhu, Bing-Yan; Tsui, Vickie; Le, Hoa; Lee, Leslie; Lesnick, John; Lewis, Cristina; Murray, Jeremy M.; Nonomiya, Jim; Pang, Jodie; Prior, Wei Wei; Salphati, Laurent; Rouge, Lionel; Sampath, Deepak; Sideris, Steve; Wiesmann, Christian; Wu, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4054-4058</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from thienobenzopyran HTS hit 1 (I), co-crystn., mol. modeling and metabolic anal. were used to design potent and metabolically stable inhibitors of PI3-kinase.  Compd. 15 demonstrated PI3K pathway suppression in a mouse MCF7 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5PrbzVKCkbVg90H21EOLACvtfcHk0lhdI3S3xk3Xrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLs%253D&md5=9b807be1ac4093a6f139c0304757037a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.124%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DZhu%26aufirst%3DB.%2BY.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520of%2520thienobenzoxepin%2520inhibitors%2520of%2520PI3-kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4054%26epage%3D4058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Fugel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberholzer, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschloessl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dzikowski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pressburger, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okun, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerig, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruggel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemcke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunick, C.</span><span> </span><span class="NLM_article-title">3,6-Diamino-4-(2-halophenyl)-2-benzoylthieno[2,3-<i>b</i>]pyridine-5-carbonitriles are selective inhibitors of <i>Plasmodium falciparum</i> glycogen synthase kinase-3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301575n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=264-275&author=W.+Fugelauthor=A.+E.+Oberholzerauthor=B.+Gschloesslauthor=R.+Dzikowskiauthor=N.+Pressburgerauthor=L.+Preuauthor=L.+H.+Pearlauthor=B.+Baratteauthor=M.+Ratinauthor=I.+Okunauthor=C.+Doerigauthor=S.+Kruggelauthor=T.+Lemckeauthor=L.+Meijerauthor=C.+Kunick&title=3%2C6-Diamino-4-%282-halophenyl%29-2-benzoylthieno%5B2%2C3-b%5Dpyridine-5-carbonitriles+are+selective+inhibitors+of+Plasmodium+falciparum+glycogen+synthase+kinase-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm301575n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301575n%26sid%3Dliteratum%253Aachs%26aulast%3DFugel%26aufirst%3DW.%26aulast%3DOberholzer%26aufirst%3DA.%2BE.%26aulast%3DGschloessl%26aufirst%3DB.%26aulast%3DDzikowski%26aufirst%3DR.%26aulast%3DPressburger%26aufirst%3DN.%26aulast%3DPreu%26aufirst%3DL.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DBaratte%26aufirst%3DB.%26aulast%3DRatin%26aufirst%3DM.%26aulast%3DOkun%26aufirst%3DI.%26aulast%3DDoerig%26aufirst%3DC.%26aulast%3DKruggel%26aufirst%3DS.%26aulast%3DLemcke%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKunick%26aufirst%3DC.%26atitle%3D3%252C6-Diamino-4-%25282-halophenyl%2529-2-benzoylthieno%255B2%252C3-b%255Dpyridine-5-carbonitriles%2520are%2520selective%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520glycogen%2520synthase%2520kinase-3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D264%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspnes, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagley, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brosius, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckbinder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dibrino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffor, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimaraes, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman-Perez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klug-McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Irizarry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southers, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawistoski, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span> </span><span class="NLM_article-title">Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7523</span><span class="NLM_x">–</span> <span class="NLM_lpage">7529</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7523-7529&author=S.+K.+Bhattacharyaauthor=G.+E.+Aspnesauthor=S.+W.+Bagleyauthor=M.+Boehmauthor=A.+D.+Brosiusauthor=L.+Buckbinderauthor=J.+S.+Changauthor=J.+Dibrinoauthor=H.+Engauthor=K.+S.+Frederickauthor=D.+A.+Griffithauthor=M.+C.+Grifforauthor=C.+R.+Guimaraesauthor=A.+Guzman-Perezauthor=S.+Hanauthor=A.+S.+Kalgutkarauthor=J.+Klug-McLeodauthor=C.+Garcia-Irizarryauthor=J.+Liauthor=B.+Lippaauthor=D.+A.+Priceauthor=J.+A.+Southersauthor=D.+P.+Walkerauthor=L.+Weiauthor=J.+Xiaoauthor=M.+P.+Zawistoskiauthor=X.+Zhao&title=Identification+of+novel+series+of+pyrazole+and+indole-urea+based+DFG-out+PYK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DAspnes%26aufirst%3DG.%2BE.%26aulast%3DBagley%26aufirst%3DS.%2BW.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DBrosius%26aufirst%3DA.%2BD.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DDibrino%26aufirst%3DJ.%26aulast%3DEng%26aufirst%3DH.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DGuimaraes%26aufirst%3DC.%2BR.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DGarcia-Irizarry%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DSouthers%26aufirst%3DJ.%2BA.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DZhao%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520novel%2520series%2520of%2520pyrazole%2520and%2520indole-urea%2520based%2520DFG-out%2520PYK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7523%26epage%3D7529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Forsyth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aay, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcalas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epshteyn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koltun, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyr, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridgway, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gendreau, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassees, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolfrey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span> </span><span class="NLM_article-title">SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7653</span><span class="NLM_x">–</span> <span class="NLM_lpage">7658</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7653-7658&author=T.+Forsythauthor=P.+C.+Kearneyauthor=B.+G.+Kimauthor=H.+W.+Johnsonauthor=N.+Aayauthor=A.+Arcalasauthor=D.+S.+Brownauthor=V.+Chanauthor=J.+Chenauthor=H.+Duauthor=S.+Epshteynauthor=A.+A.+Galanauthor=T.+P.+Huynhauthor=M.+A.+Ibrahimauthor=B.+Kaneauthor=E.+S.+Koltunauthor=G.+Mannauthor=L.+E.+Meyrauthor=M.+S.+Leeauthor=G.+L.+Lewisauthor=R.+T.+Noguchiauthor=M.+Packauthor=B.+H.+Ridgwayauthor=X.+Shiauthor=C.+S.+Takeuchiauthor=P.+Zuauthor=J.+W.+Leahyauthor=J.+M.+Nussauthor=R.+Aoyamaauthor=S.+Engstauthor=S.+B.+Gendreauauthor=R.+Kasseesauthor=J.+Liauthor=S.+H.+Linauthor=J.+F.+Martiniauthor=T.+Stoutauthor=P.+Tongauthor=J.+Woolfreyauthor=W.+Zhangauthor=P.+Yu&title=SAR+and+in+vivo+evaluation+of+4-aryl-2-aminoalkylpyrimidines+as+potent+and+selective+Janus+kinase+2+%28JAK2%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForsyth%26aufirst%3DT.%26aulast%3DKearney%26aufirst%3DP.%2BC.%26aulast%3DKim%26aufirst%3DB.%2BG.%26aulast%3DJohnson%26aufirst%3DH.%2BW.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DArcalas%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DD.%2BS.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DH.%26aulast%3DEpshteyn%26aufirst%3DS.%26aulast%3DGalan%26aufirst%3DA.%2BA.%26aulast%3DHuynh%26aufirst%3DT.%2BP.%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%26aulast%3DKane%26aufirst%3DB.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DMann%26aufirst%3DG.%26aulast%3DMeyr%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DLewis%26aufirst%3DG.%2BL.%26aulast%3DNoguchi%26aufirst%3DR.%2BT.%26aulast%3DPack%26aufirst%3DM.%26aulast%3DRidgway%26aufirst%3DB.%2BH.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTakeuchi%26aufirst%3DC.%2BS.%26aulast%3DZu%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DJ.%2BW.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DAoyama%26aufirst%3DR.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DGendreau%26aufirst%3DS.%2BB.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DMartini%26aufirst%3DJ.%2BF.%26aulast%3DStout%26aufirst%3DT.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DWoolfrey%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DP.%26atitle%3DSAR%2520and%2520in%2520vivo%2520evaluation%2520of%25204-aryl-2-aminoalkylpyrimidines%2520as%2520potent%2520and%2520selective%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7653%26epage%3D7658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturgis, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span> </span><span class="NLM_article-title">Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6237</span><span class="NLM_x">–</span> <span class="NLM_lpage">6241</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6237-6241&author=S.+Wenglowskyauthor=D.+Morenoauthor=E.+R.+Lairdauthor=S.+L.+Gloorauthor=L.+Renauthor=T.+Risomauthor=J.+Rudolphauthor=H.+L.+Sturgisauthor=W.+C.+Voegtli&title=Pyrazolopyridine+inhibitors+of+B-Raf%28V600E%29.+Part+4%3A+rational+design+and+kinase+selectivity+profile+of+cell+potent+type+II+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26atitle%3DPyrazolopyridine%2520inhibitors%2520of%2520B-Raf%2528V600E%2529.%2520Part%25204%253A%2520rational%2520design%2520and%2520kinase%2520selectivity%2520profile%2520of%2520cell%2520potent%2520type%2520II%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6237%26epage%3D6241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Zapf, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstenberger, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limburg, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaulding, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medley, Q. G.</span><span> </span><span class="NLM_article-title">Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10047</span><span class="NLM_x">–</span> <span class="NLM_lpage">10063</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301190s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10047-10063&author=C.+W.+Zapfauthor=B.+S.+Gerstenbergerauthor=L.+Xingauthor=D.+C.+Limburgauthor=D.+R.+Andersonauthor=N.+Caspersauthor=S.+Hanauthor=A.+Aulabaughauthor=R.+Kurumbailauthor=S.+Shakyaauthor=X.+Liauthor=V.+Spauldingauthor=R.+M.+Czerwinskiauthor=N.+Sethauthor=Q.+G.+Medley&title=Covalent+inhibitors+of+interleukin-2+inducible+T+cell+kinase+%28itk%29+with+nanomolar+potency+in+a+whole-blood+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay</span></div><div class="casAuthors">Zapf, Christoph W.; Gerstenberger, Brian S.; Xing, Li; Limburg, David C.; Anderson, David R.; Caspers, Nicole; Han, Seungil; Aulabaugh, Ann; Kurumbail, Ravi; Shakya, Subarna; Li, Xin; Spaulding, Vikki; Czerwinski, Robert M.; Seth, Nilufer; Medley, Quintus G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10047-10063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We wish to report a strategy that targets interleukin-2 inducible T cell kinase (Itk) with covalent inhibitors.  Thus far, covalent inhibition of Itk has not been disclosed in the literature.  Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concns.  Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates.  The analogs are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay.  Despite a half-life of approx. 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h.  This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnh9j28SM8jbVg90H21EOLACvtfcHk0lhWCif6bF19lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP&md5=7e39a17151dc9493d13439bc48fa83a3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm301190s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301190s%26sid%3Dliteratum%253Aachs%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSpaulding%26aufirst%3DV.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DMedley%26aufirst%3DQ.%2BG.%26atitle%3DCovalent%2520inhibitors%2520of%2520interleukin-2%2520inducible%2520T%2520cell%2520kinase%2520%2528itk%2529%2520with%2520nanomolar%2520potency%2520in%2520a%2520whole-blood%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10047%26epage%3D10063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Ranjitkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaney, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurty, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maly, D. J.</span><span> </span><span class="NLM_article-title">Affinity-based probes based on type II kinase inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">19017</span><span class="NLM_x">–</span> <span class="NLM_lpage">19025</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja306035v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=19017-19025&author=P.+Ranjitkarauthor=B.+G.+Pereraauthor=D.+L.+Swaneyauthor=S.+B.+Hariauthor=E.+T.+Larsonauthor=R.+Krishnamurtyauthor=E.+A.+Merrittauthor=J.+Villenauthor=D.+J.+Maly&title=Affinity-based+probes+based+on+type+II+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fja306035v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja306035v%26sid%3Dliteratum%253Aachs%26aulast%3DRanjitkar%26aufirst%3DP.%26aulast%3DPerera%26aufirst%3DB.%2BG.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DHari%26aufirst%3DS.%2BB.%26aulast%3DLarson%26aufirst%3DE.%2BT.%26aulast%3DKrishnamurty%26aufirst%3DR.%26aulast%3DMerritt%26aufirst%3DE.%2BA.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DAffinity-based%2520probes%2520based%2520on%2520type%2520II%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D19017%26epage%3D19025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1287</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061381f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1280-1287&author=A.+M.+Aronovauthor=C.+Bakerauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+W.+Janetkaauthor=F.+Maltaisauthor=G.+Martinez-Botellaauthor=M.+N.+Namchukauthor=J.+Straubauthor=Q.+Tangauthor=X.+Xie&title=Flipped+out%3A+structure-guided+design+of+selective+pyrazolylpyrrole+ERK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm061381f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061381f%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DFlipped%2520out%253A%2520structure-guided%2520design%2520of%2520selective%2520pyrazolylpyrrole%2520ERK%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1280%26epage%3D1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0lh4O3OMJtO_Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Huang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafleur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevado, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span> </span><span class="NLM_article-title">Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis</span> <span class="citation_source-journal">Bioinformatics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1093%2Fbioinformatics%2Fbtp650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19942586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2010&pages=198-204&author=D.+Huangauthor=T.+Zhouauthor=K.+Lafleurauthor=C.+Nevadoauthor=A.+Caflisch&title=Kinase+selectivity+potential+for+inhibitors+targeting+the+ATP+binding+site%3A+a+network+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis</span></div><div class="casAuthors">Huang, Danzhi; Zhou, Ting; Lafleur, Karine; Nevado, Cristina; Caflisch, Amedeo</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-204</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Small-mol. inhibitors targeting the ATP binding pocket of the catalytic domain of protein kinases have potential to become drugs devoid of (major) side effects, particularly if they bind selectively.  Here, the sequences of the 518 human kinases are first mapped onto the structural alignment of 116 kinases of known three-dimensional structure.  The multiple structure alignment is then used to encode the known strategies for developing selective inhibitors into a fingerprint.  Finally, a network anal. is used to partition the kinases into clusters according to similarity of their fingerprints, i.e., physico-chem. characteristics of the residues responsible for selective binding.  For each kinase the network anal. reveals the likelihood to find selective inhibitors targeting the ATP binding site.  Systematic guidelines are proposed to develop selective inhibitors.  Importantly, the network anal. suggests that the tyrosine kinase EphB4 has high selectivity potential, which is consistent with the selectivity profile of two novel EphB4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQVQsrpqB_ILVg90H21EOLACvtfcHk0lh4O3OMJtO_Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlGkug%253D%253D&md5=b6c63ccd4654219a56752f9cfc1356a3</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtp650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtp650%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DLafleur%26aufirst%3DK.%26aulast%3DNevado%26aufirst%3DC.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DKinase%2520selectivity%2520potential%2520for%2520inhibitors%2520targeting%2520the%2520ATP%2520binding%2520site%253A%2520a%2520network%2520analysis%26jtitle%3DBioinformatics%26date%3D2010%26volume%3D26%26spage%3D198%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurwitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span> </span><span class="NLM_article-title">Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2F376313a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=7630397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Sjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=1995&pages=313-320&author=P.+D.+Jeffreyauthor=A.+A.+Russoauthor=K.+Polyakauthor=E.+Gibbsauthor=J.+Hurwitzauthor=J.+Massagueauthor=N.+P.+Pavletich&title=Mechanism+of+CDK+activation+revealed+by+the+structure+of+a+cyclinA-CDK2+complex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex</span></div><div class="casAuthors">Jeffrey, Philip D.; Russo, Alicia A.; Polyak, Kornelia; Gibbs, Emma; Hurwitz, Jerard; Massague, Joan; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">6538</span>),
    <span class="NLM_cas:pages">313-20</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The crystal structure of the human cyclin A-cyclin-dependent kinase 2 (CDK2)-ATP complex was detd. at 2.3 Å resoln.  Cyclin A was found to bind to one side of the catalytic cleft of CDK2, inducing large conformational changes in its PSTAIRE helix and T-loop.  These changes activate the kinase by realigning active site residues and relieving the steric blockade at the entrance of the catalytic cleft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj6tVVZjR6SrVg90H21EOLACvtfcHk0li6H-AFFbEvjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Sjsrk%253D&md5=582f0a3741e0417ff650c3172b39249c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2F376313a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F376313a0%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DRusso%26aufirst%3DA.%2BA.%26aulast%3DPolyak%26aufirst%3DK.%26aulast%3DGibbs%26aufirst%3DE.%26aulast%3DHurwitz%26aufirst%3DJ.%26aulast%3DMassague%26aufirst%3DJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DMechanism%2520of%2520CDK%2520activation%2520revealed%2520by%2520the%2520structure%2520of%2520a%2520cyclinA-CDK2%2520complex%26jtitle%3DNature%26date%3D1995%26volume%3D376%26spage%3D313%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. R.</span><span> </span><span class="NLM_article-title">A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2008&pages=89-94&author=W.+H.+Linauthor=J.+S.+Songauthor=T.+Y.+Changauthor=C.+Y.+Changauthor=Y.+N.+Fuauthor=C.+L.+Yehauthor=S.+H.+Wuauthor=Y.+W.+Huangauthor=M.+Y.+Fangauthor=T.+W.+Lienauthor=H.+P.+Hsiehauthor=Y.+S.+Chaoauthor=S.+F.+Huangauthor=S.+F.+Tsaiauthor=L.+M.+Wangauthor=J.+T.+Hsuauthor=Y.+R.+Chen&title=A+cell-based+high-throughput+screen+for+epidermal+growth+factor+receptor+pathway+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DT.%2BY.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DFu%26aufirst%3DY.%2BN.%26aulast%3DYeh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DS.%2BH.%26aulast%3DHuang%26aufirst%3DY.%2BW.%26aulast%3DFang%26aufirst%3DM.%2BY.%26aulast%3DLien%26aufirst%3DT.%2BW.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DHuang%26aufirst%3DS.%2BF.%26aulast%3DTsai%26aufirst%3DS.%2BF.%26aulast%3DWang%26aufirst%3DL.%2BM.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BR.%26atitle%3DA%2520cell-based%2520high-throughput%2520screen%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520pathway%2520inhibitors%26jtitle%3DAnal.%2520Biochem.%26date%3D2008%26volume%3D377%26spage%3D89%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teplyakov, A.</span><span> </span><span class="NLM_article-title">MOLREP: an automated program for molecular replacement</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1025</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0021889897006766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=1022-1025&author=A.+Vaginauthor=A.+Teplyakov&title=MOLREP%3A+an+automated+program+for+molecular+replacement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">MOLREP: an automated program for molecular replacement</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1022-1025</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement which uses effective new approaches in data processing and rotational and translational searching.  These include an automatic choice of all parameters, scaling by Patterson origin peaks and soft resoln. cutoff.  One of the cornerstones of the program is an original full-symmetry translation function combined with a packing function.  Information from the model already placed in the cell is incorporated in both translation and packing functions.  A no. of tests using exptl. data proved the ability of the program to find the correct soln. in difficult cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkGXdZ-nTKxLVg90H21EOLACvtfcHk0li6H-AFFbEvjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D&md5=96af64aedd8a8f018c3c18b57a6b4b21</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1107%2FS0021889897006766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889897006766%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMOLREP%253A%2520an%2520automated%2520program%2520for%2520molecular%2520replacement%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1997%26volume%3D30%26spage%3D1022%26epage%3D1025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Bailey, S.</span><span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography</span> <span class="citation_source-journal">Acta.Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15299374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=S.+Bailey&title=The+CCP4+suite%3A+programs+for+protein+crystallography"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DS.%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%26jtitle%3DActa.Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0li6H-AFFbEvjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Jones, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjeldgaard, M.</span><span> </span><span class="NLM_article-title">Improved methods for building protein models in electron density maps and the location of errors in these models</span> <span class="citation_source-journal">Acta Crystallogr., Sect. A: Found. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0108767390010224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=2025413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A280%3ADyaK3M3it1CmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1991&pages=110-119&author=T.+A.+Jonesauthor=J.+Y.+Zouauthor=S.+W.+Cowanauthor=M.+Kjeldgaard&title=Improved+methods+for+building+protein+models+in+electron+density+maps+and+the+location+of+errors+in+these+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Improved methods for building protein models in electron density maps and the location of errors in these models</span></div><div class="casAuthors">Jones T A; Zou J Y; Cowan S W; Kjeldgaard M</div><div class="citationInfo"><span class="NLM_cas:title">Acta crystallographica. Section A, Foundations of crystallography</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">47 ( Pt 2)</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">110-9</span>
        ISSN:<span class="NLM_cas:issn">0108-7673</span>.
    </div><div class="casAbstract">Map interpretation remains a critical step in solving the structure of a macromolecule.  Errors introduced at this early stage may persist throughout crystallographic refinement and result in an incorrect structure.  The normally quoted crystallographic residual is often a poor description for the quality of the model.  Strategies and tools are described that help to alleviate this problem.  These simplify the model-building process, quantify the goodness of fit of the model on a per-residue basis and locate possible errors in peptide and side-chain conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhby6yNdW8QMKL0FlyGHDofW6udTcc2ebT83pfFG4OAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3it1CmsQ%253D%253D&md5=fd4d4a3cdb4ecb3f05bbad8b2300ef45</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1107%2FS0108767390010224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767390010224%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DT.%2BA.%26aulast%3DZou%26aufirst%3DJ.%2BY.%26aulast%3DCowan%26aufirst%3DS.%2BW.%26aulast%3DKjeldgaard%26aufirst%3DM.%26atitle%3DImproved%2520methods%2520for%2520building%2520protein%2520models%2520in%2520electron%2520density%2520maps%2520and%2520the%2520location%2520of%2520errors%2520in%2520these%2520models%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D1991%26volume%3D47%26spage%3D110%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Joosten, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzemann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockinger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglund, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bongcam-Rudloff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Costa, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deleage, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diarena, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbretti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fettahi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flegel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gisel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kervinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korpelainen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattila, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichstadt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tickle, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vriend, G.</span><span> </span><span class="NLM_article-title">PDB_REDO: automated re-refinement of X-ray structure models in the PDB</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">376</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0021889809008784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22477769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVehsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2009&pages=376-384&author=R.+P.+Joostenauthor=J.+Salzemannauthor=V.+Blochauthor=H.+Stockingerauthor=A.-C.+Berglundauthor=C.+Blanchetauthor=E.+Bongcam-Rudloffauthor=C.+Combetauthor=A.+L.+Da+Costaauthor=G.+Deleageauthor=M.+Diarenaauthor=R.+Fabbrettiauthor=G.+Fettahiauthor=V.+Flegelauthor=A.+Giselauthor=V.+Kasamauthor=T.+Kervinenauthor=E.+Korpelainenauthor=K.+Mattilaauthor=M.+Pagniauthor=M.+Reichstadtauthor=V.+Bretonauthor=I.+J.+Tickleauthor=G.+Vriend&title=PDB_REDO%3A+automated+re-refinement+of+X-ray+structure+models+in+the+PDB"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">PDBREDO: automated re-refinement of X-ray structure models in the PDB</span></div><div class="casAuthors">Joosten, Robbie P.; Salzemann, Jean; Bloch, Vincent; Stockinger, Heinz; Berglund, Ann Charlott; Blanchet, Christophe; Bongcam-Rudloff, Erik; Combet, Christophe; Da Costa, Ana L.; Deleage, Gilbert; Diarena, Matteo; Fabbretti, Roberto; Fettahi, Geraldine; Flegel, Volker; Gisel, Andreas; Kasam, Vinod; Kervinen, Timo; Korpelainen, Eija; Mattila, Kimmo; Pagni, Marco; Reichstadt, Matthieu; Breton, Vincent; Tickle, Ian J.; Vriend, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">376-384</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Structural biol., homol. modeling and rational drug design require accurate three-dimensional macromol. coordinates.  However, the coordinates in the Protein Data Bank (PDB) have not all been obtained using the latest exptl. and computational methods.  In this study a method is presented for automated re-refinement of existing structure models in the PDB.  A large-scale benchmark with 16 807 PDB entries showed that they can be improved in terms of fit to the deposited exptl. X-ray data as well as in terms of geometric quality.  The re-refinement protocol uses TLS models to describe concerted atom movement.  The resulting structure models are made available through the PDBREDO databank (http://www.cmbi.ru.nl/pdbredo/).  Grid computing techniques were used to overcome the computational requirements of this endeavour.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfH-Y9l34B8bVg90H21EOLACvtfcHk0ljfpZc-JRXW4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVehsbo%253D&md5=7ed056bcc218ec1fc00a870eb3eaa58a</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1107%2FS0021889809008784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889809008784%26sid%3Dliteratum%253Aachs%26aulast%3DJoosten%26aufirst%3DR.%2BP.%26aulast%3DSalzemann%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DV.%26aulast%3DStockinger%26aufirst%3DH.%26aulast%3DBerglund%26aufirst%3DA.-C.%26aulast%3DBlanchet%26aufirst%3DC.%26aulast%3DBongcam-Rudloff%26aufirst%3DE.%26aulast%3DCombet%26aufirst%3DC.%26aulast%3DDa%2BCosta%26aufirst%3DA.%2BL.%26aulast%3DDeleage%26aufirst%3DG.%26aulast%3DDiarena%26aufirst%3DM.%26aulast%3DFabbretti%26aufirst%3DR.%26aulast%3DFettahi%26aufirst%3DG.%26aulast%3DFlegel%26aufirst%3DV.%26aulast%3DGisel%26aufirst%3DA.%26aulast%3DKasam%26aufirst%3DV.%26aulast%3DKervinen%26aufirst%3DT.%26aulast%3DKorpelainen%26aufirst%3DE.%26aulast%3DMattila%26aufirst%3DK.%26aulast%3DPagni%26aufirst%3DM.%26aulast%3DReichstadt%26aufirst%3DM.%26aulast%3DBreton%26aufirst%3DV.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DVriend%26aufirst%3DG.%26atitle%3DPDB_REDO%253A%2520automated%2520re-refinement%2520of%2520X-ray%2520structure%2520models%2520in%2520the%2520PDB%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2009%26volume%3D42%26spage%3D376%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arendall, W. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keedy, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Immormino, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0ljfpZc-JRXW4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 56 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Luca Pinzi, <span class="NLM_string-name hlFld-ContribAuthor">Giulio Rastelli</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (1)
                                     , 372-390. <a href="https://doi.org/10.1021/acs.jcim.9b00821" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00821%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Bof%252BTarget%252BAssociations%252Bfor%252BPolypharmacology%252Bfrom%252BAnalysis%252Bof%252BCrystallographic%252BLigands%252Bof%252Bthe%252BProtein%252BData%252BBank%26aulast%3DPinzi%26aufirst%3DLuca%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D20092019%26date%3D19122019%26date%3D04122019%26volume%3D60%26issue%3D1%26spage%3D372%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shu-Yu Lin, Yung Chang Hsu, Yi-Hui Peng, Yi-Yu Ke, Wen-Hsing Lin, Hsu-Yi Sun, Hui-Yi Shiao, Fu-Ming Kuo, Pei-Yi Chen, Tzu-Wen Lien, Chun-Hwa Chen, Chang-Ying Chu, Sing-Yi Wang, Kai-Chia Yeh, Ching-Ping Chen, Tsu-An Hsu, Su-Ying Wu, Teng-Kuang Yeh, Chiung-Tong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Hsing-Pang Hsieh</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10108-10123. <a href="https://doi.org/10.1021/acs.jmedchem.9b00722" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00722</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00722%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BFuranopyrimidine-Based%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252B%252528DBPR112%252529%252Bas%252Ba%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small%252BCell%252BLung%252BCancer%26aulast%3DLin%26aufirst%3DShu-Yu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03052019%26date%3D15112019%26date%3D27092019%26volume%3D62%26issue%3D22%26spage%3D10108%26epage%3D10123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jagannath  Mondal</span>, <span class="hlFld-ContribAuthor ">Pratyush  Tiwary</span>, and <span class="hlFld-ContribAuthor ">B. J.  Berne</span>  . </span><span class="cited-content_cbyCitation_article-title">How a Kinase Inhibitor Withstands Gatekeeper Residue Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2016,</strong> <em>138 </em>
                                    (13)
                                     , 4608-4615. <a href="https://doi.org/10.1021/jacs.6b01232" title="DOI URL">https://doi.org/10.1021/jacs.6b01232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.6b01232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.6b01232%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DHow%252Ba%252BKinase%252BInhibitor%252BWithstands%252BGatekeeper%252BResidue%252BMutations%26aulast%3DMondal%26aufirst%3DJagannath%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D02022016%26date%3D22032016%26date%3D06042016%26date%3D08032016%26volume%3D138%26issue%3D13%26spage%3D4608%26epage%3D4615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian-Sung  Wu</span>, <span class="hlFld-ContribAuthor ">Shu-Yu  Lin</span>, <span class="hlFld-ContribAuthor ">Fang-Yu  Liao</span>, <span class="hlFld-ContribAuthor ">Wen-Chi  Hsiao</span>, <span class="hlFld-ContribAuthor ">Lung-Chun  Lee</span>, <span class="hlFld-ContribAuthor ">Yi-Hui  Peng</span>, <span class="hlFld-ContribAuthor ">Chia-Ling  Hsieh</span>, <span class="hlFld-ContribAuthor ">Mine-Hsine  Wu</span>, <span class="hlFld-ContribAuthor ">Jen-Shin  Song</span>, <span class="hlFld-ContribAuthor ">Andrew  Yueh</span>, <span class="hlFld-ContribAuthor ">Chun-Hwa  Chen</span>, <span class="hlFld-ContribAuthor ">Shiu-Hwa  Yeh</span>, <span class="hlFld-ContribAuthor ">Chia-Yeh  Liu</span>, <span class="hlFld-ContribAuthor ">Shu-Yi  Lin</span>, <span class="hlFld-ContribAuthor ">Teng-Kuang  Yeh</span>, <span class="hlFld-ContribAuthor ">John T.-A.  Hsu</span>, <span class="hlFld-ContribAuthor ">Chuan  Shih</span>, <span class="hlFld-ContribAuthor ">Shau-Hua  Ueng</span>, <span class="hlFld-ContribAuthor ">Ming-Shiu  Hung</span>, and <span class="hlFld-ContribAuthor ">Su-Ying  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (19)
                                     , 7807-7819. <a href="https://doi.org/10.1021/acs.jmedchem.5b00921" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00921</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00921%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BSubstituted%252BNaphthotriazolediones%252Bas%252BNovel%252BTryptophan%252B2%25252C3-Dioxygenase%252B%252528TDO%252529%252BInhibitors%252Bthrough%252BStructure-Based%252BVirtual%252BScreening%26aulast%3DWu%26aufirst%3DJian-Sung%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D16062015%26date%3D16092015%26date%3D08102015%26date%3D08092015%26volume%3D58%26issue%3D19%26spage%3D7807%26epage%3D7819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Mahsa  Toolabi</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113523. <a href="https://doi.org/10.1016/j.ejmech.2021.113523" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113523%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidine-based%252BEGFR%252BTK%252Binhibitors%252Bin%252Btargeted%252Bcancer%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2021%26volume%3D221%26spage%3D113523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed A.E.  Mourad</span>, <span class="hlFld-ContribAuthor ">N.A.  Farouk</span>, <span class="hlFld-ContribAuthor ">El-Sherbiny H.  El-Sayed</span>, <span class="hlFld-ContribAuthor ">Ahmed R.E.  Mahdy</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2021,</strong> <em>277 </em>, 119531. <a href="https://doi.org/10.1016/j.lfs.2021.119531" title="DOI URL">https://doi.org/10.1016/j.lfs.2021.119531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2021.119531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2021.119531%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DEGFR%25252FVEGFR-2%252Bdual%252Binhibitor%252Band%252Bapoptotic%252Binducer%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Banticancer%252Bactivity%252Band%252Bdocking%252Bstudy%252Bof%252Bnew%252B2-thioxoimidazolidin-4one%252Bderivatives%26aulast%3DMourad%26aufirst%3DAhmed%2BA.E.%26date%3D2021%26volume%3D277%26spage%3D119531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunhua  Rui</span>, <span class="hlFld-ContribAuthor ">Shen-nan  Shi</span>, <span class="hlFld-ContribAuthor ">Wenqing  Ren</span>, <span class="hlFld-ContribAuthor ">Xia  Qin</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Chen</span>, <span class="hlFld-ContribAuthor ">Gang  Chen</span>, <span class="hlFld-ContribAuthor ">Jianqiang  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-yang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>188 </em>, 114542. <a href="https://doi.org/10.1016/j.bcp.2021.114542" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114542%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DThe%252Bmultitargeted%252Bkinase%252Binhibitor%252BKW-2449%252Bameliorates%252Bcisplatin-induced%252Bnephrotoxicity%252Bby%252Btargeting%252BRIPK1-mediated%252Bnecroptosis%26aulast%3DRui%26aufirst%3DChunhua%26date%3D2021%26volume%3D188%26spage%3D114542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.-Mohsen M.E.  Omar</span>, <span class="hlFld-ContribAuthor ">Omaima M.  AboulWafa</span>, <span class="hlFld-ContribAuthor ">Mai E.  Amr</span>, <span class="hlFld-ContribAuthor ">Mai S.  El-Shoukrofy</span>. </span><span class="cited-content_cbyCitation_article-title">Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104752. <a href="https://doi.org/10.1016/j.bioorg.2021.104752" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104752</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104752%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAntiproliferative%252Bactivity%25252C%252Benzymatic%252Binhibition%252Band%252Bapoptosis-promoting%252Beffects%252Bof%252Bbenzoxazole-based%252Bhybrids%252Bon%252Bhuman%252Bbreast%252Bcancer%252Bcells%26aulast%3DOmar%26aufirst%3DA.-Mohsen%2BM.E.%26date%3D2021%26volume%3D109%26spage%3D104752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yazan  Haddad</span>, <span class="hlFld-ContribAuthor ">Marek  Remes</span>, <span class="hlFld-ContribAuthor ">Vojtech  Adam</span>, <span class="hlFld-ContribAuthor ">Zbynek  Heger</span>. </span><span class="cited-content_cbyCitation_article-title">Toward structure-based drug design against the epidermal growth factor receptor (EGFR). </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 289-295. <a href="https://doi.org/10.1016/j.drudis.2020.10.007" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.10.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.10.007%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DToward%252Bstructure-based%252Bdrug%252Bdesign%252Bagainst%252Bthe%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%26aulast%3DHaddad%26aufirst%3DYazan%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D289%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prabhakar  Singh</span>, <span class="hlFld-ContribAuthor ">Srinivasarao  Arulananda Babu</span>, <span class="hlFld-ContribAuthor ">Yashika  Aggarwal</span>, <span class="hlFld-ContribAuthor ">Pooja  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">Pd(II)‐catalyzed, Picolinamide‐aided sp
              2
              γ−C−H Functionalization of Phenylglycinol: Access to γ−C−H Arylated, Alkylated and Halogenated Phenylglycinol Scaffolds. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>10 </em>
                                    (1)
                                     , 180-185. <a href="https://doi.org/10.1002/ajoc.202000560" title="DOI URL">https://doi.org/10.1002/ajoc.202000560</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.202000560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.202000560%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPd%252528II%252529%2525E2%252580%252590catalyzed%25252C%252BPicolinamide%2525E2%252580%252590aided%252Bsp%252B2%252B%2525CE%2525B3%2525E2%252588%252592C%2525E2%252588%252592H%252BFunctionalization%252Bof%252BPhenylglycinol%25253A%252BAccess%252Bto%252B%2525CE%2525B3%2525E2%252588%252592C%2525E2%252588%252592H%252BArylated%25252C%252BAlkylated%252Band%252BHalogenated%252BPhenylglycinol%252BScaffolds%26aulast%3DSingh%26aufirst%3DPrabhakar%26date%3D2021%26date%3D2020%26volume%3D10%26issue%3D1%26spage%3D180%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frangky  Sangande</span>, <span class="hlFld-ContribAuthor ">Elin  Julianti</span>, <span class="hlFld-ContribAuthor ">Daryono Hadi  Tjahjono</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (20)
                                     , 7779. <a href="https://doi.org/10.3390/ijms21207779" title="DOI URL">https://doi.org/10.3390/ijms21207779</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21207779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21207779%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DLigand-Based%252BPharmacophore%252BModeling%25252C%252BMolecular%252BDocking%25252C%252Band%252BMolecular%252BDynamic%252BStudies%252Bof%252BDual%252BTyrosine%252BKinase%252BInhibitor%252Bof%252BEGFR%252Band%252BVEGFR2%26aulast%3DSangande%26aufirst%3DFrangky%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D20%26spage%3D7779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prateek  Pathak</span>, <span class="hlFld-ContribAuthor ">Vladislav  Naumovich</span>, <span class="hlFld-ContribAuthor ">Maria  Grishina</span>, <span class="hlFld-ContribAuthor ">Vladimir  Potemkin</span>. </span><span class="cited-content_cbyCitation_article-title">The study of EGFR-ligand complex electron property relationship with biological activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>1 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2020.1813629" title="DOI URL">https://doi.org/10.1080/07391102.2020.1813629</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1813629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1813629%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DThe%252Bstudy%252Bof%252BEGFR-ligand%252Bcomplex%252Belectron%252Bproperty%252Brelationship%252Bwith%252Bbiological%252Bactivity%26aulast%3DPathak%26aufirst%3DPrateek%26date%3D2020%26date%3D2020%26volume%3D1%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Narittira  Ornnork</span>, <span class="hlFld-ContribAuthor ">Duangnapa  Kiriwan</span>, <span class="hlFld-ContribAuthor ">Kriengsak  Lirdprapamongkol</span>, <span class="hlFld-ContribAuthor ">Kiattawee  Choowongkomon</span>, <span class="hlFld-ContribAuthor ">Jisnuson  Svasti</span>, <span class="hlFld-ContribAuthor ">Chatchakorn  Eurtivong</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics, MM/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2020,</strong> <em>99 </em>, 107639. <a href="https://doi.org/10.1016/j.jmgm.2020.107639" title="DOI URL">https://doi.org/10.1016/j.jmgm.2020.107639</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2020.107639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2020.107639%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DMolecular%252Bdynamics%25252C%252BMM%25252FPBSA%252Band%252Bin%2525C2%2525A0vitro%252Bvalidation%252Bof%252Ba%252Bnovel%252Bquinazoline-based%252BEGFR%252Btyrosine%252Bkinase%252Binhibitor%252Bidentified%252Busing%252Bstructure-based%252Bin%252Bsilico%252Bscreening%26aulast%3DOrnnork%26aufirst%3DNarittira%26date%3D2020%26volume%3D99%26spage%3D107639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xia  Qin</span>, <span class="hlFld-ContribAuthor ">Longmiao  Hu</span>, <span class="hlFld-ContribAuthor ">Shen-nan  Shi</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Chen</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Siriporn  Jitkaew</span>, <span class="hlFld-ContribAuthor ">Xiufeng  Pang</span>, <span class="hlFld-ContribAuthor ">Jianqiang  Yu</span>, <span class="hlFld-ContribAuthor ">Ye-xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Hong-yang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>177 </em>, 113947. <a href="https://doi.org/10.1016/j.bcp.2020.113947" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.113947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.113947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.113947%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DThe%252BBcr-Abl%252Binhibitor%252BGNF-7%252Binhibits%252Bnecroptosis%252Band%252Bameliorates%252Bacute%252Bkidney%252Binjury%252Bby%252Btargeting%252BRIPK1%252Band%252BRIPK3%252Bkinases%26aulast%3DQin%26aufirst%3DXia%26date%3D2020%26volume%3D177%26spage%3D113947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. Samuel  Metibemu</span>, <span class="hlFld-ContribAuthor ">O. Adeboye  Akinloye</span>, <span class="hlFld-ContribAuthor ">A. Jamiu  Akamo</span>, <span class="hlFld-ContribAuthor ">D. Ajiboye  Ojo</span>, <span class="hlFld-ContribAuthor ">O. Tolulope  Okeowo</span>, <span class="hlFld-ContribAuthor ">I. Olaposi  Omotuyi</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. </span><span class="cited-content_cbyCitation_journal-name">Egyptian Journal of Medical Human Genetics</span><span> <strong>2019,</strong> <em>20 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s43042-019-0035-0" title="DOI URL">https://doi.org/10.1186/s43042-019-0035-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s43042-019-0035-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs43042-019-0035-0%26sid%3Dliteratum%253Aachs%26jtitle%3DEgyptian%2520Journal%2520of%2520Medical%2520Human%2520Genetics%26atitle%3DExploring%252Breceptor%252Btyrosine%252Bkinases-inhibitors%252Bin%252BCancer%252Btreatments%26aulast%3DMetibemu%26aufirst%3DD.%2BSamuel%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Philip  Klövekorn</span>, <span class="hlFld-ContribAuthor ">Hannah L.  Tumbrink</span>, <span class="hlFld-ContribAuthor ">Janina  Niggenaber</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Müller</span>, <span class="hlFld-ContribAuthor ">Luke  Hodson</span>, <span class="hlFld-ContribAuthor ">Maren  Flaßhoff</span>, <span class="hlFld-ContribAuthor ">Julia  Hardick</span>, <span class="hlFld-ContribAuthor ">Tobias  Grabe</span>, <span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">Carsten  Schultz-Fademrecht</span>, <span class="hlFld-ContribAuthor ">Matthias  Baumann</span>, <span class="hlFld-ContribAuthor ">Julia  Ketzer</span>, <span class="hlFld-ContribAuthor ">Thomas  Mühlenberg</span>, <span class="hlFld-ContribAuthor ">Wolf  Hiller</span>, <span class="hlFld-ContribAuthor ">Georgia  Günther</span>, <span class="hlFld-ContribAuthor ">Anke  Unger</span>, <span class="hlFld-ContribAuthor ">Heiko  Müller</span>, <span class="hlFld-ContribAuthor ">Alena  Heimsoeth</span>, <span class="hlFld-ContribAuthor ">Christopher  Golz</span>, <span class="hlFld-ContribAuthor ">Bernhard  Blank-Landeshammer</span>, <span class="hlFld-ContribAuthor ">Laxmikanth  Kollipara</span>, <span class="hlFld-ContribAuthor ">René P.  Zahedi</span>, <span class="hlFld-ContribAuthor ">Carsten  Strohmann</span>, <span class="hlFld-ContribAuthor ">Jan G.  Hengstler</span>, <span class="hlFld-ContribAuthor ">Willem A. L.  van Otterlo</span>, <span class="hlFld-ContribAuthor ">Sebastian  Bauer</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (46)
                                     , 10789-10801. <a href="https://doi.org/10.1039/C9SC03445E" title="DOI URL">https://doi.org/10.1039/C9SC03445E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC03445E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC03445E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DInhibition%252Bof%252Bosimertinib-resistant%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252BEGFR-T790M%25252FC797S%26aulast%3DLategahn%26aufirst%3DJonas%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D46%26spage%3D10789%26epage%3D10801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ekta  Rathi</span>, <span class="hlFld-ContribAuthor ">Avinash  Kumar</span>, <span class="hlFld-ContribAuthor ">Suvarna G.  Kini</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2019,</strong> <em>39 </em>
                                    (5-6)
                                     , 415-433. <a href="https://doi.org/10.1080/10799893.2019.1690509" title="DOI URL">https://doi.org/10.1080/10799893.2019.1690509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2019.1690509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2019.1690509%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DMolecular%252Bdynamics%252Bguided%252Binsight%25252C%252Bbinding%252Bfree%252Benergy%252Bcalculations%252Band%252Bpharmacophore-based%252Bvirtual%252Bscreening%252Bfor%252Bthe%252Bidentification%252Bof%252Bpotential%252BVEGFR2%252Binhibitors%26aulast%3DRathi%26aufirst%3DEkta%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D5-6%26spage%3D415%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Minli  Zhang</span>, <span class="hlFld-ContribAuthor ">Tong  Li</span>, <span class="hlFld-ContribAuthor ">Xixi  Song</span>. </span><span class="cited-content_cbyCitation_article-title">AlCl
              3
              ‐Promoted Stereospecific Cloke‐Wilson Rearrangement of Spirocyclopropyl Barbiturates for the Synthesis of Substituted Dihydrofuro[2,3‐
              d
              ]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (36)
                                     , 10838-10842. <a href="https://doi.org/10.1002/slct.201903330" title="DOI URL">https://doi.org/10.1002/slct.201903330</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201903330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201903330%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DAlCl%252B3%252B%2525E2%252580%252590Promoted%252BStereospecific%252BCloke%2525E2%252580%252590Wilson%252BRearrangement%252Bof%252BSpirocyclopropyl%252BBarbiturates%252Bfor%252Bthe%252BSynthesis%252Bof%252BSubstituted%252BDihydrofuro%25255B2%25252C3%2525E2%252580%252590%252Bd%252B%25255Dpyrimidines%26aulast%3DZhu%26aufirst%3DYuanyuan%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D36%26spage%3D10838%26epage%3D10842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farial  Tavakoli</span>, <span class="hlFld-ContribAuthor ">Mohamad Reza  Ganjalikhany</span>, . </span><span class="cited-content_cbyCitation_article-title">Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2019,</strong> <em>14 </em>
                                    (5)
                                     , e0217031. <a href="https://doi.org/10.1371/journal.pone.0217031" title="DOI URL">https://doi.org/10.1371/journal.pone.0217031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0217031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0217031%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DStructure-based%252Binhibitory%252Bpeptide%252Bdesign%252Btargeting%252Bpeptide-substrate%252Bbinding%252Bsite%252Bin%252BEGFR%252Btyrosine%252Bkinase%26aulast%3DTavakoli%26aufirst%3DFarial%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D5%26spage%3De0217031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sh.  Hashemzadeh</span>, <span class="hlFld-ContribAuthor ">F.  Ramezani</span>, <span class="hlFld-ContribAuthor ">H.  Rafii-Tabar</span>. </span><span class="cited-content_cbyCitation_article-title">Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation. </span><span class="cited-content_cbyCitation_journal-name">Interdisciplinary Sciences: Computational Life Sciences</span><span> <strong>2019,</strong> <em>11 </em>
                                    (1)
                                     , 115-124. <a href="https://doi.org/10.1007/s12539-018-0305-4" title="DOI URL">https://doi.org/10.1007/s12539-018-0305-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12539-018-0305-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12539-018-0305-4%26sid%3Dliteratum%253Aachs%26jtitle%3DInterdisciplinary%2520Sciences%253A%2520Computational%2520Life%2520Sciences%26atitle%3DStudy%252Bof%252BMolecular%252BMechanism%252Bof%252Bthe%252BInteraction%252BBetween%252BMEK1%25252F2%252Band%252BTrametinib%252Bwith%252BDocking%252Band%252BMolecular%252BDynamic%252BSimulation%26aulast%3DHashemzadeh%26aufirst%3DSh.%26date%3D2019%26date%3D2018%26volume%3D11%26issue%3D1%26spage%3D115%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit  Shraga</span>, <span class="hlFld-ContribAuthor ">Evgenia  Olshvang</span>, <span class="hlFld-ContribAuthor ">Natalia  Davidzohn</span>, <span class="hlFld-ContribAuthor ">Payam  Khoshkenar</span>, <span class="hlFld-ContribAuthor ">Nicolas  Germain</span>, <span class="hlFld-ContribAuthor ">Khriesto  Shurrush</span>, <span class="hlFld-ContribAuthor ">Silvia  Carvalho</span>, <span class="hlFld-ContribAuthor ">Liat  Avram</span>, <span class="hlFld-ContribAuthor ">Shira  Albeck</span>, <span class="hlFld-ContribAuthor ">Tamar  Unger</span>, <span class="hlFld-ContribAuthor ">Bruce  Lefker</span>, <span class="hlFld-ContribAuthor ">Chakrapani  Subramanyam</span>, <span class="hlFld-ContribAuthor ">Robert L.  Hudkins</span>, <span class="hlFld-ContribAuthor ">Amir  Mitchell</span>, <span class="hlFld-ContribAuthor ">Ziv  Shulman</span>, <span class="hlFld-ContribAuthor ">Takayoshi  Kinoshita</span>, <span class="hlFld-ContribAuthor ">Nir  London</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2019,</strong> <em>26 </em>
                                    (1)
                                     , 98-108.e5. <a href="https://doi.org/10.1016/j.chembiol.2018.10.011" title="DOI URL">https://doi.org/10.1016/j.chembiol.2018.10.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2018.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2018.10.011%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DCovalent%252BDocking%252BIdentifies%252Ba%252BPotent%252Band%252BSelective%252BMKK7%252BInhibitor%26aulast%3DShraga%26aufirst%3DAmit%26date%3D2019%26volume%3D26%26issue%3D1%26spage%3D98%26epage%3D108.e5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ravi Kumar Vyas  Devambatla</span>, <span class="hlFld-ContribAuthor ">Shruti  Choudhary</span>, <span class="hlFld-ContribAuthor ">Michael  Ihnat</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (18)
                                     , 3085-3093. <a href="https://doi.org/10.1016/j.bmcl.2018.07.039" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.07.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.07.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpreclinical%252Bevaluation%252Bof%252B5-methyl-N4-aryl-furo%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bsingle%252Bagents%252Bwith%252Bcombination%252Bchemotherapy%252Bpotential%26aulast%3DDevambatla%26aufirst%3DRavi%2BKumar%2BVyas%26date%3D2018%26volume%3D28%26issue%3D18%26spage%3D3085%26epage%3D3093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruth A.  Mitchell</span>, <span class="hlFld-ContribAuthor ">Rodney B.  Luwor</span>, <span class="hlFld-ContribAuthor ">Antony W.  Burgess</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Experimental Cell Research</span><span> <strong>2018,</strong> <em>371 </em>
                                    (1)
                                     , 1-19. <a href="https://doi.org/10.1016/j.yexcr.2018.08.009" title="DOI URL">https://doi.org/10.1016/j.yexcr.2018.08.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.yexcr.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.yexcr.2018.08.009%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520Cell%2520Research%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%25253A%252BStructure-function%252Binforming%252Bthe%252Bdesign%252Bof%252Banticancer%252Btherapeutics%26aulast%3DMitchell%26aufirst%3DRuth%2BA.%26date%3D2018%26volume%3D371%26issue%3D1%26spage%3D1%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Binghe  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1674-1705. <a href="https://doi.org/10.1002/med.21517" title="DOI URL">https://doi.org/10.1002/med.21517</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21517%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DNew%252Bstrategies%252Bin%252Bachieving%252Bantiangiogenic%252Beffect%25253A%252BMultiplex%252Binhibitors%252Bsuppressing%252Bcompensatory%252Bactivations%252Bof%252BRTKs%26aulast%3DShan%26aufirst%3DYuanyuan%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1674%26epage%3D1705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Malose  Mphahlele</span>, <span class="hlFld-ContribAuthor ">Marole  Maluleka</span>, <span class="hlFld-ContribAuthor ">Nishal  Parbhoo</span>, <span class="hlFld-ContribAuthor ">Sibusiso  Malindisa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Evaluation for Cytotoxicity and Molecular Docking Studies of Benzo[c]furan-Chalcones for Potential to Inhibit Tubulin Polymerization and/or EGFR-Tyrosine Kinase Phosphorylation. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (9)
                                     , 2552. <a href="https://doi.org/10.3390/ijms19092552" title="DOI URL">https://doi.org/10.3390/ijms19092552</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19092552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19092552%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DSynthesis%25252C%252BEvaluation%252Bfor%252BCytotoxicity%252Band%252BMolecular%252BDocking%252BStudies%252Bof%252BBenzo%25255Bc%25255Dfuran-Chalcones%252Bfor%252BPotential%252Bto%252BInhibit%252BTubulin%252BPolymerization%252Band%25252For%252BEGFR-Tyrosine%252BKinase%252BPhosphorylation%26aulast%3DMphahlele%26aufirst%3DMalose%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D9%26spage%3D2552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2018,</strong> <em>74 </em>, 167-189. <a href="https://doi.org/10.1016/j.compbiolchem.2018.03.026" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2018.03.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2018.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2018.03.026%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DIn-silico%252Bevidences%252Bfor%252Bbinding%252Bof%252BGlucokinase%252Bactivators%252Bto%252BEGFR%252BC797S%252Bto%252Bovercome%252BEGFR%252Bresistance%252Bobstacle%252Bwith%252Bmutant-selective%252Ballosteric%252Binhibition%26aulast%3DPatel%26aufirst%3DHarun%26date%3D2018%26volume%3D74%26spage%3D167%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Yu  Ke</span>, <span class="hlFld-ContribAuthor ">Chun-Ping  Chang</span>, <span class="hlFld-ContribAuthor ">Wen-Hsing  Lin</span>, <span class="hlFld-ContribAuthor ">Chia-Hua  Tsai</span>, <span class="hlFld-ContribAuthor ">I-Chen  Chiu</span>, <span class="hlFld-ContribAuthor ">Wan-Ping  Wang</span>, <span class="hlFld-ContribAuthor ">Pei-Chen  Wang</span>, <span class="hlFld-ContribAuthor ">Pei-Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Wen-Hsin  Lin</span>, <span class="hlFld-ContribAuthor ">Chun-Feng  Chang</span>, <span class="hlFld-ContribAuthor ">Po-Chu  Kuo</span>, <span class="hlFld-ContribAuthor ">Jen-Shin  Song</span>, <span class="hlFld-ContribAuthor ">Chuan  Shih</span>, <span class="hlFld-ContribAuthor ">Hsing-Pang  Hsieh</span>, <span class="hlFld-ContribAuthor ">Ya-Hui  Chi</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 533-545. <a href="https://doi.org/10.1016/j.ejmech.2018.03.064" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.064%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252BBPR1K653%252Bderivatives%252Btargeting%252Bthe%252Bback%252Bpocket%252Bof%252BAurora%252Bkinases%252Bfor%252Bselective%252Bisoform%252Binhibition%26aulast%3DKe%26aufirst%3DYi-Yu%26date%3D2018%26volume%3D151%26spage%3D533%26epage%3D545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaling  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Hongjiang  Xu</span>, <span class="hlFld-ContribAuthor ">Xiabing  Li</span>, <span class="hlFld-ContribAuthor ">Lijun  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Baolin  Li</span>, <span class="hlFld-ContribAuthor ">Xiquan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>147 </em>, 77-89. <a href="https://doi.org/10.1016/j.ejmech.2018.01.090" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.090%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D6%25252C7-Dimorpholinoalkoxy%252Bquinazoline%252Bderivatives%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bwith%252Benhanced%252Bantiproliferative%252Bactivities%252Bagainst%252Btumor%252Bcells%26aulast%3DZhang%26aufirst%3DYaling%26date%3D2018%26volume%3D147%26spage%3D77%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.  Sudhagar</span>, <span class="hlFld-ContribAuthor ">S.  Sathya</span>, <span class="hlFld-ContribAuthor ">R.  Anuradha</span>, <span class="hlFld-ContribAuthor ">G.  Gokulapriya</span>, <span class="hlFld-ContribAuthor ">Y.  Geetharani</span>, <span class="hlFld-ContribAuthor ">B. S.  Lakshmi</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of epidermal growth factor receptor by ferulic acid and 4-vinylguaiacol in human breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Biotechnology Letters</span><span> <strong>2018,</strong> <em>40 </em>
                                    (2)
                                     , 257-262. <a href="https://doi.org/10.1007/s10529-017-2475-2" title="DOI URL">https://doi.org/10.1007/s10529-017-2475-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10529-017-2475-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10529-017-2475-2%26sid%3Dliteratum%253Aachs%26jtitle%3DBiotechnology%2520Letters%26atitle%3DInhibition%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Bby%252Bferulic%252Bacid%252Band%252B4-vinylguaiacol%252Bin%252Bhuman%252Bbreast%252Bcancer%252Bcells%26aulast%3DSudhagar%26aufirst%3DS.%26date%3D2018%26date%3D2017%26volume%3D40%26issue%3D2%26spage%3D257%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ho-Chung  Chen</span>, <span class="hlFld-ContribAuthor ">Jairo  Sierra</span>, <span class="hlFld-ContribAuthor ">Lumeng Jenny  Yu</span>, <span class="hlFld-ContribAuthor ">Robert  Cerchio</span>, <span class="hlFld-ContribAuthor ">Brian A.  Wall</span>, <span class="hlFld-ContribAuthor ">James  Goydos</span>, <span class="hlFld-ContribAuthor ">Suzie  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Activation of Grm1 expression by mutated BRaf (V600E)
              in vitro
              and
              in vivo. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (5)
                                     , 5861-5875. <a href="https://doi.org/10.18632/oncotarget.23637" title="DOI URL">https://doi.org/10.18632/oncotarget.23637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.23637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.23637%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DActivation%252Bof%252BGrm1%252Bexpression%252Bby%252Bmutated%252BBRaf%252B%252528V600E%252529%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DChen%26aufirst%3DHo-Chung%26date%3D2018%26date%3D2017%26volume%3D9%26issue%3D5%26spage%3D5861%26epage%3D5875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Drug-target interactions that involve the replacement or displacement of magnesium ions. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (24)
                                     , 5355-5372. <a href="https://doi.org/10.1016/j.bmcl.2017.11.002" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.11.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDrug-target%252Binteractions%252Bthat%252Binvolve%252Bthe%252Breplacement%252Bor%252Bdisplacement%252Bof%252Bmagnesium%252Bions%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2017%26volume%3D27%26issue%3D24%26spage%3D5355%26epage%3D5372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Sun</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Chuansheng  Li</span>, <span class="hlFld-ContribAuthor ">Ru  Si</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Pan</span>, <span class="hlFld-ContribAuthor ">Binghe  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1 H -indazole-3-amine as multi-target RTKs inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>141 </em>, 373-385. <a href="https://doi.org/10.1016/j.ejmech.2017.10.008" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Banti-angiogenesis%252Bagents.%252BPart%252B8%25253A%252BDiaryl%252Bthiourea%252Bbearing%252B1%252BH%252B-indazole-3-amine%252Bas%252Bmulti-target%252BRTKs%252Binhibitors%26aulast%3DSun%26aufirst%3DYing%26date%3D2017%26volume%3D141%26spage%3D373%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Xingyue  Ji</span>, <span class="hlFld-ContribAuthor ">Mengyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Chuansheng  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Sun</span>, <span class="hlFld-ContribAuthor ">Ru  Si</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Pan</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Wang</span>, <span class="hlFld-ContribAuthor ">Weina  Ma</span>, <span class="hlFld-ContribAuthor ">Bingling  Dai</span>, <span class="hlFld-ContribAuthor ">Binghe  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (62)
                                     , 104745-104760. <a href="https://doi.org/10.18632/oncotarget.20065" title="DOI URL">https://doi.org/10.18632/oncotarget.20065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.20065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.20065%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DDiscovery%252Band%252Bevaluation%252Bof%252Btriple%252Binhibitors%252Bof%252BVEGFR-2%25252C%252BTIE-2%252Band%252BEphB4%252Bas%252Banti-angiogenic%252Band%252Banti-cancer%252Bagents%26aulast%3DZhang%26aufirst%3DLin%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D62%26spage%3D104745%26epage%3D104760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunmei  Li</span>, <span class="hlFld-ContribAuthor ">Furen  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient synthesis of novel furo[2,3- d ]pyrimidine derivatives under catalyst-free conditions. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (16)
                                     , 1572-1575. <a href="https://doi.org/10.1016/j.tetlet.2017.03.019" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.03.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.03.019%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DEfficient%252Bsynthesis%252Bof%252Bnovel%252Bfuro%25255B2%25252C3-%252Bd%252B%25255Dpyrimidine%252Bderivatives%252Bunder%252Bcatalyst-free%252Bconditions%26aulast%3DLi%26aufirst%3DChunmei%26date%3D2017%26volume%3D58%26issue%3D16%26spage%3D1572%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Darcie A.  Cook</span>, <span class="hlFld-ContribAuthor ">Malú G.  Tansey</span>. </span><span class="cited-content_cbyCitation_article-title">LRRK2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 107-116. <a href="https://doi.org/10.1007/978-3-319-44022-4_9" title="DOI URL">https://doi.org/10.1007/978-3-319-44022-4_9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-44022-4_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-44022-4_9%26sid%3Dliteratum%253Aachs%26atitle%3DLRRK2%26aulast%3DCook%26aufirst%3DDarcie%2BA.%26date%3D2017%26date%3D2016%26spage%3D107%26epage%3D116%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNeuroimmune%252BPharmacology%26aulast%3DIkezu%26aufirst%3DTsuneya%26date%3D2017%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priya  Mahajan</span>, <span class="hlFld-ContribAuthor ">Nitasha  Suri</span>, <span class="hlFld-ContribAuthor ">Rukmankesh  Mehra</span>, <span class="hlFld-ContribAuthor ">Monika  Gupta</span>, <span class="hlFld-ContribAuthor ">Amit  Kumar</span>, <span class="hlFld-ContribAuthor ">Shashank Kr.  Singh</span>, <span class="hlFld-ContribAuthor ">Amit  Nargotra</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel small molecule EGFR inhibitory leads by structure and ligand-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2017,</strong> <em>26 </em>
                                    (1)
                                     , 74-92. <a href="https://doi.org/10.1007/s00044-016-1728-2" title="DOI URL">https://doi.org/10.1007/s00044-016-1728-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-016-1728-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-016-1728-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DDiscovery%252Bof%252Bnovel%252Bsmall%252Bmolecule%252BEGFR%252Binhibitory%252Bleads%252Bby%252Bstructure%252Band%252Bligand-based%252Bvirtual%252Bscreening%26aulast%3DMahajan%26aufirst%3DPriya%26date%3D2017%26date%3D2016%26volume%3D26%26issue%3D1%26spage%3D74%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tomislav  Gregorić</span>, <span class="hlFld-ContribAuthor ">Mirela  Sedić</span>, <span class="hlFld-ContribAuthor ">Petra  Grbčić</span>, <span class="hlFld-ContribAuthor ">Andrea  Tomljenović Paravić</span>, <span class="hlFld-ContribAuthor ">Sandra  Kraljević Pavelić</span>, <span class="hlFld-ContribAuthor ">Mario  Cetina</span>, <span class="hlFld-ContribAuthor ">Robert  Vianello</span>, <span class="hlFld-ContribAuthor ">Silvana  Raić-Malić</span>. </span><span class="cited-content_cbyCitation_article-title">Novel pyrimidine-2,4-dione–1,2,3-triazole and furo[2,3-d]pyrimidine-2-one–1,2,3-triazole hybrids as potential anti-cancer agents: Synthesis, computational and X-ray analysis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>125 </em>, 1247-1267. <a href="https://doi.org/10.1016/j.ejmech.2016.11.028" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.11.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.11.028%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bpyrimidine-2%25252C4-dione%2525E2%252580%2525931%25252C2%25252C3-triazole%252Band%252Bfuro%25255B2%25252C3-d%25255Dpyrimidine-2-one%2525E2%252580%2525931%25252C2%25252C3-triazole%252Bhybrids%252Bas%252Bpotential%252Banti-cancer%252Bagents%25253A%252BSynthesis%25252C%252Bcomputational%252Band%252BX-ray%252Banalysis%252Band%252Bbiological%252Bevaluation%26aulast%3DGregori%25C4%2587%26aufirst%3DTomislav%26date%3D2017%26volume%3D125%26spage%3D1247%26epage%3D1267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renato  Ferreira de Freitas</span>, <span class="hlFld-ContribAuthor ">Matthieu  Schapira</span>. </span><span class="cited-content_cbyCitation_article-title">A systematic analysis of atomic protein–ligand interactions in the PDB. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2017,</strong> <em>8 </em>
                                    (10)
                                     , 1970-1981. <a href="https://doi.org/10.1039/C7MD00381A" title="DOI URL">https://doi.org/10.1039/C7MD00381A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00381A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00381A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DA%252Bsystematic%252Banalysis%252Bof%252Batomic%252Bprotein%2525E2%252580%252593ligand%252Binteractions%252Bin%252Bthe%252BPDB%26aulast%3DFerreira%2Bde%2BFreitas%26aufirst%3DRenato%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D10%26spage%3D1970%26epage%3D1981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">F.  Bysting</span>, <span class="hlFld-ContribAuthor ">S.  Bugge</span>, <span class="hlFld-ContribAuthor ">E.  Sundby</span>, <span class="hlFld-ContribAuthor ">B. H.  Hoff</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of Heck coupling on 6-bromo[2,3-d]thienopyrimidines for construction of new EGFR inhibitor lead structures. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2017,</strong> <em>7 </em>
                                    (30)
                                     , 18569-18577. <a href="https://doi.org/10.1039/C7RA01961K" title="DOI URL">https://doi.org/10.1039/C7RA01961K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA01961K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA01961K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DInvestigation%252Bof%252BHeck%252Bcoupling%252Bon%252B6-bromo%25255B2%25252C3-d%25255Dthienopyrimidines%252Bfor%252Bconstruction%252Bof%252Bnew%252BEGFR%252Binhibitor%252Blead%252Bstructures%26aulast%3DBysting%26aufirst%3DF.%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D30%26spage%3D18569%26epage%3D18577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Han</span>, <span class="hlFld-ContribAuthor ">Svein Jacob  Kaspersen</span>, <span class="hlFld-ContribAuthor ">Sondre  Nervik</span>, <span class="hlFld-ContribAuthor ">Kristin G.  Nørsett</span>, <span class="hlFld-ContribAuthor ">Eirik  Sundby</span>, <span class="hlFld-ContribAuthor ">Bård Helge  Hoff</span>. </span><span class="cited-content_cbyCitation_article-title">Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>119 </em>, 278-299. <a href="https://doi.org/10.1016/j.ejmech.2016.04.054" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.054%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChiral%252B6-aryl-furo%25255B2%25252C3-d%25255Dpyrimidin-4-amines%252Bas%252BEGFR%252Binhibitors%26aulast%3DHan%26aufirst%3DJin%26date%3D2016%26volume%3D119%26spage%3D278%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Xiang  Li</span>, <span class="hlFld-ContribAuthor ">Zigang  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Statistical analysis of EGFR structures’ performance in virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2015,</strong> <em>29 </em>
                                    (11)
                                     , 1045-1055. <a href="https://doi.org/10.1007/s10822-015-9877-9" title="DOI URL">https://doi.org/10.1007/s10822-015-9877-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-015-9877-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-015-9877-9%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DStatistical%252Banalysis%252Bof%252BEGFR%252Bstructures%2525E2%252580%252599%252Bperformance%252Bin%252Bvirtual%252Bscreening%26aulast%3DLi%26aufirst%3DYan%26date%3D2015%26date%3D2015%26volume%3D29%26issue%3D11%26spage%3D1045%26epage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Sun</span>, <span class="hlFld-ContribAuthor ">Xin-Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Peng-Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2015,</strong> <em>5 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep13934" title="DOI URL">https://doi.org/10.1038/srep13934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep13934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep13934%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDiscovery%252Bof%252Ba%252Bseries%252Bof%252Bnovel%252Bphenylpiperazine%252Bderivatives%252Bas%252BEGFR%252BTK%252Binhibitors%26aulast%3DSun%26aufirst%3DJuan%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linlu  Qi</span>, <span class="hlFld-ContribAuthor ">Yangseon  Kim</span>, <span class="hlFld-ContribAuthor ">Cong  Jiang</span>, <span class="hlFld-ContribAuthor ">Yang  Li</span>, <span class="hlFld-ContribAuthor ">Youliang  Peng</span>, <span class="hlFld-ContribAuthor ">Jin-Rong  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Activation of Mst11 and Feedback Inhibition of Germ Tube Growth in
              Magnaporthe oryzae. </span><span class="cited-content_cbyCitation_journal-name">Molecular Plant-Microbe Interactions®</span><span> <strong>2015,</strong> <em>28 </em>
                                    (8)
                                     , 881-891. <a href="https://doi.org/10.1094/MPMI-12-14-0391-R" title="DOI URL">https://doi.org/10.1094/MPMI-12-14-0391-R</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1094/MPMI-12-14-0391-R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1094%2FMPMI-12-14-0391-R%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Plant-Microbe%2520Interactions%25C2%25AE%26atitle%3DActivation%252Bof%252BMst11%252Band%252BFeedback%252BInhibition%252Bof%252BGerm%252BTube%252BGrowth%252Bin%252BMagnaporthe%252Boryzae%26aulast%3DQi%26aufirst%3DLinlu%26date%3D2015%26volume%3D28%26issue%3D8%26spage%3D881%26epage%3D891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steffen  Bugge</span>, <span class="hlFld-ContribAuthor ">Ingri Ullestad  Moen</span>, <span class="hlFld-ContribAuthor ">Kent-Ove  Kragseth Sylte</span>, <span class="hlFld-ContribAuthor ">Eirik  Sundby</span>, <span class="hlFld-ContribAuthor ">Bård Helge  Hoff</span>. </span><span class="cited-content_cbyCitation_article-title">Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>94 </em>, 175-194. <a href="https://doi.org/10.1016/j.ejmech.2015.03.004" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTruncated%252Bstructures%252Bused%252Bin%252Bsearch%252Bfor%252Bnew%252Blead%252Bcompounds%252Band%252Bin%252Ba%252Bretrospective%252Banalysis%252Bof%252Bthienopyrimidine-based%252BEGFR%252Binhibitors%26aulast%3DBugge%26aufirst%3DSteffen%26date%3D2015%26volume%3D94%26spage%3D175%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2015,</strong> <em>94 </em>, 9-25. <a href="https://doi.org/10.1016/j.phrs.2015.01.003" title="DOI URL">https://doi.org/10.1016/j.phrs.2015.01.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2015.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2015.01.003%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DSrc%252Bprotein-tyrosine%252Bkinase%252Bstructure%25252C%252Bmechanism%25252C%252Band%252Bsmall%252Bmolecule%252Binhibitors%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2015%26volume%3D94%26spage%3D9%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew B.  West</span>. </span><span class="cited-content_cbyCitation_article-title">Ten
              Y
              ears and
              C
              ounting:
              M
              oving
              L
              eucine‐
              R
              ich
              Repeat
              K
              inase 2
              I
              nhibitors to the
              C
              linic. </span><span class="cited-content_cbyCitation_journal-name">Movement Disorders</span><span> <strong>2015,</strong> <em>30 </em>
                                    (2)
                                     , 180-189. <a href="https://doi.org/10.1002/mds.26075" title="DOI URL">https://doi.org/10.1002/mds.26075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/mds.26075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmds.26075%26sid%3Dliteratum%253Aachs%26jtitle%3DMovement%2520Disorders%26atitle%3DTen%252BY%252Bears%252Band%252BC%252Bounting%25253A%252BM%252Boving%252BL%252Beucine%2525E2%252580%252590%252BR%252Bich%252BRepeat%252BK%252Binase%252B2%252BI%252Bnhibitors%252Bto%252Bthe%252BC%252Blinic%26aulast%3DWest%26aufirst%3DAndrew%2BB.%26date%3D2015%26date%3D2014%26volume%3D30%26issue%3D2%26spage%3D180%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kumaravel  Mohankumar</span>, <span class="hlFld-ContribAuthor ">Sankar  Pajaniradje</span>, <span class="hlFld-ContribAuthor ">Subhashree  Sridharan</span>, <span class="hlFld-ContribAuthor ">Vivek Kumar  Singh</span>, <span class="hlFld-ContribAuthor ">Larance  Ronsard</span>, <span class="hlFld-ContribAuthor ">Akhil C.  Banerjea</span>, <span class="hlFld-ContribAuthor ">Benson Chellakkan  Selvanesan</span>, <span class="hlFld-ContribAuthor ">Mohane Selvaraj  Coumar</span>, <span class="hlFld-ContribAuthor ">Latha  Periyasamy</span>, <span class="hlFld-ContribAuthor ">Rukkumani  Rajagopalan</span>. </span><span class="cited-content_cbyCitation_article-title">Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways. </span><span class="cited-content_cbyCitation_journal-name">Cellular Oncology</span><span> <strong>2014,</strong> <em>37 </em>
                                    (6)
                                     , 439-454. <a href="https://doi.org/10.1007/s13402-014-0207-3" title="DOI URL">https://doi.org/10.1007/s13402-014-0207-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13402-014-0207-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13402-014-0207-3%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520Oncology%26atitle%3DApoptosis%252Binduction%252Bby%252Ban%252Banalog%252Bof%252Bcurcumin%252B%252528BDMC-A%252529%252Bin%252Bhuman%252Blaryngeal%252Bcarcinoma%252Bcells%252Bthrough%252Bintrinsic%252Band%252Bextrinsic%252Bpathways%26aulast%3DMohankumar%26aufirst%3DKumaravel%26date%3D2014%26date%3D2014%26volume%3D37%26issue%3D6%26spage%3D439%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Shen</span>, <span class="hlFld-ContribAuthor ">Hua  Yang</span>, <span class="hlFld-ContribAuthor ">Jinjie  Shen</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR mutants with non-cognate kinase inhibitors in non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2014,</strong> <em>23 </em>
                                    (10)
                                     , 4510-4530. <a href="https://doi.org/10.1007/s00044-014-1012-2" title="DOI URL">https://doi.org/10.1007/s00044-014-1012-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-014-1012-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-014-1012-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DTargeting%252BEGFR%252Bmutants%252Bwith%252Bnon-cognate%252Bkinase%252Binhibitors%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DWang%26aufirst%3DBo%26date%3D2014%26date%3D2014%26volume%3D23%26issue%3D10%26spage%3D4510%26epage%3D4530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Cong</span>, <span class="hlFld-ContribAuthor ">Zhi-Kuan  Xia</span>, <span class="hlFld-ContribAuthor ">Rong-Ya  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the TGF-β Receptor with Kinase Inhibitors for Scleroderma Therapy. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2014,</strong> <em>347 </em>
                                    (9)
                                     , 609-615. <a href="https://doi.org/10.1002/ardp.201400116" title="DOI URL">https://doi.org/10.1002/ardp.201400116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201400116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201400116%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DTargeting%252Bthe%252BTGF-%2525CE%2525B2%252BReceptor%252Bwith%252BKinase%252BInhibitors%252Bfor%252BScleroderma%252BTherapy%26aulast%3DCong%26aufirst%3DLin%26date%3D2014%26date%3D2014%26volume%3D347%26issue%3D9%26spage%3D609%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2014,</strong> <em>87 </em>, 42-59. <a href="https://doi.org/10.1016/j.phrs.2014.06.001" title="DOI URL">https://doi.org/10.1016/j.phrs.2014.06.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2014.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2014.06.001%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DErbB%25252FHER%252Bprotein-tyrosine%252Bkinases%25253A%252BStructures%252Band%252Bsmall%252Bmolecule%252Binhibitors%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2014%26volume%3D87%26spage%3D42%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Svein Jacob  Kaspersen</span>, <span class="hlFld-ContribAuthor ">Jin  Han</span>, <span class="hlFld-ContribAuthor ">Kristin G.  Nørsett</span>, <span class="hlFld-ContribAuthor ">Line  Rydså</span>, <span class="hlFld-ContribAuthor ">Eli  Kjøbli</span>, <span class="hlFld-ContribAuthor ">Steffen  Bugge</span>, <span class="hlFld-ContribAuthor ">Geir  Bjørkøy</span>, <span class="hlFld-ContribAuthor ">Eirik  Sundby</span>, <span class="hlFld-ContribAuthor ">Bård Helge  Hoff</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2014,</strong> <em>59 </em>, 69-82. <a href="https://doi.org/10.1016/j.ejps.2014.04.011" title="DOI URL">https://doi.org/10.1016/j.ejps.2014.04.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2014.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2014.04.011%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DIdentification%252Bof%252Bnew%252B4-N-substituted%252B6-aryl-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine-4-amines%252Bas%252Bhighly%252Bpotent%252BEGFR-TK%252Binhibitors%252Bwith%252BSrc-family%252Bactivity%26aulast%3DKaspersen%26aufirst%3DSvein%2BJacob%26date%3D2014%26volume%3D59%26spage%3D69%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinghao  Ai</span>, <span class="hlFld-ContribAuthor ">Yingjia  Sun</span>, <span class="hlFld-ContribAuthor ">Haidong  Wang</span>, <span class="hlFld-ContribAuthor ">Shun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity. </span><span class="cited-content_cbyCitation_journal-name">Amino Acids</span><span> <strong>2014,</strong> <em>46 </em>
                                    (7)
                                     , 1635-1648. <a href="https://doi.org/10.1007/s00726-014-1716-0" title="DOI URL">https://doi.org/10.1007/s00726-014-1716-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00726-014-1716-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00726-014-1716-0%26sid%3Dliteratum%253Aachs%26jtitle%3DAmino%2520Acids%26atitle%3DA%252Bsystematic%252Bprofile%252Bof%252Bclinical%252Binhibitors%252Bresponsive%252Bto%252BEGFR%252Bsomatic%252Bamino%252Bacid%252Bmutations%252Bin%252Blung%252Bcancer%25253A%252Bimplication%252Bfor%252Bthe%252Bmolecular%252Bmechanism%252Bof%252Bdrug%252Bresistance%252Band%252Bsensitivity%26aulast%3DAi%26aufirst%3DXinghao%26date%3D2014%26date%3D2014%26volume%3D46%26issue%3D7%26spage%3D1635%26epage%3D1648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Sudhir  Raghavan</span>, <span class="hlFld-ContribAuthor ">Michael  Ihnat</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Thorpe</span>, <span class="hlFld-ContribAuthor ">Bryan C.  Disch</span>, <span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Lora C.  Bailey-Downs</span>, <span class="hlFld-ContribAuthor ">Nicholas F.  Dybdal-Hargreaves</span>, <span class="hlFld-ContribAuthor ">Cristina C.  Rohena</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (14)
                                     , 3753-3772. <a href="https://doi.org/10.1016/j.bmc.2014.04.049" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.04.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bdesign%252Band%252Bdiscovery%252Bof%252Bwater%252Bsoluble%252B4-substituted-2%25252C6-dimethylfuro%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bmultitargeted%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Band%252Bmicrotubule%252Btargeting%252Bantitumor%252Bagents%26aulast%3DZhang%26aufirst%3DXin%26date%3D2014%26volume%3D22%26issue%3D14%26spage%3D3753%26epage%3D3772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yung  Chang Hsu</span>, <span class="hlFld-ContribAuthor ">Yi-Yu  Ke</span>, <span class="hlFld-ContribAuthor ">Hui-Yi  Shiao</span>, <span class="hlFld-ContribAuthor ">Chieh-Chien  Lee</span>, <span class="hlFld-ContribAuthor ">Wen-Hsing  Lin</span>, <span class="hlFld-ContribAuthor ">Chun-Hwa  Chen</span>, <span class="hlFld-ContribAuthor ">Kuei-Jung  Yen</span>, <span class="hlFld-ContribAuthor ">John T.-A.  Hsu</span>, <span class="hlFld-ContribAuthor ">Chungming  Chang</span>, <span class="hlFld-ContribAuthor ">Hsing-Pang  Hsieh</span>. </span><span class="cited-content_cbyCitation_article-title">Facile Identification of Dual FLT3-Aurora A Inhibitors: A Computer-Guided Drug Design Approach. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2014,</strong> <em>9 </em>
                                    (5)
                                     , 953-961. <a href="https://doi.org/10.1002/cmdc.201300571" title="DOI URL">https://doi.org/10.1002/cmdc.201300571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201300571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201300571%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DFacile%252BIdentification%252Bof%252BDual%252BFLT3-Aurora%2525E2%252580%252585A%252BInhibitors%25253A%252BA%252BComputer-Guided%252BDrug%252BDesign%252BApproach%26aulast%3DChang%25E2%2580%2585Hsu%26aufirst%3DYung%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D5%26spage%3D953%26epage%3D961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steffen  Bugge</span>, <span class="hlFld-ContribAuthor ">Svein Jacob  Kaspersen</span>, <span class="hlFld-ContribAuthor ">Synne  Larsen</span>, <span class="hlFld-ContribAuthor ">Unni  Nonstad</span>, <span class="hlFld-ContribAuthor ">Geir  Bjørkøy</span>, <span class="hlFld-ContribAuthor ">Eirik  Sundby</span>, <span class="hlFld-ContribAuthor ">Bård Helge  Hoff</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>75 </em>, 354-374. <a href="https://doi.org/10.1016/j.ejmech.2014.01.042" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.01.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.01.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.01.042%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593activity%252Bstudy%252Bleading%252Bto%252Bidentification%252Bof%252Ba%252Bhighly%252Bactive%252Bthienopyrimidine%252Bbased%252BEGFR%252Binhibitor%26aulast%3DBugge%26aufirst%3DSteffen%26date%3D2014%26volume%3D75%26spage%3D354%26epage%3D374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of EGFR small molecule inhibitors and their bindings to EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Construction of Furanopyrimidine Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amine, EtOH, Et<sub>3</sub>N, reflux: (b) boronic acid, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux; (c) carboxylic acid, EDCl, DCM, rt.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Interactions of <b>2a</b>, <b>3g</b>, and <b>4b</b> with EGFR. Hydrogen bonds are shown in red. Hydrophobic interactions are shown in black. Salt bridges are shown in pink. (B) Superimposition of structures of compound <b>2a</b> (orange) and <b>3g</b> (green) with EGFR. The distance of the meta position on ring-5 of <b>2a</b> to the carboxyl group (OD2 atom) of Asp831 is 5.91 Å (orange line), while adding the acetamide group to this meta position, the shortest distance between <b>3g</b> (C24 atom) with the carboxyl group (OD2 atom) of Asp831 decreases to 3.76 Å (red line). The H-bond between the primary hydroxyl group of <b>2a</b> and Asp831 is shown with a magenta dotted line. For clarity, the H-bond between <b>2a</b> and the residue M769 and all H-bonds between <b>3g</b> and EGFR are omitted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Structure of furanopyrimidine compound <b>4b</b> (yellow) bound to EGFR. (B) Superimposition of structures of EGFR (gray)/<b>2a</b> (orange) with EGFR (dark-green)/<b>4b</b> (yellow). The intramolecular and intermolecular H-bonds between <b>4b</b> and Asp831 are shown with brown dotted lines; the H-bond between <b>2a</b> and Asp831 is depicted with a purple dotted line; the salt bridge between <b>4b</b> and Asp831 is shown with a light-blue dotted line. (C) Superimposition of structures of EGFR (dark-green)/<b>4b</b> (yellow) with EGFR (purple)/<b>4c</b> (light-orange). The H-bond between <b>4c</b> and Asp831 is depicted with a dark-blue dotted line; the salt bridge between <b>4c</b> and Asp831 is shown with a magenta dotted line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/medium/jm-2013-00072p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Comparison of structures of EGFR (green)/<b>4b</b> (yellow) and EGFR (purple)/gefitinib (cyan). (B) Comparison of structures of EGFR (green)/<b>4b</b> (yellow) and EGFR (pink)/AEE788 (magenta). (C) Structures of <b>4b</b>, gefitinib, and AEE788. For comparison, the rings of compound structures are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-10/jm400072p/production/images/large/jm-2013-00072p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400072p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32467" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32467" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 71 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0ljRsl7Ll3yC_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through the “gatekeeper door”: exploiting the active kinase conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2681</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+the+%E2%80%9Cgatekeeper+door%E2%80%9D%3A+exploiting+the+active+kinase+conformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520the%2520%25E2%2580%259Cgatekeeper%2520door%25E2%2580%259D%253A%2520exploiting%2520the%2520active%2520kinase%2520conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2681%26epage%3D2694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0ljRsl7Ll3yC_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Huse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">The conformational plasticity of protein kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2FS0092-8674%2802%2900741-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12015977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=275-282&author=M.+Huseauthor=J.+Kuriyan&title=The+conformational+plasticity+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The conformational plasticity of protein kinases</span></div><div class="casAuthors">Huse, Morgan; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-282</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 48 refs.  Protein kinases operate in a large no. of distinct signaling pathways, where the tight regulation of their catalytic activity is crucial to the development and maintenance of eukaryotic organisms.  The catalytic domains of different kinases adopt strikingly similar structures when they are active.  By contrast, crystal structures of inactive kinases have revealed a marked plasticity in the kinase domain that allows the adoption of distinct conformations in response to interactions with specific regulatory domains or proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJrn7F3h4ej7Vg90H21EOLACvtfcHk0lgQZvdkfFcu3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D&md5=cd56edae94ad239f2ce7a5d6c8930cbb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900741-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900741-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuse%26aufirst%3DM.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DThe%2520conformational%2520plasticity%2520of%2520protein%2520kinases%26jtitle%3DCell%26date%3D2002%26volume%3D109%26spage%3D275%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Nagar, B.</span><span> </span><span class="NLM_article-title">c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)</span> <span class="citation_source-journal">J. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">1518S</span><span class="NLM_x">–</span> <span class="NLM_lpage">1523S</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1093%2Fjn%2F137.6.1518S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=17513418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1elur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2007&pages=1518S-1523S&author=B.+Nagar&title=c-Abl+tyrosine+kinase+and+inhibition+by+the+cancer+drug+imatinib+%28Gleevec%2FSTI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)</span></div><div class="casAuthors">Nagar, Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutrition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">6S-1</span>),
    <span class="NLM_cas:pages">1518S-1523S</span>CODEN:
                <span class="NLM_cas:coden">JONUAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-3166</span>.
    
            (<span class="NLM_cas:orgname">American Society for Nutrition</span>)
        </div><div class="casAbstract">The search for specific protein kinase inhibitors is an intense area of research because of the potential for drug development.  The small-mol. inhibitor imatinib (Gleevec/STI-571) can specifically inactivate the tyrosine kinase c-Abl, whose normal mechanism of autoinhibition is disrupted in chronic myelogenous leukemia.  Crystallog. anal. of c-Abl reveals that imatinib recognizes a distinct inactive conformation of the Abl kinase domain that relies on the mechanism of autoinhibition achieved in the context of a larger fragment of the protein.  This mechanism is distinct from that seen in the related Src family kinases, where autoinhibition is achieved through the internal engagement of a C-terminal phosphotyrosine residue by the Src homol. 2 domain (SH2) domain.  Notably, this phosphotyrosine residue is lacking in c-Abl, where instead autoinhibition is mediated by an interaction between the kinase domain and the N-terminal myristoyl modification.  Within the framework of these 2 distinct modes of autoinhibition, the SH3-SH2 unit is structurally conserved between Abl and Src, leading to large conformational differences in their kinase domains.  These differences help explain the ability of imatinib to preferentially inhibit Abl over Src.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbSjfYUuL1FLVg90H21EOLACvtfcHk0lgQZvdkfFcu3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1elur4%253D&md5=8c11f5f4abed3ab4b86ad99158ef0d8d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fjn%2F137.6.1518S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjn%252F137.6.1518S%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26atitle%3Dc-Abl%2520tyrosine%2520kinase%2520and%2520inhibition%2520by%2520the%2520cancer%2520drug%2520imatinib%2520%2528Gleevec%252FSTI-571%2529%26jtitle%3DJ.%2520Nutr.%26date%3D2007%26volume%3D137%26spage%3D1518S%26epage%3D1523S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Hubbard, S. R.</span><span> </span><span class="NLM_article-title">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5572</span><span class="NLM_x">–</span> <span class="NLM_lpage">5581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1093%2Femboj%2F16.18.5572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=9312016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFWmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=5572-5581&author=S.+R.+Hubbard&title=Crystal+structure+of+the+activated+insulin+receptor+tyrosine+kinase+in+complex+with+peptide+substrate+and+ATP+analog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span></div><div class="casAuthors">Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5572-5581</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The crystal structure of the phosphorylated, activated form of insulin receptor tyrosine kinase (I) in complex with an 18-residue peptide substrate (KKKLPATGDYMNMSPVGD), and the nonhydrolyzable ATP analog, AMP-PNP, was detd. at 1.9 Å resoln.  The activation loop (A-loop) of I undergoes a major conformational change upon autophosphorylation of Tyr-1158, Tyr-1162, and Tyr-1163 within the loop, resulting in unrestricted access of ATP and protein substrates to the I active site.  Phosphorylated Tyr-1163 (pTyr-1163) was the key phospho-Tyr group in stabilizing the conformation of the tris-phosphorylated A-loop, whereas pTyr-1158 was completely solvent-exposed, suggesting an availability for interaction with downstream signaling proteins.  The YMXM-contg. peptide substrate bound as a short anti-parallel β-strand to the C-terminal end of the A-loop, with the Met side-chains occupying 2 hydrophobic pockets on the C-terminal lobe of I.  The structure thus reveals the mol. basis for insulin receptor activation via autophosphorylation, and provides insights into I substrate specificity and the mechanism of phosphotransfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlJGdy9gorfbVg90H21EOLACvtfcHk0lgQZvdkfFcu3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFWmt74%253D&md5=99c1865418541c085220185310b7b533</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.18.5572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.18.5572%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520the%2520activated%2520insulin%2520receptor%2520tyrosine%2520kinase%2520in%2520complex%2520with%2520peptide%2520substrate%2520and%2520ATP%2520analog%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D5572%26epage%3D5581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, W. A.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">746</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2F372746a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=7997262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1994&pages=746-754&author=S.+R.+Hubbardauthor=L.+Weiauthor=L.+Ellisauthor=W.+A.+Hendrickson&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+human+insulin+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span></div><div class="casAuthors">Hubbard, Stevan R.; Wei, Lei; Ellis, Leland; Hendrickson, Wayne A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6508</span>),
    <span class="NLM_cas:pages">746-54</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The x-ray crystal structure of the tyrosine kinase domain of the human insulin receptor has been detd. by multiwavelength anomalous diffraction phasing and refined to 2.1 Å resoln.  The structure reveals the determinants of substrate preference for tyrosine rather than serine or threonine and a novel autoinhibition mechanism whereby one of the tyrosines that is autophosphorylated in response to insulin, Tyr 1162, is bound in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp222kk0byoTrVg90H21EOLACvtfcHk0lgQZvdkfFcu3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D&md5=ad60bacc76a642b2957c55ff82274cab</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F372746a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F372746a0%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520human%2520insulin%2520receptor%26jtitle%3DNature%26date%3D1994%26volume%3D372%26spage%3D746%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Sicheri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moarefi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the Src family tyrosine kinase Hck</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">602</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2F385602a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=9024658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2sXht1ymtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=1997&pages=602-609&author=F.+Sicheriauthor=I.+Moarefiauthor=J.+Kuriyan&title=Crystal+structure+of+the+Src+family+tyrosine+kinase+Hck"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the Src family tyrosine kinase Hck</span></div><div class="casAuthors">Sicheri, Frank; Moarefi, Ismail; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">6617</span>),
    <span class="NLM_cas:pages">602-609</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The crystal structure of the hematopoietic cell kinase Hck has been detd. at 2.6/2.9 Å resoln.  Inhibition of enzymic activity is a consequence of intramol. interactions of the enzyme's Src-homol. domains SH2 and SH3, with concomitant displacement of elements of the catalytic domain.  The conformation of the active site has similarities with that of inactive cyclin-dependent protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdo3t4KV6jLVg90H21EOLACvtfcHk0lhhPuMwNLDWjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1ymtLs%253D&md5=5703b01ea960313345d43e0f8047ffcf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2F385602a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F385602a0%26sid%3Dliteratum%253Aachs%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DMoarefi%26aufirst%3DI.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520Src%2520family%2520tyrosine%2520kinase%2520Hck%26jtitle%3DNature%26date%3D1997%26volume%3D385%26spage%3D602%26epage%3D609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Common and distinct elements in cellular signaling via EGF and FGF receptors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">1506</span><span class="NLM_x">–</span> <span class="NLM_lpage">1507</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2004&pages=1506-1507&author=J.+Schlessinger&title=Common+and+distinct+elements+in+cellular+signaling+via+EGF+and+FGF+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCommon%2520and%2520distinct%2520elements%2520in%2520cellular%2520signaling%2520via%2520EGF%2520and%2520FGF%2520receptors%26jtitle%3DScience%26date%3D2004%26volume%3D306%26spage%3D1506%26epage%3D1507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G.</span><span> </span><span class="NLM_article-title">ErbB receptors and signaling pathways in cancer</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.ceb.2008.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19208461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVClurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=177-184&author=N.+E.+Hynesauthor=G.+MacDonald&title=ErbB+receptors+and+signaling+pathways+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">ErbB receptors and signaling pathways in cancer</span></div><div class="casAuthors">Hynes, Nancy E.; MacDonald, Gwen</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-184</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ErbB receptor tyrosine kinases play important roles in normal physiol. and in cancer.  Epidermal growth factor receptor (EGFR) and ErbB2 in particular are mutated in many epithelial tumors, and clin. studies suggest that they play roles in cancer development and progression.  These receptors were intensely studied, not only to understand the mechanisms underlying their oncogenic potential, but also to exploit them as therapeutic targets.  ErbB receptors activate a multiplicity of intracellular pathways via their ability to interact with numerous signal transducers.  Furthermore, there are now many ErbB-targeted inhibitors used in the clinic.  In this review we will conc. on breast tumors with ERBB2 gene amplification/receptor overexpression and non-small cell lung cancer (NSCLC) with activating EGFR mutations.  We will discuss data showing the important role that the PI3K/Akt pathway plays, not only in cancer development, but also in response to targeted therapies.  Finally, mechanisms contributing to resistance to ErbB-targeted therapeutics will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0lju0mdtYpbVg90H21EOLACvtfcHk0lhhPuMwNLDWjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVClurc%253D&md5=217703dc2eff6a8157ce74a7c100a3fe</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2008.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2008.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DMacDonald%26aufirst%3DG.%26atitle%3DErbB%2520receptors%2520and%2520signaling%2520pathways%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D177%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ernst, E.</span><span> </span><span class="NLM_article-title">Mistletoe for cancer?</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=9-11&author=E.+Ernst&title=Mistletoe+for+cancer%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DE.%26atitle%3DMistletoe%2520for%2520cancer%253F%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D9%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Klapper, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschbaum, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sela, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarden, Y.</span><span> </span><span class="NLM_article-title">Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2000&pages=25-79&author=L.+N.+Klapperauthor=M.+H.+Kirschbaumauthor=M.+Selaauthor=Y.+Yarden&title=Biochemical+and+clinical+implications+of+the+ErbB%2FHER+signaling+network+of+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlapper%26aufirst%3DL.%2BN.%26aulast%3DKirschbaum%26aufirst%3DM.%2BH.%26aulast%3DSela%26aufirst%3DM.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DBiochemical%2520and%2520clinical%2520implications%2520of%2520the%2520ErbB%252FHER%2520signaling%2520network%2520of%2520growth%2520factor%2520receptors%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2000%26volume%3D77%26spage%3D25%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0lhhPuMwNLDWjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Å resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0lgcVI1mIq0YeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prichard, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasser, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekele, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. N.</span><span> </span><span class="NLM_article-title">Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F1078-0432.CCR-05-1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=16428506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=600-607&author=S.+Kimauthor=C.+N.+Prichardauthor=M.+N.+Younesauthor=Y.+D.+Yaziciauthor=S.+A.+Jasserauthor=B.+N.+Bekeleauthor=J.+N.+Myers&title=Cetuximab+and+irinotecan+interact+synergistically+to+inhibit+the+growth+of+orthotopic+anaplastic+thyroid+carcinoma+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice</span></div><div class="casAuthors">Kim, Seungwon; Prichard, Christopher N.; Younes, Maher N.; Yazici, Yasemin D.; Jasser, Samar A.; Bekele, B. Nebiyou; Myers, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">600-607</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic thyroid carcinoma (ATC) remains one of the most lethal known human cancers.  Targeted mol. therapy with cetuximab, a monoclonal antibody against epidermal growth factor receptor, offers new treatment potentials for patient with ATC.  Cetuximab has also been reported to have synergistic effects when combined with irinotecan, a topoisomerase inhibitor.  Therefore, we hypothesized that cetuximab and irinotecan would be effective in inhibiting the growth and progression of ATC in a murine orthotopic model.  Exptl. Design: The in vitro antiproliferative effects of cetuximab and irinotecan on ATC cell line ARO were examd.  We also studied the in vivo effects of cetuximab and irinotecan on the growth, invasion, and metastasis of orthotopic ATC tumors in nude mice.  The in vivo antitumor efficacy of cetuximab/irinotecan combination was also compared with that of doxorubicin.  Results: Cetuximab alone did not show any antiproliferative or proapoptotic effect on this cell line.  However, when combined with irinotecan, cetuximab potentiated the in vitro antiproliferative and proapoptotic effect of irinotecan.  Cetuximab, irinotecan, and cetuximab/irinotecan combination resulted in 77%, 79%, and 93% in vivo inhibition of tumor growth, resp.  Incidences of lymph node metastasis, laryngeal invasion, and tumor microvessel d. were also significantly decreased in these treatment groups.  Furthermore, the cetuximab/irinotecan combination was significantly more effective than doxorubicin in inhibiting the growth of orthotopic ATC xenografts.  Conclusions: Combination therapy with cetuximab/irinotecan inhibits the growth and progression of orthotopic ATC xenografts in nude mice.  Given the lack of curative options for patients with ATC, combination therapy with cetuximab and irinotecan treatment warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsHzVhsFHwebVg90H21EOLACvtfcHk0lgcVI1mIq0YeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlKgsA%253D%253D&md5=90f0a52d3c65268632c168a4cb4b633c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1325%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPrichard%26aufirst%3DC.%2BN.%26aulast%3DYounes%26aufirst%3DM.%2BN.%26aulast%3DYazici%26aufirst%3DY.%2BD.%26aulast%3DJasser%26aufirst%3DS.%2BA.%26aulast%3DBekele%26aufirst%3DB.%2BN.%26aulast%3DMyers%26aufirst%3DJ.%2BN.%26atitle%3DCetuximab%2520and%2520irinotecan%2520interact%2520synergistically%2520to%2520inhibit%2520the%2520growth%2520of%2520orthotopic%2520anaplastic%2520thyroid%2520carcinoma%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D600%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averbuch, S. D.</span><span> </span><span class="NLM_article-title">ZD1839 (‘Iressa’) as an anticancer agent</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=33-40&author=J.+Baselgaauthor=S.+D.+Averbuch&title=ZD1839+%28%E2%80%98Iressa%E2%80%99%29+as+an+anticancer+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26atitle%3DZD1839%2520%2528%25E2%2580%2598Iressa%25E2%2580%2599%2529%2520as%2520an%2520anticancer%2520agent%26jtitle%3DDrugs%26date%3D2000%26volume%3D60%26spage%3D33%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lgcVI1mIq0YeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12467226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=85-94&author=D.+W.+Rusnakauthor=K.+Lackeyauthor=K.+Affleckauthor=E.+R.+Woodauthor=K.+J.+Alligoodauthor=N.+Rhodesauthor=B.+R.+Keithauthor=D.+M.+Murrayauthor=W.+B.+Knightauthor=R.+J.+Mullinauthor=T.+M.+Gilmer&title=The+effects+of+the+novel%2C+reversible+epidermal+growth+factor+receptor%2FErbB-2+tyrosine+kinase+inhibitor%2C+GW2016%2C+on+the+growth+of+human+normal+and+tumor-derived+cell+lines+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo</span></div><div class="casAuthors">Rusnak, David W.; Lackey, Karen; Affleck, Karen; Wood, Edgar R.; Alligood, Krystal J.; Rhodes, Nelson; Keith, Barry R.; Murray, Doris M.; Knight, W. Blaine; Mullin, Robert J.; Gilmer, Tona M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) and ErbB-2 transmembrane tyrosine kinases are currently being targeted by various mechanisms in the treatment of cancer.  GW2016 is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, resp.  This report describes the efficacy in cell growth assays of GW2016 on human tumor cell lines overexpressing either EGFR or ErbB-2: HN5 (head and neck), A-431 (vulva), BT474 (breast), CaLu-3 (lung), and N87 (gastric).  Normal human foreskin fibroblasts, nontumorigenic epithelial cells (HB4a), and nonoverexpressing tumor cells (MCF-7 and T47D) were tested as neg. controls.  After 3 days of compd. exposure, av. IC50 values for growth inhibition in the EGFR- and ErbB-2-overexpressing tumor cell lines were <0.16 μM.  The av. selectivity for the tumor cells vs. the human foreskin fibroblast cell line was 100-fold.  Inhibition of EGFR and ErbB-2 receptor autophosphorylation and phosphorylation of the downstream modulator, AKT, was verified by Western blot anal. in the BT474 and HN5 cell lines.  As a measure of cytotoxicity vs. growth arrest, the HN5 and BT474 cells were assessed in an outgrowth assay after a transient exposure to GW2016.  The cells were treated for 3 days in five concns. of GW2016, and cell growth was monitored for an addnl. 12 days after removal of the compd.  In each of these tumor cell lines, concns. of GW2016 were reached where outgrowth did not occur.  Furthermore, growth arrest and cell death were obsd. in parallel expts., as detd. by bromodeoxyuridine incorporation and propidium iodide staining.  GW2016 treatment inhibited tumor xenograft growth of the HN5 and BT474 cells in a dose-responsive manner at 30 and 100 mg/kg orally, twice daily, with complete inhibition of tumor growth at the higher dose.  Together, these results indicate that GW2016 achieves excellent potency on tumor cells with selectivity for tumor vs. normal cells and suggest that GW2016 has value as a therapy for patients with tumors overexpressing either EGFR or ErbB-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5OJ41zsWu6rVg90H21EOLACvtfcHk0lhh1PF3SfT6ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtbs%253D&md5=64fd8cadce83eda3b9b82ab50f1e57b0</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DMurray%26aufirst%3DD.%2BM.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DThe%2520effects%2520of%2520the%2520novel%252C%2520reversible%2520epidermal%2520growth%2520factor%2520receptor%252FErbB-2%2520tyrosine%2520kinase%2520inhibitor%252C%2520GW2016%252C%2520on%2520the%2520growth%2520of%2520human%2520normal%2520and%2520tumor-derived%2520cell%2520lines%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2001%26volume%3D1%26spage%3D85%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0lhh1PF3SfT6ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Yokoi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaker, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazici, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebhun, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3716</span><span class="NLM_x">–</span> <span class="NLM_lpage">3725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3716-3725&author=K.+Yokoiauthor=P.+H.+Thakerauthor=S.+Yaziciauthor=R.+R.+Rebhunauthor=D.+H.+Namauthor=J.+Heauthor=S.+J.+Kimauthor=J.+L.+Abbruzzeseauthor=S.+R.+Hamiltonauthor=I.+J.+Fidler&title=Dual+inhibition+of+epidermal+growth+factor+receptor+and+vascular+endothelial+growth+factor+receptor+phosphorylation+by+AEE788+reduces+growth+and+metastasis+of+human+colon+carcinoma+in+an+orthotopic+nude+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DYazici%26aufirst%3DS.%26aulast%3DRebhun%26aufirst%3DR.%2BR.%26aulast%3DNam%26aufirst%3DD.%2BH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DHamilton%26aufirst%3DS.%2BR.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DDual%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520phosphorylation%2520by%2520AEE788%2520reduces%2520growth%2520and%2520metastasis%2520of%2520human%2520colon%2520carcinoma%2520in%2520an%2520orthotopic%2520nude%2520mouse%2520model%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3716%26epage%3D3725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavai, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6186</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F1078-0432.CCR-06-0642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=17062696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6186-6193&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=C.+Yuauthor=F.+R.+Luoauthor=S.+Oppenheimerauthor=H.+Zhangauthor=R.+A.+Smyklaauthor=H.+Mastalerzauthor=B.+E.+Finkauthor=J.+T.+Huntauthor=A.+V.+Gavaiauthor=G.+D.+Vite&title=Preclinical+antitumor+activity+of+BMS-599626%2C+a+pan-HER+kinase+inhibitor+that+inhibits+HER1%2FHER2+homodimer+and+heterodimer+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling</span></div><div class="casAuthors">Wong, Tai W.; Lee, Francis Y.; Yu, Chiang; Luo, Feng R.; Oppenheimer, Simone; Zhang, Hongjian; Smykla, Richard A.; Mastalerz, Harold; Fink, Brian E.; Hunt, John T.; Gavai, Ashvinikumar V.; Vite, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6186-6193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The studies described here are intended to characterize the ability of BMS-599626, a small-mol. inhibitor of the human epidermal growth factor receptor (HER) kinase family, to modulate signaling and growth of tumor cells that depend on HER1 and/or HER2.  Exptl. Design: The potency and selectivity of BMS-599626 were assessed in biochem. assays using recombinant protein kinases, as well as in cell proliferation assays using tumor cell lines with varying degrees of dependence on HER1 or HER2 signaling.  Modulation of receptor signaling was detd. in cell assays by Western blot analyses of receptor autophosphorylation and downstream signaling.  The ability of BMS-599626 to inhibit receptor heterodimer signaling in tumor cells was studied by receptor coimmunopptn.  Antitumor activity of BMS-599626 was evaluated using a no. of different xenograft models that represent a spectrum of human tumors with HER1 or HER2 overexpression.  Results: BMS-599626 inhibited HER1 and HER2 with IC50 of 20 and 30 nmol/L, resp., and was highly selective when tested against a broad panel of diverse protein kinases.  Biochem. studies suggested that BMS-599626 inhibited HER1 and HER2 through distinct mechanisms.  BMS-599626 abrogated HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 μmol/L.  BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors.  In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling.  BMS-599626 had antitumor activity in models that overexpress HER1 (GEO), as well as in models that have HER2 gene amplification (KPL4) or overexpression (Sal2), and there was good correlation between the inhibition of receptor signaling and antitumor activity.  Conclusions: BMS-599626 is a highly selective and potent inhibitor of HER1 and HER2 kinases and inhibits tumor cell proliferation through modulation of receptor signaling.  BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an addnl. mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth.  The preclin. data support the advancement of BMS-599626 into clin. development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgsCF6GDMPbVg90H21EOLACvtfcHk0lg-oD5PfMrwOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK&md5=a8350e2eb304a091fa82f1159e44c119</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0642%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmykla%26aufirst%3DR.%2BA.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DGavai%26aufirst%3DA.%2BV.%26aulast%3DVite%26aufirst%3DG.%2BD.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-599626%252C%2520a%2520pan-HER%2520kinase%2520inhibitor%2520that%2520inhibits%2520HER1%252FHER2%2520homodimer%2520and%2520heterodimer%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6186%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span> </span><span class="NLM_article-title">Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">18756</span><span class="NLM_x">–</span> <span class="NLM_lpage">18765</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1074%2Fjbc.M110.206193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=21454582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=18756-18765&author=K.+Aertgeertsauthor=R.+Skeneauthor=J.+Yanoauthor=B.+C.+Sangauthor=H.+Zouauthor=G.+Snellauthor=A.+Jenningsauthor=K.+Iwamotoauthor=N.+Habukaauthor=A.+Hirokawaauthor=T.+Ishikawaauthor=T.+Tanakaauthor=H.+Mikiauthor=Y.+Ohtaauthor=S.+Sogabe&title=Structural+analysis+of+the+mechanism+of+inhibition+and+allosteric+activation+of+the+kinase+domain+of+HER2+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein</span></div><div class="casAuthors">Aertgeerts, Kathleen; Skene, Robert; Yano, Jason; Sang, Bi-Ching; Zou, Hua; Snell, Gyorgy; Jennings, Andy; Iwamoto, Keiji; Habuka, Noriyuki; Hirokawa, Aki; Ishikawa, Tomoyasu; Tanaka, Toshimasa; Miki, Hiroshi; Ohta, Yoshikazu; Sogabe, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">18756-18765</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is implicated in many human cancers, and HER2 expression is predictive of human disease recurrence and prognosis.  Small mol. kinase inhibitors of EGFR and of both HER2 and EGFR have received approval for the treatment of cancer.  We present the first high resoln. crystal structure of the kinase domain of HER2 in complex with a selective inhibitor to understand protein activation, inhibition, and function at the mol. level.  HER2 kinase domain crystallizes as a dimer and suggests evidence for an allosteric mechanism of activation comparable with previously reported activation mechanisms for EGFR and HER4.  A unique Gly-rich region in HER2 following the α-helix C is responsible for increased conformational flexibility within the active site and could explain the low intrinsic catalytic activity previously reported for HER2.  In addn., we solved the crystal structure of the kinase domain of EGFR in complex with a HER2/EGFR dual inhibitor (TAK-285).  Comparison with previously reported inactive and active EGFR kinase domain structures gave insight into the mechanism of HER2 and EGFR inhibition and may help guide the design and development of new cancer drugs with improved potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomtAlJ0FGUX7Vg90H21EOLACvtfcHk0lg-oD5PfMrwOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL0%253D&md5=c7897f5363d6452f7b60a8ced0f2bc30</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.206193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.206193%26sid%3Dliteratum%253Aachs%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DHirokawa%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DSogabe%26aufirst%3DS.%26atitle%3DStructural%2520analysis%2520of%2520the%2520mechanism%2520of%2520inhibition%2520and%2520allosteric%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520HER2%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D18756%26epage%3D18765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oorui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, K.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-<i>d</i>]pyrimidine scaffold</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8030</span><span class="NLM_x">–</span> <span class="NLM_lpage">8050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2008634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8030-8050&author=T.+Ishikawaauthor=M.+Setoauthor=H.+Bannoauthor=Y.+Kawakitaauthor=M.+Ooruiauthor=T.+Taniguchiauthor=Y.+Ohtaauthor=T.+Tamuraauthor=A.+Nakayamaauthor=H.+Mikiauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=N.+Habukaauthor=S.+Sogabeauthor=J.+Yanoauthor=K.+Aertgeertsauthor=K.+Kamiyama&title=Design+and+synthesis+of+novel+human+epidermal+growth+factor+receptor+2+%28HER2%29%2Fepidermal+growth+factor+receptor+%28EGFR%29+dual+inhibitors+bearing+a+pyrrolo%5B3%2C2-d%5Dpyrimidine+scaffold"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold</span></div><div class="casAuthors">Ishikawa, Tomoyasu; Seto, Masaki; Banno, Hiroshi; Kawakita, Youichi; Oorui, Mami; Taniguchi, Takahiko; Ohta, Yoshikazu; Tamura, Toshiya; Nakayama, Akiko; Miki, Hiroshi; Kamiguchi, Hidenori; Tanaka, Toshimasa; Habuka, Noriyuki; Sogabe, Satoshi; Yano, Jason; Aertgeerts, Kathleen; Kamiyama, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8030-8050</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer.  To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivs., e.g. I, capable of fitting into the receptors' ATP binding site.  Among the prepd. compds., I showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity.  The X-ray cocrystal structures of I with both HER2 and EGFR demonstrated that I interacts with the expected residues in their resp. ATP pockets.  Furthermore, reflecting its good oral bioavailability, I exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models.  On the basis of these findings, we report I (TAK-285) as a promising candidate for clin. development as a novel HER2/EGFR dual kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QtqAj6idYrVg90H21EOLACvtfcHk0lg-oD5PfMrwOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M&md5=ce030ac133a1c0ff7cb78b269ff85987</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm2008634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008634%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DBanno%26aufirst%3DH.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DOorui%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DKamiyama%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252Fepidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520dual%2520inhibitors%2520bearing%2520a%2520pyrrolo%255B3%252C2-d%255Dpyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8030%26epage%3D8050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+HER-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0lhHqtG8RImZkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520HER-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U S A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lhHqtG8RImZkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U%2520S%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0liaRJYe04EI-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Eskens, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mom, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amelsberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fsj.bjc.6604108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=18026190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=80-85&author=F.+A.+Eskensauthor=C.+H.+Momauthor=A.+S.+Plantingauthor=J.+A.+Gietemaauthor=A.+Amelsbergauthor=H.+Huismanauthor=L.+van+Doornauthor=H.+Burgerauthor=P.+Stopferauthor=J.+Verweijauthor=E.+G.+de+Vries&title=A+phase+I+dose+escalation+study+of+BIBW+2992%2C+an+irreversible+dual+inhibitor+of+epidermal+growth+factor+receptor+1+%28EGFR%29+and+2+%28HER2%29+tyrosine+kinase+in+a+2-week+on%2C+2-week+off+schedule+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clin. activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992.  An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was explored.  Thirty-eight patients were enrolled.  Dose levels were 10, 20, 30, 45, 70, 85, and 100 mg.  At 100 mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhea despite treatment with loperamide) occurred in two patients.  In the next-lower dose of 70 mg, DLT (grade 3 fatigue and ALAT elevation) occurred in one of six patients.  An intermediate dose level of 85 mg was studied.  Here DLT occurred in two patients (grade 3 diarrhea despite treatment and grade 2 diarrhea lasting more than 7 days despite treatment).  An addnl. 12 patients were treated at 70 mg.  BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose proportionality.  Pharmacodynamics anal. in skin biopsies did not show significant changes in EGFR-assocd. biomarkers.  However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was obsd.  No partial or complete responses were obsd., stable disease lasting more than four cycles was seen in seven patients.  The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD.  British Journal of Cancer (2008) 98, 80-85. doi:10.1038/sj.bjc.6604108 www.bjcancer.com Published online 20 Nov. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZL8pTnjAwrVg90H21EOLACvtfcHk0liaRJYe04EI-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D&md5=96a0be31145bf1691640109d69ff5dc0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604108%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%26aulast%3DMom%26aufirst%3DC.%2BH.%26aulast%3DPlanting%26aufirst%3DA.%2BS.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26aulast%3DAmelsberg%26aufirst%3DA.%26aulast%3DHuisman%26aufirst%3DH.%26aulast%3Dvan%2BDoorn%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%2520dual%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%25201%2520%2528EGFR%2529%2520and%25202%2520%2528HER2%2529%2520tyrosine%2520kinase%2520in%2520a%25202-week%2520on%252C%25202-week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraemer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1124%2Fjpet.112.197756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22888144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=342-350&author=F.+Solcaauthor=G.+Dahlauthor=A.+Zoephelauthor=G.+Baderauthor=M.+Sandersonauthor=C.+Kleinauthor=O.+Kraemerauthor=F.+Himmelsbachauthor=E.+Haaksmaauthor=G.+R.+Adolf&title=Target+Binding+Properties+and+Cellular+Activity+of+Afatinib+%28BIBW+2992%29%2C+an+Irreversible+ErbB+Family+Blocker"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span></div><div class="casAuthors">Solca, Flavio; Dahl, Goeran; Zoephel, Andreas; Bader, Gerd; Sanderson, Michael; Klein, Christian; Kraemer, Oliver; Himmelsbach, Frank; Haaksma, Eric; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers.  Several targeted drugs have been developed, including antibodies and small-mol. kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions.  Understanding the precise pharmacol. properties of these compds. is important for optimal use in clin. practice.  Afatinib [BIBW 2992; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide] is an ATP-competitive anilinoquinazoline deriv. harboring a reactive acrylamide group.  It was designed to covalently bind and irreversibly block enzymically active ErbB receptor family members.  Here, we show by X-ray crystallog. the covalent binding of afatinib to wild-type epidermal growth factor receptor (EGFR) and by mass spectrometry the covalent interaction with EGFR, EGFRL858R/T790M, human epidermal growth factor receptor 2 (HER2), and ErbB-4.  Afatinib potently inhibits the enzymatic activity of ErbB-4 (EC50 = 1 nM) and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concns. below 100 nM.  N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butanamide (BI 37781), a close analog of afatinib lacking the acrylamide group and thus incapable of covalent bond formation, had similar potency on cells driven by EGFR or EGFRL858R, but less or no detectable activity on cells expressing EGFRL858R/T790M HER2 or ErbB-4.  These results stress the importance of the acrylamide group and show that afatinib differs from approved ErbB targeting agents by irreversibly inhibiting the kinase activity of all ErbB family members.  They provide a mechanistic rationale for the distinct pharmacol. features of this compd. and explain the clin. activity seen in some patients who are resistant to antibody or kinase inhibitor therapy because of secondary mutations or ErbB receptor "reprogramming.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofXgQqaKXv-bVg90H21EOLACvtfcHk0liaRJYe04EI-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE&md5=4a57df32abe8101f287fc6251f63f92d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.197756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.197756%26sid%3Dliteratum%253Aachs%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DKraemer%26aufirst%3DO.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DTarget%2520Binding%2520Properties%2520and%2520Cellular%2520Activity%2520of%2520Afatinib%2520%2528BIBW%25202992%2529%252C%2520an%2520Irreversible%2520ErbB%2520Family%2520Blocker%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D342%26epage%3D350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1978</span><span class="NLM_x">–</span> <span class="NLM_lpage">1987</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F1535-7163.MCT-11-0730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22761403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1978-1987&author=O.+Kalousauthor=D.+Conklinauthor=A.+J.+Desaiauthor=N.+A.+O%E2%80%99Brienauthor=C.+Gintherauthor=L.+Andersonauthor=D.+J.+Cohenauthor=C.+D.+Brittenauthor=I.+Taylorauthor=J.+G.+Christensenauthor=D.+J.+Slamonauthor=R.+S.+Finn&title=Dacomitinib+%28PF-00299804%29%2C+an+irreversible+Pan-HER+inhibitor%2C+inhibits+proliferation+of+HER2-amplified+breast+cancer+cell+lines+resistant+to+trastuzumab+and+lapatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib</span></div><div class="casAuthors">Kalous, Ondrej; Conklin, Dylan; Desai, Amrita J.; O'Brien, Neil A.; Ginther, Charles; Anderson, Lee; Cohen, David J.; Britten, Carolyn D.; Taylor, Ian; Christensen, James G.; Slamon, Dennis J.; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1978-1987</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies.  Trastuzumab and lapatinib are std. treatments for HER2-amplified breast cancer, but a significant no. of patients do not respond or develop resistance to these drugs.  Here we evaluate the in vitro activity of dacomitinib (PF-00299804), an irreversible small mol. pan-HER inhibitor, in a large panel of human breast cancer cell lines with variable expression of the HER family receptors and ligands, and with variable sensitivity to trastuzumab and lapatinib.  Forty-seven human breast cancer and immortalized breast epithelial lines representing the known mol. subgroups of breast cancer were treated with dacomitinib to det. IC50 values.  HER2-amplified lines were far more likely to respond to dacomitinib than nonamplified lines (RR, 3.39; P < 0.0001).  Furthermore, HER2 mRNA and protein expression were quant. assocd. with response.  Dacomitinib reduced the phosphorylation of HER2, EGFR, HER4, AKT, and ERK in the majority of sensitive lines.  Dacomitinib exerted its antiproliferative effect through a combined G0-G1 arrest and an induction of apoptosis.  Dacomitinib inhibited growth in several HER2-amplified lines with de novo and acquired resistance to trastuzumab.  Dacomitinib maintained a high activity in lines with acquired resistance to lapatinib.  This study identifies HER2-amplified breast cancer lines as most sensitive to the antiproliferative effect of dacomitinib and provides a strong rationale for its clin. testing in HER2-amplified breast cancers resistant to trastuzumab and lapatinib.  Mol Cancer Ther; 11(9); 1978-87. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp55-QHIJqDk7Vg90H21EOLACvtfcHk0lh3lZsJhUJCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI&md5=b2b0677cbecb66e1e629742adffb0782</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0730%26sid%3Dliteratum%253Aachs%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DDacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520Pan-HER%2520inhibitor%252C%2520inhibits%2520proliferation%2520of%2520HER2-amplified%2520breast%2520cancer%2520cell%2520lines%2520resistant%2520to%2520trastuzumab%2520and%2520lapatinib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1978%26epage%3D1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seog Heo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbot, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span> </span><span class="NLM_article-title">Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3337</span><span class="NLM_x">–</span> <span class="NLM_lpage">3344</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1200%2FJCO.2011.40.9433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22753918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3337-3344&author=S.+S.+Ramalingamauthor=F.+Blackhallauthor=M.+Krzakowskiauthor=C.+H.+Barriosauthor=K.+Parkauthor=I.+Boverauthor=D.+Seog+Heoauthor=R.+Rosellauthor=D.+C.+Talbotauthor=R.+Frankauthor=S.+P.+Letrentauthor=A.+Ruiz-Garciaauthor=I.+Taylorauthor=J.+Q.+Liangauthor=A.+K.+Campbellauthor=J.+O%E2%80%99Connellauthor=M.+Boyer&title=Randomized+phase+II+study+of+dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-human+epidermal+growth+factor+receptor+inhibitor%2C+versus+erlotinib+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of dacomitinib (PF-00299804), and irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Blackhall, Fiona; Krzakowski, Maciej; Barrios, Carlos H.; Park, Keunchil; Bover, Isabel; Heo, Dae Seog; Rosell, Rafael; Talbot, Denis C.; Frank, Richard; Letrent, Stephen P.; Ruiz-Garcia, Ana; Taylor, Ian; Liang, Jane Q.; Campbell, Alicyn K.; O'Connell, Joseph; Boyer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3337-3344</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR1/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).  Patients and Methods Patients with NSCLC, Eastern Cooperative Oncol. Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily.  Results One hundred eighty-eight patients were randomly assigned.  Treatment arms were balanced for most clin. and mol. characteristics.  Median progression-free survival (PFS; primary end point) was 2.86 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (hazard ratio [HR] = 0.66; 95% CI, 0.47 to 0.91; two-sided P = .012); in patients with KRAS wild-type tumors, median PFS was 3.71 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (HR = 0.55; 95% CI, 0.35 to 0.85; two-sided P = .006); and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 mo for patients treated with dacomitinib and 1.84 mo for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37 to 0.99; two-sided P = .043).  Median overall survival was 9.53 mo for patients treated with dacomitinib and 7.44 mo for patients treated with erlotinib (HR = 0.80; 95% CI, 0.56 to 1.13; two-sided P = .205).  Adverse event-related discontinuations were uncommon in both arms.  Common treatment-related adverse events were dermatol. and gastrointestinal, predominantly grade 1 to 2, and more frequent with dacomitinib.  Conclusion Dacomitinib demonstrated significantly improved PFS vs. erlotinib, with acceptable toxicity.  PFS benefit was obsd. in most clin. and mol. subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHl-bReesXsbVg90H21EOLACvtfcHk0lh3lZsJhUJCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK&md5=bdc76102e0ae37fb3f5307c285f952d4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.9433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.9433%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DKrzakowski%26aufirst%3DM.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DSeog%2BHeo%26aufirst%3DD.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTalbot%26aufirst%3DD.%2BC.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DLetrent%26aufirst%3DS.%2BP.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DJ.%2BQ.%26aulast%3DCampbell%26aufirst%3DA.%2BK.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DM.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-human%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520versus%2520erlotinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3337%26epage%3D3344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Chang, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C. J.</span><span> </span><span class="NLM_article-title">Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.cllc.2012.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22607779" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=55-61&author=S.+C.+Changauthor=C.+Y.+Changauthor=S.+J.+Changauthor=M.+K.+Yuanauthor=Y.+C.+Laiauthor=Y.+C.+Liuauthor=C.+Y.+Chenauthor=L.+C.+Kuoauthor=C.+J.+Yu&title=Gefitinib-Related+Interstitial+Lung+Disease+in+Taiwanese+Patients+With+Non-Small-Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2012.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2012.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DChang%26aufirst%3DS.%2BJ.%26aulast%3DYuan%26aufirst%3DM.%2BK.%26aulast%3DLai%26aufirst%3DY.%2BC.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DKuo%26aufirst%3DL.%2BC.%26aulast%3DYu%26aufirst%3DC.%2BJ.%26atitle%3DGefitinib-Related%2520Interstitial%2520Lung%2520Disease%2520in%2520Taiwanese%2520Patients%2520With%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2012%26volume%3D14%26spage%3D55%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Widakowich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro, G.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Azambuja, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awada, A.</span><span> </span><span class="NLM_article-title">Review: side effects of approved molecular targeted therapies in solid cancers</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1443</span><span class="NLM_x">–</span> <span class="NLM_lpage">1455</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1634%2Ftheoncologist.12-12-1443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=18165622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslSntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1443-1455&author=C.+Widakowichauthor=G.+de+Castroauthor=E.+de+Azambujaauthor=P.+Dinhauthor=A.+Awada&title=Review%3A+side+effects+of+approved+molecular+targeted+therapies+in+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Review: side effects of approved molecular targeted therapies in solid cancers</span></div><div class="casAuthors">Widakowich, Christian; de Castro, Gilberto, Jr.; de Azambuja, Evandro; Dinh, Phuong; Awada, Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1443-1455</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Major advances have been achieved in the field of biol. based therapies for cancer in the last few years, and some of the recently approved mol.-targeted therapies are now being used in daily clin. practice.  These mol. targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function.  In general, targeted mol. therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities.  In this article, we review the toxicity and safety of various small mols. and monoclonal antibodies used in solid tumors, with discussion of the pathophysiol., correlation with response, and strategies for prevention and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQLiiHG_Az7Vg90H21EOLACvtfcHk0lgz0eGZ61clWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslSntb8%253D&md5=56e9026df40a921510114079777e84b7</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-12-1443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-12-1443%26sid%3Dliteratum%253Aachs%26aulast%3DWidakowich%26aufirst%3DC.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26aulast%3Dde%2BAzambuja%26aufirst%3DE.%26aulast%3DDinh%26aufirst%3DP.%26aulast%3DAwada%26aufirst%3DA.%26atitle%3DReview%253A%2520side%2520effects%2520of%2520approved%2520molecular%2520targeted%2520therapies%2520in%2520solid%2520cancers%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1443%26epage%3D1455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Castellino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borts, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowers, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLauchlin, C.</span><span> </span><span class="NLM_article-title">Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=139-150&author=S.+Castellinoauthor=M.+O%E2%80%99Maraauthor=K.+Kochauthor=D.+J.+Bortsauthor=G.+D.+Bowersauthor=C.+MacLauchlin&title=Human+metabolism+of+lapatinib%2C+a+dual+kinase+inhibitor%3A+implications+for+hepatotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCastellino%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Mara%26aufirst%3DM.%26aulast%3DKoch%26aufirst%3DK.%26aulast%3DBorts%26aufirst%3DD.%2BJ.%26aulast%3DBowers%26aufirst%3DG.%2BD.%26aulast%3DMacLauchlin%26aufirst%3DC.%26atitle%3DHuman%2520metabolism%2520of%2520lapatinib%252C%2520a%2520dual%2520kinase%2520inhibitor%253A%2520implications%2520for%2520hepatotoxicity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D139%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span> </span><span class="NLM_article-title">Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC</span> <span class="citation_source-journal">Curr. Treat. Options Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1007%2Fs11864-012-0204-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22833206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A280%3ADC%252BC38fjtV2jsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=516-526&author=C.+M.+Lovlyauthor=L.+Horn&title=Strategies+for+Overcoming+EGFR+Resistance+in+the+Treatment+of+Advanced-Stage+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC</span></div><div class="casAuthors">Lovly Christine M; Horn Leora</div><div class="citationInfo"><span class="NLM_cas:title">Current treatment options in oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">516-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OPINION STATEMENT:  Patients whose tumors harbor somatic-activating mutations within the epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of lung cancers with increased sensitivity to the EGFR tyrosine kinase inhibitors (TKIs), including the "first-generation" reversible inhibitors, erlotinib and gefitinib, and the "second-generation" irreversible inhibitors, afatinib and dacomitinib.  Several, large, phase III studies have shown already that patients with EGFR-mutant tumors display radiographic response rates of >60 % and improved progression free survival (PFS) when treated with an EGFR TKI compared with chemotherapy.  Unfortunately, despite these initial responses, patients inevitably develop progressive disease, a concept referred to clinically as acquired resistance.  Novel strategies are needed to delay or overcome acquired resistance to EGFR TKIs.  These strategies include second-generation EGFR inhibitors, rationale combinations of targeted small molecule inhibitors and/or monoclonal antibodies, and addition of traditional cytotoxic chemotherapy to EGFR TKI therapy at the time of progression.  Unfortunately, to date, there is no genotype-specific standard of care, and enrollment of patients with acquired resistance to EGFR TKIs into clinical trials specifically addressed at overcoming resistance is paramount to continue to advance the field and to improve outcomes for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDoPP1h2yk22yYR5VtavbzfW6udTcc2eYKLQknLzM7crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fjtV2jsA%253D%253D&md5=120951d5f7ddca457581fc3421bca772</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs11864-012-0204-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11864-012-0204-6%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHorn%26aufirst%3DL.%26atitle%3DStrategies%2520for%2520Overcoming%2520EGFR%2520Resistance%2520in%2520the%2520Treatment%2520of%2520Advanced-Stage%2520NSCLC%26jtitle%3DCurr.%2520Treat.%2520Options%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D516%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, H.</span><span> </span><span class="NLM_article-title">Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">475</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=466-475&author=N.+Yamamotoauthor=M.+Honmaauthor=H.+Suzuki&title=Off-target+serine%2Fthreonine+kinase+10+inhibition+by+erlotinib+enhances+lymphocytic+activity+leading+to+severe+skin+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DHonma%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DOff-target%2520serine%252Fthreonine%2520kinase%252010%2520inhibition%2520by%2520erlotinib%2520enhances%2520lymphocytic%2520activity%2520leading%2520to%2520severe%2520skin%2520disorders%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D466%26epage%3D475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0liUupU8S6FUMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leou, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittimalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span> </span><span class="NLM_article-title">Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4988</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.+Y.+Chuauthor=C.+W.+Linauthor=H.+Y.+Shiaoauthor=Y.+L.+Hoauthor=R.+Reddyauthor=W.+H.+Linauthor=C.+H.+Chenauthor=Y.+H.+Pengauthor=J.+S.+Leouauthor=T.+W.+Lienauthor=C.+T.+Huangauthor=M.+Y.+Fangauthor=S.+H.+Wuauthor=J.+S.+Wuauthor=S.+K.+Chittimallaauthor=J.+S.+Songauthor=J.+T.+Hsuauthor=S.+Y.+Wuauthor=C.+C.+Liaoauthor=Y.+S.+Chaoauthor=H.+P.+Hsieh&title=Fast-forwarding+hit+to+lead%3A+aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Chu, Chang-Ying; Lin, Cheng-Wei; Shiao, Hui-Yi; Ho, Yun-Lung; Reddy, Randheer; Lin, Wen-Hsing; Chen, Chun-Hwa; Peng, Yi-Hui; Leou, Jiun-Shyang; Lien, Tzu-Wen; Huang, Chin-Ting; Fang, Ming-Yu; Wu, Szu-Huei; Wu, Jian-Sung; Chittimalla, Santhosh Kumar; Song, Jen-Shin; Hsu, John T.-A.; Wu, Su-Ying; Liao, Chun-Chen; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4980-4988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Furanopyrimidines such as I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] are prepd. as Aurora A kinase and epidermal growth factor receptor (EGFR) inhibitors by prepn. of a combinatorial library of approx. 350 furanopyridines and optimization of the inhibitors found from the library.  The initial hit compd. I (R = HOCH2CH2; R1 = Ph) was modified to better fit the back pocket to produce the potent Aurora A kinase inhibitor I (R = 4-PhNHCONHC6H4; R1 = Ph) with submicromolar antiproliferative activity in the HCT-116 human colon cancer cell line.  On the basis of docking studies with EGFR hit I [R = (S)-HOCH2CHPh; R1 = Ph], introduction of an acrylamide Michael acceptor group led to I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4], which inhibited both the wild and mutant EGFR kinases and also showed antiproliferative activity in the gefitinib-resistant HCC827 human lung cancer cells.  The X-ray cocrystal structures of I (R = HOCH2CH2, 4-PhNHCONHC6H4; R1 = Ph) bound to Aurora A kinase and the crystal structure of I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] bound to EGFR confirmed their hypothesized binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCOPMtJ1xilrVg90H21EOLACvtfcHk0liUupU8S6FUMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D&md5=8064e99d8d31603c7186b5fa33e019a6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DShiao%26aufirst%3DH.%2BY.%26aulast%3DHo%26aufirst%3DY.%2BL.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DLeou%26aufirst%3DJ.%2BS.%26aulast%3DLien%26aufirst%3DT.%2BW.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DFang%26aufirst%3DM.%2BY.%26aulast%3DWu%26aufirst%3DS.%2BH.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DChittimalla%26aufirst%3DS.%2BK.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DC.%2BC.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DFast-forwarding%2520hit%2520to%2520lead%253A%2520aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Huang, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. F.</span><span> </span><span class="NLM_article-title">High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">8195</span><span class="NLM_x">–</span> <span class="NLM_lpage">8203</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F1078-0432.CCR-04-1245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15623594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGjsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=8195-8203&author=S.+F.+Huangauthor=H.+P.+Liuauthor=L.+H.+Liauthor=Y.+C.+Kuauthor=Y.+N.+Fuauthor=H.+Y.+Tsaiauthor=Y.+T.+Chenauthor=Y.+F.+Linauthor=W.+C.+Changauthor=H.+P.+Kuoauthor=Y.+C.+Wuauthor=Y.+R.+Chenauthor=S.+F.+Tsai&title=High+frequency+of+epidermal+growth+factor+receptor+mutations+with+complex+patterns+in+non-small+cell+lung+cancers+related+to+gefitinib+responsiveness+in+Taiwan"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan</span></div><div class="casAuthors">Huang, Shiu-Feng; Liu, Hui-Ping; Li, Ling-Hui; Ku, Yuan-Chieh; Fu, Yu-Ning; Tsai, Hsien-Yu; Chen, Ya-Ting; Lin, Yung-Feng; Chang, Wen-Cheng; Kuo, Han-Pin; Wu, Yi-Cheng; Chen, Yi-Rong; Tsai, Shih-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8195-8203</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutations related to gefitinib responsiveness in non-small cell lung cancer have been found recently.  Detection of EGFR mutations has become an important issue for therapeutic decision-making in non-small cell lung cancer.  Mutational anal. of the kinase domain of EGFR coding sequence was done on 101 fresh frozen tumor tissues from patients without prior gefitinib treatment and 16 paraffin-embedded tumor tissues from patients treated with gefitinib.  Detection of phosphorylated EGFR by immunoblot was also done on frozen tumor tissues.  The 101 non-small cell lung cancer tumor specimens include 69 adenocarcinomas, 24 squamous cell carcinomas, and 8 other types of non-small cell lung cancers.  Mutation(s) in the kinase domain (exon 18 to exon 21) of the EGFR gene were identified in 39 patients.  All of the mutations occurred in adenocarcinoma, except one that was in an adenosquamous carcinoma.  The mutation rate in adenocarcinoma was 55% (38 of 69).  For the 16 patients treated with gefitinib, 7 of the 9 responders had EGFR mutations, and only 1 of the 7 nonresponders had mutations, which included a nonsense mutation.  The mutations seem to be complex in that altogether 23 different mutations were obsd., and 9 tumors carried 2 mutations.  Data from our study would predict a higher gefitinib response rate in lung adenocarcinoma patients in Chinese and, possibly, other East Asian populations.  The tight assocn. with adenocarcinoma and the high frequency of mutations raise the possibility that EGFR mutations play an important role in the tumorigenesis of adenocarcinoma of lung, esp. in East Asians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQvlewXRMI67Vg90H21EOLACvtfcHk0liUupU8S6FUMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGjsrjK&md5=4908f9d05ea8bb425c1a35f7848964d0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1245%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.%2BF.%26aulast%3DLiu%26aufirst%3DH.%2BP.%26aulast%3DLi%26aufirst%3DL.%2BH.%26aulast%3DKu%26aufirst%3DY.%2BC.%26aulast%3DFu%26aufirst%3DY.%2BN.%26aulast%3DTsai%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DLin%26aufirst%3DY.%2BF.%26aulast%3DChang%26aufirst%3DW.%2BC.%26aulast%3DKuo%26aufirst%3DH.%2BP.%26aulast%3DWu%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BR.%26aulast%3DTsai%26aufirst%3DS.%2BF.%26atitle%3DHigh%2520frequency%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520with%2520complex%2520patterns%2520in%2520non-small%2520cell%2520lung%2520cancers%2520related%2520to%2520gefitinib%2520responsiveness%2520in%2520Taiwan%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D8195%26epage%3D8203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lhjIt_oBsBz1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Lawrence, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pireddu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gevariya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozcan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elias, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schonbrunn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, N. J.</span><span> </span><span class="NLM_article-title">Development of <i>o</i>-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7392</span><span class="NLM_x">–</span> <span class="NLM_lpage">7416</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300334d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7392-7416&author=H.+R.+Lawrenceauthor=M.+P.+Martinauthor=Y.+Luoauthor=R.+Piredduauthor=H.+Yangauthor=H.+Gevariyaauthor=S.+Ozcanauthor=J.+Y.+Zhuauthor=R.+Kendigauthor=M.+Rodriguezauthor=R.+Eliasauthor=J.+Q.+Chengauthor=S.+M.+Sebtiauthor=E.+Schonbrunnauthor=N.+J.+Lawrence&title=Development+of+o-chlorophenyl+substituted+pyrimidines+as+exceptionally+potent+aurora+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Development of o-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors</span></div><div class="casAuthors">Lawrence, Harshani R.; Martin, Mathew P.; Luo, Yunting; Pireddu, Roberta; Yang, Hua; Gevariya, Harsukh; Ozcan, Sevil; Zhu, Jin-Yi; Kendig, Robert; Rodriguez, Mercedes; Elias, Roy; Cheng, Jin Q.; Sebti, Said M.; Schonbrunn, Ernst; Lawrence, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7392-7416</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The o-carboxylic acid substituted bisanilinopyrimidine I was identified as a potent hit (Aurora A IC50 = 6.1 ± 1.0 nM) from inhouse screening.  Detailed structure-activity relationship (SAR) studies indicated that polar substituents at the para position of the B-ring are crit. for potent activity.  X-ray crystallog. studies revealed that compd. I is a type I inhibitor that binds the Aurora kinase active site in a DFG-in conformation.  Structure-activity guided replacement of the A-ring carboxylic acid with halogens and incorporation of fluorine at the pyrimidine 5-position led to highly potent inhibitors of Aurora A that bind in a DFG-out conformation.  B-Ring modifications were undertaken to improve the soly. and cell permeability.  Compds. such as II with water-solubilizing moieties at the para position of the B-ring inhibited the autophosphorylation of Aurora A in MDA-MB-468 breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeJbI5uTT-4bVg90H21EOLACvtfcHk0lhjIt_oBsBz1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhsrfN&md5=8158e18d9d2a26dfce7a831a353f333c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm300334d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300334d%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DPireddu%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DGevariya%26aufirst%3DH.%26aulast%3DOzcan%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DKendig%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DElias%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DJ.%2BQ.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DSchonbrunn%26aufirst%3DE.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26atitle%3DDevelopment%2520of%2520o-chlorophenyl%2520substituted%2520pyrimidines%2520as%2520exceptionally%2520potent%2520aurora%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7392%26epage%3D7416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghate, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span> </span><span class="NLM_article-title">X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5217</span><span class="NLM_x">–</span> <span class="NLM_lpage">5220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5217-5220&author=A.+Kuglstatterauthor=M.+Ghateauthor=S.+Tsingauthor=A.+G.+Villasenorauthor=D.+Shawauthor=J.+W.+Barnettauthor=M.+F.+Browner&title=X-ray+crystal+structure+of+JNK2+complexed+with+the+p38alpha+inhibitor+BIRB796%3A+insights+into+the+rational+design+of+DFG-out+binding+MAP+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DGhate%26aufirst%3DM.%26aulast%3DTsing%26aufirst%3DS.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26atitle%3DX-ray%2520crystal%2520structure%2520of%2520JNK2%2520complexed%2520with%2520the%2520p38alpha%2520inhibitor%2520BIRB796%253A%2520insights%2520into%2520the%2520rational%2520design%2520of%2520DFG-out%2520binding%2520MAP%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5217%26epage%3D5220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nature Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0lj78g2GUHfXxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNature%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Alevy, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roswit, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heier, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holtzman, M. J.</span><span> </span><span class="NLM_article-title">IL-13-induced airway mucus production is attenuated by MAPK13 inhibition</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">4555</span><span class="NLM_x">–</span> <span class="NLM_lpage">4568</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=4555-4568&author=Y.+G.+Alevyauthor=A.+C.+Patelauthor=A.+G.+Romeroauthor=D.+A.+Patelauthor=J.+Tuckerauthor=W.+T.+Roswitauthor=C.+A.+Millerauthor=R.+F.+Heierauthor=D.+E.+Byersauthor=T.+J.+Brettauthor=M.+J.+Holtzman&title=IL-13-induced+airway+mucus+production+is+attenuated+by+MAPK13+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlevy%26aufirst%3DY.%2BG.%26aulast%3DPatel%26aufirst%3DA.%2BC.%26aulast%3DRomero%26aufirst%3DA.%2BG.%26aulast%3DPatel%26aufirst%3DD.%2BA.%26aulast%3DTucker%26aufirst%3DJ.%26aulast%3DRoswit%26aufirst%3DW.%2BT.%26aulast%3DMiller%26aufirst%3DC.%2BA.%26aulast%3DHeier%26aufirst%3DR.%2BF.%26aulast%3DByers%26aufirst%3DD.%2BE.%26aulast%3DBrett%26aufirst%3DT.%2BJ.%26aulast%3DHoltzman%26aufirst%3DM.%2BJ.%26atitle%3DIL-13-induced%2520airway%2520mucus%2520production%2520is%2520attenuated%2520by%2520MAPK13%2520inhibition%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D4555%26epage%3D4568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranjitkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasap, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maly, D. J.</span><span> </span><span class="NLM_article-title">Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2384</span><span class="NLM_x">–</span> <span class="NLM_lpage">2392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1158%2F0008-5472.CAN-08-3953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19276351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFyqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2384-2392&author=M.+A.+Seeligerauthor=P.+Ranjitkarauthor=C.+Kasapauthor=Y.+Shanauthor=D.+E.+Shawauthor=N.+P.+Shahauthor=J.+Kuriyanauthor=D.+J.+Maly&title=Equally+potent+inhibition+of+c-Src+and+Abl+by+compounds+that+recognize+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations</span></div><div class="casAuthors">Seeliger, Markus A.; Ranjitkar, Pratistha; Kasap, Corynn; Shan, Yibing; Shaw, David E.; Shah, Neil P.; Kuriyan, John; Maly, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2384-2392</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Imatinib is an inhibitor of the Abl tyrosine kinase domain that is effective in the treatment of chronic myelogenic leukemia.  Although imatinib binds tightly to the Abl kinase domain, its affinity for the closely related kinase domain of c-Src is at least 2,000-fold lower.  Imatinib recognition requires a specific inactive conformation of the kinase domain, in which a conserved Asp-Phe-Gly (DFG) motif is flipped with respect to the active conformation.  The inability of c-Src to readily adopt this flipped DFG conformation was thought to underlie the selectivity of imatinib for Abl over c-Src.  Here, we present a series of inhibitors (DSA compds.) that are based on the core scaffold of imatinib but which bind with equally high potency to c-Src and Abl.  The DSA compds. bind to c-Src in the DFG-flipped conformation, as confirmed by crystal structures and kinetic anal.  The origin of the high affinity of these compds. for c-Src is suggested by the fact that they also inhibit clin. relevant Abl variants bearing mutations in a structural element, the P-loop, that normally interacts with the phosphate groups of ATP but is folded over a substructure of imatinib in Abl.  Importantly, several of the DSA compds. block the growth of Ba/F3 cells harboring imatinib-resistant BCR-ABL mutants, including the Thr315Ile "gatekeeper" mutation, but do not suppress the growth of parental Ba/F3 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjllvXItGitrVg90H21EOLACvtfcHk0lj78g2GUHfXxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFyqtb0%253D&md5=d6e719acb5b216c073d79c242d15f587</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-3953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-3953%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DRanjitkar%26aufirst%3DP.%26aulast%3DKasap%26aufirst%3DC.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DEqually%2520potent%2520inhibition%2520of%2520c-Src%2520and%2520Abl%2520by%2520compounds%2520that%2520recognize%2520inactive%2520kinase%2520conformations%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D2384%26epage%3D2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=17355866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Caoauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=c-Src+binds+to+the+cancer+drug+imatinib+with+an+inactive+Abl%2Fc-Kit+conformation+and+a+distributed+thermodynamic+penalty"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span></div><div class="casAuthors">Seeliger, Markus A.; Nagar, Bhushan; Frank, Filipp; Cao, Xiaoxian; Henderson, M. Nidanie; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-311</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor.  Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src.  The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl•imatinib and c-Kit•imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases.  Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodn. penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure.  Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2SQGjjXdg1LVg90H21EOLACvtfcHk0lj78g2GUHfXxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D&md5=ddfbcf06d91b408ca5fb25af9774c334</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520imatinib%2520with%2520an%2520inactive%2520Abl%252Fc-Kit%2520conformation%2520and%2520a%2520distributed%2520thermodynamic%2520penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26spage%3D299%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Hodous, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaffee, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span> </span><span class="NLM_article-title">Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2886</span><span class="NLM_x">–</span> <span class="NLM_lpage">2889</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2886-2889&author=B.+L.+Hodousauthor=S.+D.+Geuns-Meyerauthor=P.+E.+Hughesauthor=B.+K.+Albrechtauthor=S.+Bellonauthor=S.+Caenepeelauthor=V.+J.+Ceeauthor=S.+C.+Chaffeeauthor=M.+Emeryauthor=J.+Fretlandauthor=P.+Gallantauthor=Y.+Guauthor=R.+E.+Johnsonauthor=J.+L.+Kimauthor=A.+M.+Longauthor=M.+Morrisonauthor=P.+R.+Olivieriauthor=V.+F.+Patelauthor=A.+Polverinoauthor=P.+Roseauthor=L.+Wangauthor=H.+Zhao&title=Synthesis%2C+structural+analysis%2C+and+SAR+studies+of+triazine+derivatives+as+potent%2C+selective+Tie-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%2BD.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DR.%2BE.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DP.%2BR.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DRose%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DSynthesis%252C%2520structural%2520analysis%252C%2520and%2520SAR%2520studies%2520of%2520triazine%2520derivatives%2520as%2520potent%252C%2520selective%2520Tie-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2886%26epage%3D2889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Hodous, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaffee, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tempest, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span> </span><span class="NLM_article-title">Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061107l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=611-626&author=B.+L.+Hodousauthor=S.+D.+Geuns-Meyerauthor=P.+E.+Hughesauthor=B.+K.+Albrechtauthor=S.+Bellonauthor=J.+Breadyauthor=S.+Caenepeelauthor=V.+J.+Ceeauthor=S.+C.+Chaffeeauthor=A.+Coxonauthor=M.+Emeryauthor=J.+Fretlandauthor=P.+Gallantauthor=Y.+Guauthor=D.+Hoffmanauthor=R.+E.+Johnsonauthor=R.+Kendallauthor=J.+L.+Kimauthor=A.+M.+Longauthor=M.+Morrisonauthor=P.+R.+Olivieriauthor=V.+F.+Patelauthor=A.+Polverinoauthor=P.+Roseauthor=P.+Tempestauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=H.+Zhao&title=Evolution+of+a+highly+selective+and+potent+2-%28pyridin-2-yl%29-1%2C3%2C5-triazine+Tie-2+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm061107l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061107l%26sid%3Dliteratum%253Aachs%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%2BD.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BE.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DP.%2BR.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DRose%26aufirst%3DP.%26aulast%3DTempest%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DEvolution%2520of%2520a%2520highly%2520selective%2520and%2520potent%25202-%2528pyridin-2-yl%2529-1%252C3%252C5-triazine%2520Tie-2%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D611%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Hughes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elustondo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fonzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroux, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snijders, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherepanov, P.</span><span> </span><span class="NLM_article-title">Crystal structure of human CDC7 kinase in complex with its activator DBF4</span> <span class="citation_source-journal">Nature Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1101</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2Fnsmb.2404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=23064647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1101-1107&author=S.+Hughesauthor=F.+Elustondoauthor=A.+Di+Fonzoauthor=F.+G.+Lerouxauthor=A.+C.+Wongauthor=A.+P.+Snijdersauthor=S.+J.+Matthewsauthor=P.+Cherepanov&title=Crystal+structure+of+human+CDC7+kinase+in+complex+with+its+activator+DBF4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human CDC7 kinase in complex with its activator DBF4</span></div><div class="casAuthors">Hughes, Siobhan; Elustondo, Frederic; Di Fonzo, Andrea; Leroux, Frederic G.; Wong, Ai C.; Snijders, Ambrosius P.; Matthews, Stephen J.; Cherepanov, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1101-1107</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CDC7 is a serine/threonine kinase that is essential for the initiation of eukaryotic DNA replication.  CDC7 kinase activity is controlled by its activator, DBF4 protein.  Here, the authors present crystal structures of human CDC7-DBF4 in complex with a nucleotide or ATP-competing small mols., revealing the active and inhibited forms of the kinase, resp.  DBF4 wraps around CDC7, burying ∼6000 Å2 of hydrophobic mol. surface in a bipartite interface.  The effector domain of DBF4, contg. conserved motif C, was essential and sufficient to support CDC7 kinase activity by binding to the kinase N-terminal lobe and stabilizing its canonical αC helix.  DBF4 motif M latched onto the C-terminal lobe of the kinase, acting as a tethering domain.  Thus, these results elucidate the structural basis for binding to and activation of CDC7 by DBF4 and provide a framework for the design of more potent and specific CDC7 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogBhfM_xlMUrVg90H21EOLACvtfcHk0liJ06w6XaMZDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rs7bJ&md5=7fc035d6838590b31d21d59920477a40</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2404%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DS.%26aulast%3DElustondo%26aufirst%3DF.%26aulast%3DDi%2BFonzo%26aufirst%3DA.%26aulast%3DLeroux%26aufirst%3DF.%2BG.%26aulast%3DWong%26aufirst%3DA.%2BC.%26aulast%3DSnijders%26aufirst%3DA.%2BP.%26aulast%3DMatthews%26aufirst%3DS.%2BJ.%26aulast%3DCherepanov%26aufirst%3DP.%26atitle%3DCrystal%2520structure%2520of%2520human%2520CDC7%2520kinase%2520in%2520complex%2520with%2520its%2520activator%2520DBF4%26jtitle%3DNature%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1101%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Echalier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camasses, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodimont, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheinerman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasinska, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D.</span><span> </span><span class="NLM_article-title">An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1028</span><span class="NLM_x">–</span> <span class="NLM_lpage">1040</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.chembiol.2012.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22921070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kku7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1028-1040&author=A.+Echalierauthor=E.+Cotauthor=A.+Camassesauthor=E.+Hodimontauthor=F.+Hohauthor=P.+Jayauthor=F.+Sheinermanauthor=L.+Krasinskaauthor=D.+Fisher&title=An+integrated+chemical+biology+approach+provides+insight+into+Cdk2+functional+redundancy+and+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Chemical Biology Approach Provides Insight into Cdk2 Functional Redundancy and Inhibitor Sensitivity</span></div><div class="casAuthors">Echalier, Aude; Cot, Emilie; Camasses, Alain; Hodimont, Elsie; Hoh, Francois; Jay, Philippe; Sheinerman, Felix; Krasinska, Liliana; Fisher, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1028-1040</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cdk2 promotes DNA replication and is a promising cancer therapeutic target, but its functions appear redundant with Cdk1, an essential Cdk affected by most Cdk2 inhibitors.  Here, we present an integrated multidisciplinary approach to address Cdk redundancy.  Math. modeling of enzymol. data predicted conditions allowing selective chem. Cdk2 inhibition.  Together with expts. in Xenopus egg exts., this supports a rate-limiting role for Cdk2 in DNA replication.  To confirm this we designed inhibitor-resistant (ir)-Cdk2 mutants using a novel bioinformatics approach.  Bypassing inhibition with ir-Cdk2 or with Cdk1 shows that Cdk2 is rate-limiting for replication in this system because Cdk1 is insufficiently active.  Addnl., crystal structures and kinetics reveal alternative binding modes of Cdk1-selective and Cdk2-selective inhibitors and mechanisms of Cdk2 inhibitor resistance.  Our approach thus provides insight into structure, functions, and biochem. of a cyclin-dependent kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRa9UiVuPpOLVg90H21EOLACvtfcHk0liJ06w6XaMZDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kku7zN&md5=d134c52fd1ad5442e07bec46a3edd9be</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DCot%26aufirst%3DE.%26aulast%3DCamasses%26aufirst%3DA.%26aulast%3DHodimont%26aufirst%3DE.%26aulast%3DHoh%26aufirst%3DF.%26aulast%3DJay%26aufirst%3DP.%26aulast%3DSheinerman%26aufirst%3DF.%26aulast%3DKrasinska%26aufirst%3DL.%26aulast%3DFisher%26aufirst%3DD.%26atitle%3DAn%2520integrated%2520chemical%2520biology%2520approach%2520provides%2520insight%2520into%2520Cdk2%2520functional%2520redundancy%2520and%2520inhibitor%2520sensitivity%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1028%26epage%3D1040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Hole, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E.</span><span> </span><span class="NLM_article-title">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+Structural+and+Functional+Studies+of+4-%28Thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+Inhibitors+Suggest+the+Basis+for+Isotype+Selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520Structural%2520and%2520Functional%2520Studies%2520of%25204-%2528Thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520Inhibitors%2520Suggest%2520the%2520Basis%2520for%2520Isotype%2520Selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Lafleur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevado, C.</span><span> </span><span class="NLM_article-title">Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301187e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=84-96&author=K.+Lafleurauthor=J.+Dongauthor=D.+Huangauthor=A.+Caflischauthor=C.+Nevado&title=Optimization+of+inhibitors+of+the+tyrosine+kinase+EphB4.+2.+Cellular+potency+improvement+and+binding+mode+validation+by+X-ray+crystallography"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Inhibitors of the Tyrosine Kinase EphB4. 2. Cellular Potency Improvement and Binding Mode Validation by X-ray Crystallography</span></div><div class="casAuthors">Lafleur, Karine; Dong, Jing; Huang, Danzhi; Caflisch, Amedeo; Nevado, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-96</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the tyrosine kinase erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) is an effective strategy for the treatment of solid tumors.  We have previously reported a low nanomolar ATP-competitive inhibitor of EphB4 discovered in silico by fragment-based high-throughput docking combined with explicit solvent mol. dynamics simulations.  Here we present a second generation of EphB4 inhibitors that show high inhibitory potency in both enzymic and cell-based assays while preserving the appealing selectivity profile exhibited by the parent compd.  In addn., respectable levels of antiproliferative activity for these compds. have been obtained.  Finally, the binding mode predicted by docking and mol. dynamics simulations is validated by solving the crystal structures of three members of this chem. class in complex with the EphA3 tyrosine kinase whose ATP-binding site is essentially identical to that of EphB4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbStxb4nLqLbVg90H21EOLACvtfcHk0lho6vBPcyirVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurzJ&md5=219d526caaa60798b7c9fe0bb88a48fa</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm301187e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301187e%26sid%3Dliteratum%253Aachs%26aulast%3DLafleur%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DNevado%26aufirst%3DC.%26atitle%3DOptimization%2520of%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%25202.%2520Cellular%2520potency%2520improvement%2520and%2520binding%2520mode%2520validation%2520by%2520X-ray%2520crystallography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D84%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Tsuhako, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koltun, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aay, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcalas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franzini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaharia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">The design, synthesis, and biological evaluation of PIM kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3732</span><span class="NLM_x">–</span> <span class="NLM_lpage">3738</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3732-3738&author=A.+L.+Tsuhakoauthor=D.+S.+Brownauthor=E.+S.+Koltunauthor=N.+Aayauthor=A.+Arcalasauthor=V.+Chanauthor=H.+Duauthor=S.+Engstauthor=M.+Franziniauthor=A.+Galanauthor=P.+Huangauthor=S.+Johnstonauthor=B.+Kaneauthor=M.+H.+Kimauthor=A.+D.+Lairdauthor=R.+Linauthor=L.+Mockauthor=I.+Nganauthor=M.+Packauthor=G.+Stottauthor=T.+J.+Stoutauthor=P.+Yuauthor=C.+Zahariaauthor=W.+Zhangauthor=P.+Zhouauthor=J.+M.+Nussauthor=P.+C.+Kearneyauthor=W.+Xu&title=The+design%2C+synthesis%2C+and+biological+evaluation+of+PIM+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsuhako%26aufirst%3DA.%2BL.%26aulast%3DBrown%26aufirst%3DD.%2BS.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DArcalas%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DDu%26aufirst%3DH.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DFranzini%26aufirst%3DM.%26aulast%3DGalan%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DKane%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DNgan%26aufirst%3DI.%26aulast%3DPack%26aufirst%3DM.%26aulast%3DStott%26aufirst%3DG.%26aulast%3DStout%26aufirst%3DT.%2BJ.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DZaharia%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DKearney%26aufirst%3DP.%2BC.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DThe%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520PIM%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3732%26epage%3D3738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4054</span><span class="NLM_x">–</span> <span class="NLM_lpage">4058</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.bmcl.2011.04.124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=21636270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4054-4058&author=S.+T.+Stabenauthor=M.+Siuauthor=R.+Goldsmithauthor=A.+G.+Oliveroauthor=S.+Doauthor=D.+J.+Burdickauthor=T.+P.+Heffronauthor=J.+Dotsonauthor=D.+P.+Sutherlinauthor=B.+Y.+Zhuauthor=V.+Tsuiauthor=H.+Leauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=L.+Rougeauthor=D.+Sampathauthor=S.+Siderisauthor=C.+Wiesmannauthor=P.+Wu&title=Structure-based+design+of+thienobenzoxepin+inhibitors+of+PI3-kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span></div><div class="casAuthors">Staben, Steven T.; Siu, Michael; Goldsmith, Richard; Olivero, Alan G.; Do, Steven; Burdick, Daniel J.; Heffron, Timothy P.; Dotson, Jenna; Sutherlin, Daniel P.; Zhu, Bing-Yan; Tsui, Vickie; Le, Hoa; Lee, Leslie; Lesnick, John; Lewis, Cristina; Murray, Jeremy M.; Nonomiya, Jim; Pang, Jodie; Prior, Wei Wei; Salphati, Laurent; Rouge, Lionel; Sampath, Deepak; Sideris, Steve; Wiesmann, Christian; Wu, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4054-4058</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from thienobenzopyran HTS hit 1 (I), co-crystn., mol. modeling and metabolic anal. were used to design potent and metabolically stable inhibitors of PI3-kinase.  Compd. 15 demonstrated PI3K pathway suppression in a mouse MCF7 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5PrbzVKCkbVg90H21EOLACvtfcHk0lho6vBPcyirVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLs%253D&md5=9b807be1ac4093a6f139c0304757037a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.124%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DZhu%26aufirst%3DB.%2BY.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520of%2520thienobenzoxepin%2520inhibitors%2520of%2520PI3-kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4054%26epage%3D4058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Fugel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberholzer, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschloessl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dzikowski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pressburger, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okun, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerig, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruggel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemcke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunick, C.</span><span> </span><span class="NLM_article-title">3,6-Diamino-4-(2-halophenyl)-2-benzoylthieno[2,3-<i>b</i>]pyridine-5-carbonitriles are selective inhibitors of <i>Plasmodium falciparum</i> glycogen synthase kinase-3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301575n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=264-275&author=W.+Fugelauthor=A.+E.+Oberholzerauthor=B.+Gschloesslauthor=R.+Dzikowskiauthor=N.+Pressburgerauthor=L.+Preuauthor=L.+H.+Pearlauthor=B.+Baratteauthor=M.+Ratinauthor=I.+Okunauthor=C.+Doerigauthor=S.+Kruggelauthor=T.+Lemckeauthor=L.+Meijerauthor=C.+Kunick&title=3%2C6-Diamino-4-%282-halophenyl%29-2-benzoylthieno%5B2%2C3-b%5Dpyridine-5-carbonitriles+are+selective+inhibitors+of+Plasmodium+falciparum+glycogen+synthase+kinase-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm301575n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301575n%26sid%3Dliteratum%253Aachs%26aulast%3DFugel%26aufirst%3DW.%26aulast%3DOberholzer%26aufirst%3DA.%2BE.%26aulast%3DGschloessl%26aufirst%3DB.%26aulast%3DDzikowski%26aufirst%3DR.%26aulast%3DPressburger%26aufirst%3DN.%26aulast%3DPreu%26aufirst%3DL.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DBaratte%26aufirst%3DB.%26aulast%3DRatin%26aufirst%3DM.%26aulast%3DOkun%26aufirst%3DI.%26aulast%3DDoerig%26aufirst%3DC.%26aulast%3DKruggel%26aufirst%3DS.%26aulast%3DLemcke%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKunick%26aufirst%3DC.%26atitle%3D3%252C6-Diamino-4-%25282-halophenyl%2529-2-benzoylthieno%255B2%252C3-b%255Dpyridine-5-carbonitriles%2520are%2520selective%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520glycogen%2520synthase%2520kinase-3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D264%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Bhattacharya, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspnes, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagley, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brosius, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckbinder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dibrino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffor, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimaraes, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman-Perez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klug-McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Irizarry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southers, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawistoski, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span> </span><span class="NLM_article-title">Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7523</span><span class="NLM_x">–</span> <span class="NLM_lpage">7529</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7523-7529&author=S.+K.+Bhattacharyaauthor=G.+E.+Aspnesauthor=S.+W.+Bagleyauthor=M.+Boehmauthor=A.+D.+Brosiusauthor=L.+Buckbinderauthor=J.+S.+Changauthor=J.+Dibrinoauthor=H.+Engauthor=K.+S.+Frederickauthor=D.+A.+Griffithauthor=M.+C.+Grifforauthor=C.+R.+Guimaraesauthor=A.+Guzman-Perezauthor=S.+Hanauthor=A.+S.+Kalgutkarauthor=J.+Klug-McLeodauthor=C.+Garcia-Irizarryauthor=J.+Liauthor=B.+Lippaauthor=D.+A.+Priceauthor=J.+A.+Southersauthor=D.+P.+Walkerauthor=L.+Weiauthor=J.+Xiaoauthor=M.+P.+Zawistoskiauthor=X.+Zhao&title=Identification+of+novel+series+of+pyrazole+and+indole-urea+based+DFG-out+PYK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DAspnes%26aufirst%3DG.%2BE.%26aulast%3DBagley%26aufirst%3DS.%2BW.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DBrosius%26aufirst%3DA.%2BD.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DDibrino%26aufirst%3DJ.%26aulast%3DEng%26aufirst%3DH.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DGuimaraes%26aufirst%3DC.%2BR.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DGarcia-Irizarry%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLippa%26aufirst%3DB.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DSouthers%26aufirst%3DJ.%2BA.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DZhao%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520novel%2520series%2520of%2520pyrazole%2520and%2520indole-urea%2520based%2520DFG-out%2520PYK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7523%26epage%3D7529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Forsyth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aay, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcalas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epshteyn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koltun, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyr, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridgway, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gendreau, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassees, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolfrey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span> </span><span class="NLM_article-title">SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7653</span><span class="NLM_x">–</span> <span class="NLM_lpage">7658</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7653-7658&author=T.+Forsythauthor=P.+C.+Kearneyauthor=B.+G.+Kimauthor=H.+W.+Johnsonauthor=N.+Aayauthor=A.+Arcalasauthor=D.+S.+Brownauthor=V.+Chanauthor=J.+Chenauthor=H.+Duauthor=S.+Epshteynauthor=A.+A.+Galanauthor=T.+P.+Huynhauthor=M.+A.+Ibrahimauthor=B.+Kaneauthor=E.+S.+Koltunauthor=G.+Mannauthor=L.+E.+Meyrauthor=M.+S.+Leeauthor=G.+L.+Lewisauthor=R.+T.+Noguchiauthor=M.+Packauthor=B.+H.+Ridgwayauthor=X.+Shiauthor=C.+S.+Takeuchiauthor=P.+Zuauthor=J.+W.+Leahyauthor=J.+M.+Nussauthor=R.+Aoyamaauthor=S.+Engstauthor=S.+B.+Gendreauauthor=R.+Kasseesauthor=J.+Liauthor=S.+H.+Linauthor=J.+F.+Martiniauthor=T.+Stoutauthor=P.+Tongauthor=J.+Woolfreyauthor=W.+Zhangauthor=P.+Yu&title=SAR+and+in+vivo+evaluation+of+4-aryl-2-aminoalkylpyrimidines+as+potent+and+selective+Janus+kinase+2+%28JAK2%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForsyth%26aufirst%3DT.%26aulast%3DKearney%26aufirst%3DP.%2BC.%26aulast%3DKim%26aufirst%3DB.%2BG.%26aulast%3DJohnson%26aufirst%3DH.%2BW.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DArcalas%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DD.%2BS.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DH.%26aulast%3DEpshteyn%26aufirst%3DS.%26aulast%3DGalan%26aufirst%3DA.%2BA.%26aulast%3DHuynh%26aufirst%3DT.%2BP.%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%26aulast%3DKane%26aufirst%3DB.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DMann%26aufirst%3DG.%26aulast%3DMeyr%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DLewis%26aufirst%3DG.%2BL.%26aulast%3DNoguchi%26aufirst%3DR.%2BT.%26aulast%3DPack%26aufirst%3DM.%26aulast%3DRidgway%26aufirst%3DB.%2BH.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTakeuchi%26aufirst%3DC.%2BS.%26aulast%3DZu%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DJ.%2BW.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DAoyama%26aufirst%3DR.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DGendreau%26aufirst%3DS.%2BB.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DMartini%26aufirst%3DJ.%2BF.%26aulast%3DStout%26aufirst%3DT.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DWoolfrey%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DP.%26atitle%3DSAR%2520and%2520in%2520vivo%2520evaluation%2520of%25204-aryl-2-aminoalkylpyrimidines%2520as%2520potent%2520and%2520selective%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7653%26epage%3D7658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturgis, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegtli, W. C.</span><span> </span><span class="NLM_article-title">Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6237</span><span class="NLM_x">–</span> <span class="NLM_lpage">6241</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6237-6241&author=S.+Wenglowskyauthor=D.+Morenoauthor=E.+R.+Lairdauthor=S.+L.+Gloorauthor=L.+Renauthor=T.+Risomauthor=J.+Rudolphauthor=H.+L.+Sturgisauthor=W.+C.+Voegtli&title=Pyrazolopyridine+inhibitors+of+B-Raf%28V600E%29.+Part+4%3A+rational+design+and+kinase+selectivity+profile+of+cell+potent+type+II+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26atitle%3DPyrazolopyridine%2520inhibitors%2520of%2520B-Raf%2528V600E%2529.%2520Part%25204%253A%2520rational%2520design%2520and%2520kinase%2520selectivity%2520profile%2520of%2520cell%2520potent%2520type%2520II%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6237%26epage%3D6241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Zapf, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstenberger, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limburg, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaulding, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medley, Q. G.</span><span> </span><span class="NLM_article-title">Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10047</span><span class="NLM_x">–</span> <span class="NLM_lpage">10063</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301190s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10047-10063&author=C.+W.+Zapfauthor=B.+S.+Gerstenbergerauthor=L.+Xingauthor=D.+C.+Limburgauthor=D.+R.+Andersonauthor=N.+Caspersauthor=S.+Hanauthor=A.+Aulabaughauthor=R.+Kurumbailauthor=S.+Shakyaauthor=X.+Liauthor=V.+Spauldingauthor=R.+M.+Czerwinskiauthor=N.+Sethauthor=Q.+G.+Medley&title=Covalent+inhibitors+of+interleukin-2+inducible+T+cell+kinase+%28itk%29+with+nanomolar+potency+in+a+whole-blood+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay</span></div><div class="casAuthors">Zapf, Christoph W.; Gerstenberger, Brian S.; Xing, Li; Limburg, David C.; Anderson, David R.; Caspers, Nicole; Han, Seungil; Aulabaugh, Ann; Kurumbail, Ravi; Shakya, Subarna; Li, Xin; Spaulding, Vikki; Czerwinski, Robert M.; Seth, Nilufer; Medley, Quintus G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10047-10063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We wish to report a strategy that targets interleukin-2 inducible T cell kinase (Itk) with covalent inhibitors.  Thus far, covalent inhibition of Itk has not been disclosed in the literature.  Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concns.  Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates.  The analogs are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay.  Despite a half-life of approx. 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h.  This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnh9j28SM8jbVg90H21EOLACvtfcHk0ljV8coAFnfQlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP&md5=7e39a17151dc9493d13439bc48fa83a3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm301190s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301190s%26sid%3Dliteratum%253Aachs%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSpaulding%26aufirst%3DV.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DMedley%26aufirst%3DQ.%2BG.%26atitle%3DCovalent%2520inhibitors%2520of%2520interleukin-2%2520inducible%2520T%2520cell%2520kinase%2520%2528itk%2529%2520with%2520nanomolar%2520potency%2520in%2520a%2520whole-blood%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10047%26epage%3D10063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Ranjitkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaney, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurty, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maly, D. J.</span><span> </span><span class="NLM_article-title">Affinity-based probes based on type II kinase inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">19017</span><span class="NLM_x">–</span> <span class="NLM_lpage">19025</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja306035v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=19017-19025&author=P.+Ranjitkarauthor=B.+G.+Pereraauthor=D.+L.+Swaneyauthor=S.+B.+Hariauthor=E.+T.+Larsonauthor=R.+Krishnamurtyauthor=E.+A.+Merrittauthor=J.+Villenauthor=D.+J.+Maly&title=Affinity-based+probes+based+on+type+II+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fja306035v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja306035v%26sid%3Dliteratum%253Aachs%26aulast%3DRanjitkar%26aufirst%3DP.%26aulast%3DPerera%26aufirst%3DB.%2BG.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DHari%26aufirst%3DS.%2BB.%26aulast%3DLarson%26aufirst%3DE.%2BT.%26aulast%3DKrishnamurty%26aufirst%3DR.%26aulast%3DMerritt%26aufirst%3DE.%2BA.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DAffinity-based%2520probes%2520based%2520on%2520type%2520II%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D19017%26epage%3D19025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1287</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061381f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1280-1287&author=A.+M.+Aronovauthor=C.+Bakerauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+W.+Janetkaauthor=F.+Maltaisauthor=G.+Martinez-Botellaauthor=M.+N.+Namchukauthor=J.+Straubauthor=Q.+Tangauthor=X.+Xie&title=Flipped+out%3A+structure-guided+design+of+selective+pyrazolylpyrrole+ERK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm061381f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061381f%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DFlipped%2520out%253A%2520structure-guided%2520design%2520of%2520selective%2520pyrazolylpyrrole%2520ERK%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1280%26epage%3D1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0lgKTaYoFsz9WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Huang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafleur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevado, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span> </span><span class="NLM_article-title">Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis</span> <span class="citation_source-journal">Bioinformatics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1093%2Fbioinformatics%2Fbtp650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=19942586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2010&pages=198-204&author=D.+Huangauthor=T.+Zhouauthor=K.+Lafleurauthor=C.+Nevadoauthor=A.+Caflisch&title=Kinase+selectivity+potential+for+inhibitors+targeting+the+ATP+binding+site%3A+a+network+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis</span></div><div class="casAuthors">Huang, Danzhi; Zhou, Ting; Lafleur, Karine; Nevado, Cristina; Caflisch, Amedeo</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-204</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Small-mol. inhibitors targeting the ATP binding pocket of the catalytic domain of protein kinases have potential to become drugs devoid of (major) side effects, particularly if they bind selectively.  Here, the sequences of the 518 human kinases are first mapped onto the structural alignment of 116 kinases of known three-dimensional structure.  The multiple structure alignment is then used to encode the known strategies for developing selective inhibitors into a fingerprint.  Finally, a network anal. is used to partition the kinases into clusters according to similarity of their fingerprints, i.e., physico-chem. characteristics of the residues responsible for selective binding.  For each kinase the network anal. reveals the likelihood to find selective inhibitors targeting the ATP binding site.  Systematic guidelines are proposed to develop selective inhibitors.  Importantly, the network anal. suggests that the tyrosine kinase EphB4 has high selectivity potential, which is consistent with the selectivity profile of two novel EphB4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQVQsrpqB_ILVg90H21EOLACvtfcHk0lgKTaYoFsz9WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlGkug%253D%253D&md5=b6c63ccd4654219a56752f9cfc1356a3</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtp650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtp650%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DLafleur%26aufirst%3DK.%26aulast%3DNevado%26aufirst%3DC.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DKinase%2520selectivity%2520potential%2520for%2520inhibitors%2520targeting%2520the%2520ATP%2520binding%2520site%253A%2520a%2520network%2520analysis%26jtitle%3DBioinformatics%26date%3D2010%26volume%3D26%26spage%3D198%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurwitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span> </span><span class="NLM_article-title">Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1038%2F376313a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=7630397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Sjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=1995&pages=313-320&author=P.+D.+Jeffreyauthor=A.+A.+Russoauthor=K.+Polyakauthor=E.+Gibbsauthor=J.+Hurwitzauthor=J.+Massagueauthor=N.+P.+Pavletich&title=Mechanism+of+CDK+activation+revealed+by+the+structure+of+a+cyclinA-CDK2+complex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex</span></div><div class="casAuthors">Jeffrey, Philip D.; Russo, Alicia A.; Polyak, Kornelia; Gibbs, Emma; Hurwitz, Jerard; Massague, Joan; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">6538</span>),
    <span class="NLM_cas:pages">313-20</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The crystal structure of the human cyclin A-cyclin-dependent kinase 2 (CDK2)-ATP complex was detd. at 2.3 Å resoln.  Cyclin A was found to bind to one side of the catalytic cleft of CDK2, inducing large conformational changes in its PSTAIRE helix and T-loop.  These changes activate the kinase by realigning active site residues and relieving the steric blockade at the entrance of the catalytic cleft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj6tVVZjR6SrVg90H21EOLACvtfcHk0lgKTaYoFsz9WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Sjsrk%253D&md5=582f0a3741e0417ff650c3172b39249c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2F376313a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F376313a0%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DRusso%26aufirst%3DA.%2BA.%26aulast%3DPolyak%26aufirst%3DK.%26aulast%3DGibbs%26aufirst%3DE.%26aulast%3DHurwitz%26aufirst%3DJ.%26aulast%3DMassague%26aufirst%3DJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DMechanism%2520of%2520CDK%2520activation%2520revealed%2520by%2520the%2520structure%2520of%2520a%2520cyclinA-CDK2%2520complex%26jtitle%3DNature%26date%3D1995%26volume%3D376%26spage%3D313%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. R.</span><span> </span><span class="NLM_article-title">A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2008&pages=89-94&author=W.+H.+Linauthor=J.+S.+Songauthor=T.+Y.+Changauthor=C.+Y.+Changauthor=Y.+N.+Fuauthor=C.+L.+Yehauthor=S.+H.+Wuauthor=Y.+W.+Huangauthor=M.+Y.+Fangauthor=T.+W.+Lienauthor=H.+P.+Hsiehauthor=Y.+S.+Chaoauthor=S.+F.+Huangauthor=S.+F.+Tsaiauthor=L.+M.+Wangauthor=J.+T.+Hsuauthor=Y.+R.+Chen&title=A+cell-based+high-throughput+screen+for+epidermal+growth+factor+receptor+pathway+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DT.%2BY.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DFu%26aufirst%3DY.%2BN.%26aulast%3DYeh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DS.%2BH.%26aulast%3DHuang%26aufirst%3DY.%2BW.%26aulast%3DFang%26aufirst%3DM.%2BY.%26aulast%3DLien%26aufirst%3DT.%2BW.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DHuang%26aufirst%3DS.%2BF.%26aulast%3DTsai%26aufirst%3DS.%2BF.%26aulast%3DWang%26aufirst%3DL.%2BM.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BR.%26atitle%3DA%2520cell-based%2520high-throughput%2520screen%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520pathway%2520inhibitors%26jtitle%3DAnal.%2520Biochem.%26date%3D2008%26volume%3D377%26spage%3D89%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teplyakov, A.</span><span> </span><span class="NLM_article-title">MOLREP: an automated program for molecular replacement</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1025</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0021889897006766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=1022-1025&author=A.+Vaginauthor=A.+Teplyakov&title=MOLREP%3A+an+automated+program+for+molecular+replacement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">MOLREP: an automated program for molecular replacement</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1022-1025</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement which uses effective new approaches in data processing and rotational and translational searching.  These include an automatic choice of all parameters, scaling by Patterson origin peaks and soft resoln. cutoff.  One of the cornerstones of the program is an original full-symmetry translation function combined with a packing function.  Information from the model already placed in the cell is incorporated in both translation and packing functions.  A no. of tests using exptl. data proved the ability of the program to find the correct soln. in difficult cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkGXdZ-nTKxLVg90H21EOLACvtfcHk0ljh2X9ypltbsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D&md5=96af64aedd8a8f018c3c18b57a6b4b21</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1107%2FS0021889897006766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889897006766%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMOLREP%253A%2520an%2520automated%2520program%2520for%2520molecular%2520replacement%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1997%26volume%3D30%26spage%3D1022%26epage%3D1025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Bailey, S.</span><span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography</span> <span class="citation_source-journal">Acta.Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15299374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=S.+Bailey&title=The+CCP4+suite%3A+programs+for+protein+crystallography"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DS.%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%26jtitle%3DActa.Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0ljh2X9ypltbsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Jones, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjeldgaard, M.</span><span> </span><span class="NLM_article-title">Improved methods for building protein models in electron density maps and the location of errors in these models</span> <span class="citation_source-journal">Acta Crystallogr., Sect. A: Found. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0108767390010224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=2025413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A280%3ADyaK3M3it1CmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1991&pages=110-119&author=T.+A.+Jonesauthor=J.+Y.+Zouauthor=S.+W.+Cowanauthor=M.+Kjeldgaard&title=Improved+methods+for+building+protein+models+in+electron+density+maps+and+the+location+of+errors+in+these+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Improved methods for building protein models in electron density maps and the location of errors in these models</span></div><div class="casAuthors">Jones T A; Zou J Y; Cowan S W; Kjeldgaard M</div><div class="citationInfo"><span class="NLM_cas:title">Acta crystallographica. Section A, Foundations of crystallography</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">47 ( Pt 2)</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">110-9</span>
        ISSN:<span class="NLM_cas:issn">0108-7673</span>.
    </div><div class="casAbstract">Map interpretation remains a critical step in solving the structure of a macromolecule.  Errors introduced at this early stage may persist throughout crystallographic refinement and result in an incorrect structure.  The normally quoted crystallographic residual is often a poor description for the quality of the model.  Strategies and tools are described that help to alleviate this problem.  These simplify the model-building process, quantify the goodness of fit of the model on a per-residue basis and locate possible errors in peptide and side-chain conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhby6yNdW8QMKL0FlyGHDofW6udTcc2eaXTkdJR-hki7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3it1CmsQ%253D%253D&md5=fd4d4a3cdb4ecb3f05bbad8b2300ef45</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1107%2FS0108767390010224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767390010224%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DT.%2BA.%26aulast%3DZou%26aufirst%3DJ.%2BY.%26aulast%3DCowan%26aufirst%3DS.%2BW.%26aulast%3DKjeldgaard%26aufirst%3DM.%26atitle%3DImproved%2520methods%2520for%2520building%2520protein%2520models%2520in%2520electron%2520density%2520maps%2520and%2520the%2520location%2520of%2520errors%2520in%2520these%2520models%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D1991%26volume%3D47%26spage%3D110%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Joosten, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzemann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockinger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglund, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bongcam-Rudloff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Costa, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deleage, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diarena, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbretti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fettahi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flegel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gisel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kervinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korpelainen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattila, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichstadt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tickle, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vriend, G.</span><span> </span><span class="NLM_article-title">PDB_REDO: automated re-refinement of X-ray structure models in the PDB</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">376</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0021889809008784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=22477769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVehsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2009&pages=376-384&author=R.+P.+Joostenauthor=J.+Salzemannauthor=V.+Blochauthor=H.+Stockingerauthor=A.-C.+Berglundauthor=C.+Blanchetauthor=E.+Bongcam-Rudloffauthor=C.+Combetauthor=A.+L.+Da+Costaauthor=G.+Deleageauthor=M.+Diarenaauthor=R.+Fabbrettiauthor=G.+Fettahiauthor=V.+Flegelauthor=A.+Giselauthor=V.+Kasamauthor=T.+Kervinenauthor=E.+Korpelainenauthor=K.+Mattilaauthor=M.+Pagniauthor=M.+Reichstadtauthor=V.+Bretonauthor=I.+J.+Tickleauthor=G.+Vriend&title=PDB_REDO%3A+automated+re-refinement+of+X-ray+structure+models+in+the+PDB"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">PDBREDO: automated re-refinement of X-ray structure models in the PDB</span></div><div class="casAuthors">Joosten, Robbie P.; Salzemann, Jean; Bloch, Vincent; Stockinger, Heinz; Berglund, Ann Charlott; Blanchet, Christophe; Bongcam-Rudloff, Erik; Combet, Christophe; Da Costa, Ana L.; Deleage, Gilbert; Diarena, Matteo; Fabbretti, Roberto; Fettahi, Geraldine; Flegel, Volker; Gisel, Andreas; Kasam, Vinod; Kervinen, Timo; Korpelainen, Eija; Mattila, Kimmo; Pagni, Marco; Reichstadt, Matthieu; Breton, Vincent; Tickle, Ian J.; Vriend, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">376-384</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Structural biol., homol. modeling and rational drug design require accurate three-dimensional macromol. coordinates.  However, the coordinates in the Protein Data Bank (PDB) have not all been obtained using the latest exptl. and computational methods.  In this study a method is presented for automated re-refinement of existing structure models in the PDB.  A large-scale benchmark with 16 807 PDB entries showed that they can be improved in terms of fit to the deposited exptl. X-ray data as well as in terms of geometric quality.  The re-refinement protocol uses TLS models to describe concerted atom movement.  The resulting structure models are made available through the PDBREDO databank (http://www.cmbi.ru.nl/pdbredo/).  Grid computing techniques were used to overcome the computational requirements of this endeavour.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfH-Y9l34B8bVg90H21EOLACvtfcHk0liQuRUKoz-enA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVehsbo%253D&md5=7ed056bcc218ec1fc00a870eb3eaa58a</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1107%2FS0021889809008784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889809008784%26sid%3Dliteratum%253Aachs%26aulast%3DJoosten%26aufirst%3DR.%2BP.%26aulast%3DSalzemann%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DV.%26aulast%3DStockinger%26aufirst%3DH.%26aulast%3DBerglund%26aufirst%3DA.-C.%26aulast%3DBlanchet%26aufirst%3DC.%26aulast%3DBongcam-Rudloff%26aufirst%3DE.%26aulast%3DCombet%26aufirst%3DC.%26aulast%3DDa%2BCosta%26aufirst%3DA.%2BL.%26aulast%3DDeleage%26aufirst%3DG.%26aulast%3DDiarena%26aufirst%3DM.%26aulast%3DFabbretti%26aufirst%3DR.%26aulast%3DFettahi%26aufirst%3DG.%26aulast%3DFlegel%26aufirst%3DV.%26aulast%3DGisel%26aufirst%3DA.%26aulast%3DKasam%26aufirst%3DV.%26aulast%3DKervinen%26aufirst%3DT.%26aulast%3DKorpelainen%26aufirst%3DE.%26aulast%3DMattila%26aufirst%3DK.%26aulast%3DPagni%26aufirst%3DM.%26aulast%3DReichstadt%26aufirst%3DM.%26aulast%3DBreton%26aufirst%3DV.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DVriend%26aufirst%3DG.%26atitle%3DPDB_REDO%253A%2520automated%2520re-refinement%2520of%2520X-ray%2520structure%2520models%2520in%2520the%2520PDB%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2009%26volume%3D42%26spage%3D376%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arendall, W. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keedy, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Immormino, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm400072p&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm400072p&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm400072p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0liQuRUKoz-enA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17','PDB','1M17'); return false;">PDB: 1M17</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY','PDB','2ITY'); return false;">PDB: 2ITY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M','PDB','2J6M'); return false;">PDB: 2J6M</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3POZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3POZ','PDB','3POZ'); return false;">PDB: 3POZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV','PDB','2JIV'); return false;">PDB: 2JIV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J','PDB','4G5J'); return false;">PDB: 4G5J</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK','PDB','1XKK'); return false;">PDB: 1XKK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP','PDB','1IEP'); return false;">PDB: 1IEP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UP7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UP7','PDB','3UP7'); return false;">PDB: 3UP7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NPC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NPC','PDB','3NPC'); return false;">PDB: 3NPC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2','PDB','1KV2'); return false;">PDB: 1KV2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV1','PDB','1KV1'); return false;">PDB: 1KV1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EYJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EYJ','PDB','4EYJ'); return false;">PDB: 4EYJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G6G" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G6G','PDB','3G6G'); return false;">PDB: 3G6G</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G6H" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G6H','PDB','3G6H'); return false;">PDB: 3G6H</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ','PDB','2OIQ'); return false;">PDB: 2OIQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OO8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OO8','PDB','2OO8'); return false;">PDB: 2OO8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2P4I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2P4I','PDB','2P4I'); return false;">PDB: 2P4I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F9B','PDB','4F9B'); return false;">PDB: 4F9B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EOI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EOI','PDB','4EOI'); return false;">PDB: 4EOI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCI','PDB','4BCI'); return false;">PDB: 4BCI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GK2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GK2','PDB','4GK2'); return false;">PDB: 4GK2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ALW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ALW','PDB','4ALW'); return false;">PDB: 4ALW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7Q" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7Q','PDB','3R7Q'); return false;">PDB: 3R7Q</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZDI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZDI','PDB','3ZDI'); return false;">PDB: 3ZDI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H1J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4H1J','PDB','4H1J'); return false;">PDB: 4H1J</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BBF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BBF','PDB','4BBF'); return false;">PDB: 4BBF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R','PDB','4G9R'); return false;">PDB: 4G9R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HCU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HCU','PDB','4HCU'); return false;">PDB: 4HCU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EQU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EQU','PDB','4EQU'); return false;">PDB: 4EQU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OJJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OJJ','PDB','2OJJ'); return false;">PDB: 2OJJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG','PDB','3EYG'); return false;">PDB: 3EYG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FIN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FIN','PDB','1FIN'); return false;">PDB: 1FIN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7','PDB','4JQ7'); return false;">PDB: 4JQ7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ8','PDB','4JQ8'); return false;">PDB: 4JQ8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JR3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JR3','PDB','4JR3'); return false;">PDB: 4JR3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JRV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JRV','PDB','4JRV'); return false;">PDB: 4JRV</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i41"><a href="/doi/suppl/10.1021/jm400072p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_03820"></div></div></div></div></div><hr /></hr><p class="last">Data collection and refinement statistics for X-ray crystallography, kinase profiling of compound <b>4b</b>, overlay of EGFR/<b>4b</b> structure with JAK1 and CDK2. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400072p/suppl_file/jm400072p_si_001.pdf">jm400072p_si_001.pdf (1.0 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ7">4JQ7</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JQ8">4JQ8</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JR3">4JR3</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JRV">4JRV</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400072p&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm400072p%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-10%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400072p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797d433937d94e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
